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Abstract 
A number of dihydroxyacetone kinases (DAK) have been described that can utilize 
either ATP (in animals, plants and some bacteria) or phosphoenolpyruvate (PEP) (in 
most bacteria) as the energy source to convert dihydroxyacetone (Dha) to 
dihydroxyacetone phosphate (DhaP), which plays critical roles in many metabolic 
pathways. It has also been described that Homo sapiens DAK is able to regulate the 
innate immune system via its interaction with Melanoma differentiation-associated 
protein 5 (MDA5), which is recognized as an RNA sensor during virus infection. 
These findings make H. sapiens DAK a very noteworthy research target due to its 
multiple functions in many fields. Therefore, structural studies of DAK from H. 
sapiens are presented. 
The initial structure of the wild type (WT) H. sapiens DAK was determined to 2.5Å 
resolution and solved by molecular replacement. The structure forms a homodimer 
and four dimers were shown to be present in each asymmetric unit. However, within 
each monomer, most regions of the C-terminal domain were disordered, and therefore 
in order to improve structure quality, multiple site-directed mutagenesis was used. The 
mutated protein was then crystallized and the structure was determined to 1.4Å. The 
N-terminal Dha binding domain consists of two α/β regions and the C-terminal ATP 
binding domain is comprised of eight anti-parallel α-helices, which forms a deep 
pocket and is filled with a phospholipid molecule. In addition, the structures of 
mutated DAK in complex with ATP analogues and Dha are also described in the 
current study.  
The second part of the project concerned sialidases, which are glycoside hydrolases 
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that specifically hydrolyse terminal sialic acid from various glycans. Streptococcus 
pneumoniae is one of the most common pathogenic bacteria of humans, and is 
reported to encode three sialidases that act as virulence factors in bacterial 
colonization and infection. One of these sialidases, NanA, was reported to be present 
in all clinical strains and plays a vital role during the bacterial infection.  
Consequently, the structure of N-terminal Carbohydrate-binding module (CBM) 
domain of NanA has been determined to 1.8Å, and reveals a β-sandwich fold. The apo 
form of NanA-CBM is present as a dimer in the asymmetric unit, whereas a monomer 
was detected when it is bound to sialic acid or its derivatives. Structural comparisons 
between NanA-CBM and other structures of the CBM40 family were also performed. 
The substrate binding sites of NanA-CBM forms a cavity that is able to accommodate 
the substrates. A potential molecular binding site located beside the sialic acid binding 
site was revealed, and is occupied by the side chain of a lysine from a symmetry-
related molecule. Heteronuclear single quantum coherence (HSQC) NMR 
spectroscopy and fluorescent-based thermal shift assays were also carried out to 
further characterise the protein.  
The current results reveal the structure of both DAK from H. sapiens and NanA-CBM 
from S. pneumoniae, which may contribute to a better understanding towards cell 
metabolism and bacterial colonization. 
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1.1  Introduction to Dihydroxyacetone kinase (DAK) 
Within a cell, no matter whether it is from a unicellular bacterium such as Escherichia 
coli or a multicellular organism like Homo sapiens, they all require a series of 
metabolic pathways to maintain survival and reproduction, and most of the basic 
metabolic pathways in these hugely different species are conserved (Smith and 
Morowitz, 2004; Pace, 2001). Certainly, enzymes play indispensable roles in these 
pathways, in which, the functions and mechanisms of every enzyme in each reaction 
are very distinct according to their three-dimensional structure. Even within the same 
class, enzymes between different species can be noticeably different. The 
phosphorylation of dihydroxyacetone (Dha) into dihydroxyacetone phosphate (DhaP) 
by a cytoplasmic protein named dihydroxyacetone kinase (DAK) is a recognizable 
example of this diversity (Gutknecht et al., 2001).  
1.1.1   Dha, substrate of DAK 
As one of the structurally simplest carbohydrates, Dha contains three carbon atoms 
with the formula C3H6O3, and has no chiral center and therefore no optical activity. 
Solid Dha is in the dimeric form as confirmed by X-ray diffraction of recrystallized 
Dha, and rapidly turns to monomeric in solution (Figure 1.1) (Slepokura and Lis, 
2004). In bacteria and yeast, the production of Dha could be achieved both by 
oxidation of glycerol under anaerobic conditions and aldol cleavage of fructose-6-
phosphate (Yazdani and Gonzalez, 2007; Schurmann and Sprenger, 2001). 
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Figure.1.1. Structure of Dha in solid (a) and in solution (b). 
Dha plays very important roles in biochemical synthesis among various species. In 
methylotrophic yeast, Dha is an essential intermediate in methanol assimilation in 
which methanol is primarily oxidized to formaldehyde, then Dha is synthesized by 
transfer of a glycolaldehyde from xylulose-5-phosphate to formaldehyde in a 
transketolase reaction, which is followed by phosphorylation of Dha into DhaP. This 
creates the starting point for subsequent reactions (Lüers et al., 1998; Negruta et al., 
2010; Waites and Quayle, 1981). In mammalian cells, Dha was reported to act as a 
precursor in gluconeogenesis as it could be phosphorylated into DhaP, which is a 
critical intermediate for this metabolic pathway (Azzout et al., 1984). In recent years, 
Dha has been broadly used in Maillard-type reactions due to the increased 
crosslinking ability between glyceraldehyde and Dha compared to hexoses and 
pentoses. This difference is a result of the small size of Dha, which cannot form cyclic 
hemiketals and therefore could be prone to react intermolecularly. (Prabhakaram and 
Ortweth, 1994; Tessier et al., 2003). In daily life, Dha is well known as the ingredient 
of sunless tanning sprays and lotions (Fu et al., 2004). The story of the discovery of 
this feature is an unusual one: Dha was initially used as an oral drug for treatment of 
children with glycogen storage disease. Health care workers noticed that a few hours 
after skin exposure to Dha (after accidental regurgitation), the affected areas turned 
a, Dha in solid b, Dha in solution 
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brown. Afterwards, the potential for Dha to improve sunless tanning was given 
extensive attention. It is now known that Dha interacts with various amino acids that 
exist in the keratin layer on the skin surface, forming melanoidins that can change the 
level of skin color from yellow to dark brown (Wittgenstein and Berry, 1960). So far, 
as the only color additive permitted by the Food and Drug Administration (FDA), Dha 
is currently widely used not only in food production such as bakery products and 
winemaking, but also in medical treatment for vitiligo and variegate porphyria 
(Tessier et al., 2003; Adams et al., 2004; Fesq et al., 2001; Asawanonda et al., 1999). 
1.1.2   Dihydroxyacetone phosphate (DhaP) 
The phosphorylated form of Dha, DhaP can be formed not only by phosphorylation of 
Dha, but also via many other routes. Fructose-1, 6-bisphosphate can be split into 
DhaP and glyceraldehyde-3-phosphate by fructose bisphosphate aldolase (Wong and 
Whitesides, 1983). DhaP can also be produced by isomerization of glyceraldehyde-3-
phosphate by triose phosphate isomerase and the isomerization is reversible (Wong 
and Whitesides, 1983). Additionally, it has been reported that oxidation of glycerol-3-
phosphate using glycerol phosphate oxidase can produce DhaP in situ (Eyrisch et al., 
1994). Consequently, all the above suggest that DhaP is likely to play a crucial role in 
many main metabolic pathways. It is well known that in the preparatory phase of 
glycolysis, DhaP is a product of aldol cleavage of fructose-1, 6-bisphosphate, which is 
followed by isomerization of the generated DhaP to glyceraldehyde-3-phosphate, 
starting the pay-off phase of glycolysis (Figure 1.2) (Wong and Whitesides, 1983; 
Voet, D et al., 1999). Indeed, therefore, the reverse reactions of these steps are 
essential enzyme-catalysed reactions in gluconeogenesis (Nelson and Cox, 2000) and 
also the Calvin cycle (a part of photosynthesis). Glyceraldehyde-3-phosphate, the 
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product of the first stage of the Calvin cycle, is isomerized to DhaP, which together 
with glyceraldehyde-3-phosphate, is converted into fructose 1,6-phosphate, starting 
the downstream reactions to synthesise more useful organic compounds such as 
carbohydrates (Bassham et al., 1950).  
 
Figure 1.2. Overview of the glycolysis pathway. (Garrett et al., 2005) 
Moreover, in the metabolism pathway of fructose, DhaP also plays a very important 
role as the intermediate product of this pathway: the fructose is initially 
phosphorylated to fructose-1-phosphate by fructokinase, the produced fructose-1-
phosphate is then split into DhaP and glyceraldehyde by aldolase B. Glyceraldehyde-
3-phosphate is then produced either by phosphorylation of glyceraldehyde or 
isomerization of DhaP. After this point, the reaction enters the intermediate pathway 
of gluconeogenesis, leading to synthesis of glycogen or triglyceride (Parniak and 
Kalant, 1988; Valentin and Bolte, 1993; Nelson and Cox, 2000). Also, in the glycerol 
phosphate shuttle, glycerol-3-phosphate dehydrogenase 1 (GPDH1) catalyses the 
reduction of DhaP into glycerol 3-phosphate by oxidizing NADH to NAD+, and the 
reverse reaction is catalysed by glycerol-3-phosphate dehydrogenase 2 (GPDH2) with 
reduction of flavin adenine dinucleotide (FAD) into FADH2 (Figure 1.3). These 
Dihydroxyacetone phosphate 
Preparatory phase 
Pay-off phase 
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reactions are very important in transporting reducing equivalents and have been found 
in animals, plants and fungi (Shen et al., 2006; Berg et al., 2002). Additionally, it has 
been reported that DhaP acts as an essential chemical in the production of the acyl 
dihydroxyacetone phosphate, which is a precursor in the biosynthesis of glycerolipids 
and glyceryl ether phospholipids (Bosch, 1974; Hajra and Bishop, 1982). 
 
Figure 1.3. Two reactions in glycerol phosphate shuttle.  
Transferred protons are shown in red. 
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1.1.3   Molecular functions of DAKs 
As a family of sequence-conserved enzymes, DAK can phosphorylate Dha, 3,4-
dihydroxy-2-butanone, glyceraldehyde and probably some other short chain 
carbohydrates (Erni et al., 2006; Herz et al., 2002). It has been found that DAK exists 
in all domains of life, although DAK from different species have different forms and 
may utilize different phosphate donors as the energy sources. DAK can use ATP as the 
phosphate source to convert Dha into DhaP, with dephosphorylation of ATP into ADP 
(Figure 1.4a) (Daniel et al., 1995), a process which occurs in animals, plants and 
some bacteria. Alternatively, DAK from some bacteria utilize phosphoenolpyruvate 
(PEP) as the phosphate donor, however, this phosphoryl transfer is not a direct 
transfer of phosphate from PEP to Dha, rather it is mediated by a cascade of more 
than one protein, which constitute the PEP: sugar phosphotransferase system (PTS) 
(Gutknecht et al., 2001). 
An example of an ATP-dependent kinase is DAK from Citrobacter freundii (SWISS-
PROT accession number: P45510, PDB code: 1UN9) (Daniel et al., 1995) (Siebold et 
al., 2003a). C. freundii DAK forms a homodimer and each monomer consists of a 
single polypeptide that contains an N-terminal substrate binding domain and a C-
terminal nucleotide binding domain, which are connected by a 30 amino acid linker 
(Siebold et al., 2003a) (Figure 1.5a). In PEP-dependent kinases, the structure of DAK 
from E. coli has been determined and shown to comprise three individual subunits, 
DhaK (P76015 PDB code: 1OI2) and DhaL (P76014 PDB code: 2BTD), which are 
homologous to the substrate binding domain and nucleotide binding domain of ATP-
dependent DAK, and an additional DhaM subunit (P37349), which transfers a 
phosphoryl from the phosphoryl carrier protein HPr (histidine-containing phosphoryl 
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carrier protein) of the PTS to DhaL (Siebold et al., 2003b; Oberholzer et al., 2006; 
Gutknecht et al., 2001). The process of the phosphoryl transfer in the PTS-dependent 
DAK system requires five reaction steps: (i) a phosphoryl from PEP is initially 
transferred to the first phosphoryl carrier protein named as EI (Enzyme I), (ii) the 
transferred phosphoryl is then taken up by the second phosphoryl carrier protein-HPr, 
(iii) the phosphoryl is passed to DhaM, (iv) the phosphorylated DhaM as a new 
phosphoryl donor interacts with DhaL, which contains ADP, and rapidly 
phosphorylates ADP to ATP, (v) finally, the ATP-bound DhaL consequently forms a 
complex with the Dha bound DhaK and phosphorylates Dha to DhaP. Afterwards, the 
newly formed ADP from the dephosphorylation of ATP is rephosphorylated by DhaM 
(Figure 1.5b) (Meadow et al., 1990; Gutknecht et al., 2001; Jin and Lin, 1984; Shi et 
al., 2011).  
 
Figure 1.4. Chemical reactions catalysed by DAK.  
(a). ATP-dependent DAK catalyses the phosphorylation of Dha to DhaP by dephosphorylation of ATP 
to ADP in the presence of Mg2+. (b). DAK can also act as an FAD-AMP lyase, catalysing the 
formation of cFMN and AMP from the splitting of FAD in the presence of Mn2+.  
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Therefore, the ability of DAK to catalyse the phosphorylation of Dha into DhaP plays 
a vital role in several biological areas. For example, as mentioned above, in 
methylotrophic yeasts, DAK phosphorylates the synthesized Dha to DhaP during 
methanol assimilation (Waites and Quayle, 1981). Also, DAK plays a catalytic role in 
the catabolism of glycerol, which indicates that DAK phosphorylates glycerol 
oxidation products rather than directly phosphorylating glycerol (Forage and Lin, 
1982). It has been reported that DAK is involved in the detoxification of Dha in 
Saccharomyces cerevisiae, as shown by studies in which gene knockouts of DAK 
cause hypersensitivity to Dha in yeast cells while DAK overexpression results in 
tolerance to Dha (Molin et al., 2003). It is therefore assumed that DAK may be able to 
clean up the excess Dha and other short chain carbonyl products formed in the 
metabolism of some carbohydrates. 
In contrast to most enzymes that are highly specific for their substrates, DAK has 
been described to act as a bifunctional enzyme. In addition to the functions of DAK in 
the phosphorylation of Dha to DhaP, it has been reported that DAKs from mammals 
(rat and human) have an alternative function of catalysing the reaction of 
ribonucleoside diphosphate-X (ribo-NDP-X) splitting into ribonucleotide (ribo-NMP) 
and phosphodiester-X (P=X) (X represents an acyclic or cyclic monosaccharide or 
derivative bearing an X-OH group, which could internally attack the adjacent 
phosphorus and form a P=X product) (Cabezas et al., 2001). This process is 
manganese dependent, in contrast to the magnesium dependence of the kinase 
function (Cabezas et al., 2001; Cabezas et al., 2005; Sánchez-Moreno et al., 2009). It 
is suggested that FAD is the ideal ribo-NDP-X substrate of DAK as the splitting of 
FAD into riboflavin 4’, 5’-cyclic phosphate (cyclic FMN or cFMN) and adenosine 
monophosphate (AMP) (Figure 1.4b) was determined to have the highest catalytic 
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efficiency (kcat/Km= 32.9 µM-1 min-1), compared to other ribo-NDP-X substrates such 
as ADP-glucose (kcat/Km= 16.9 µM-1 min-1) (Cabezas et al., 2001; Fraiz et al., 1998). 
The lyase activity (kcat/Km values) of DAK is at least six-fold weaker than its kinase 
activity (Cabezas et al., 2005). Moreover, substrate inhibition tests done by Sánchez-
Moreno et al. show that FAD at 500µM is a competitive inhibitor of kinase activity, 
while ATP at 0.2µM is a competitive inhibitor of lyase activity. AMP is a competitive 
inhibitor of both kinase activity and lyase activity at 10.2mM and 3.5mM, 
respectively (Sánchez-Moreno et al., 2009). In addition, docking studies using C. 
freundii DAK estimated that the ADP moiety of FAD may bind to the nucleotide 
binding site of DAK according to the structural similarities between ATP and FAD, 
whereas the FMN moiety is too flexible to access the possible position (Sánchez-
Moreno et al., 2009). The mechanism of DAK catalysing the phosphorylation of Dha 
has been well defined (described in section 1.1.5), however, the mechanisms by which 
DAK catalyses the splitting of FAD, and the interactions between enzyme and 
substrate are still poorly understood.  
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Figure 1.5. The schematics of different DAK forms.  
(a). Domain structure of DAK, which utilizes ATP as the phosphoryl donor. (b). Phosphoryl flow chart 
in the PTS system, where DAK uses PEP as the phosphoryl donor. 
Furthermore, the high sequence conservation of the members of the DAK family 
(Figure 1.6) and the structural similarities between them (described in chapter 2 &3), 
indicated that it is very possible that DAK, not only from mammals but also from 
other species, could also perform as FAD-AMP lyases. The biological functions of the 
lyase feature of DAK are still not entirely understood, therefore, further studies on 
these areas are required.  
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HUMAN            N           G                                 VA  SGGGSGMTSKKLV SVAGCADDALA LVACNPN.....LQLLQGHRVALRSDLDSLKGR  LL      
RAT              N           G                                 VA  SGGGSGMSSKKMV SVEGCAGDALA FVACNPD.....LQLLQGYRVALRSDLDSLKGR  LL      
LL               N           G                                 VA  SGGGSGMSDEKII QPQDVVSEMLD LTYAYGD......LIEKVPDFEIIQRKSPKSGK  LV      
3PNL             N           G                                 VA  SGGGSG.GSKKLI DVQDVLDEQLA LAKAHPS......LTLHQDPVYVTRADAPVAGK  LL      
pneumoniae        N           G                                 VA  SGGGSG...KKLI RVEDVLNEQLQ LAKAHPQ......LTLHQDPLYVTRTDAPVAGK  LL      
                                                               1UN9      
        70        80        90         100       110       120 
1UN9      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A V FI K   TAAVC DV A  SVDAVLTAIQAVT..GEA C   V   T  RL  GL 
HUMAN     H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A A FI K   TGVIA AV T  AVGSILAAIRAVAQAGTV T   V   T  RL  GL 
RAT       H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A A FI K   TGVIA AV A  AVGSILAAIRAVAQAGTA T   V   T  RL  GL 
LL        H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A K A A FV E   SAAVC AI T  TPDQIYEAIKSAD..EGA V   I   L  VM  EM 
3PNL      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKIFECAMQVD..GGE V   I   T  IL  ET 
pneumoniae H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKMFECAMQID..GGE V   I   T  IL  ET 
                                                               1UN9      
      130       140          150       160       170       180 
1UN9       E        V      DD            RG   T L  K  G  A     L         A KARRLGYN EMLIVG  ISLPD.NKHP..  IAG I VH IA YF ERGYN ATVLREAQY
HUMAN      E        V      DD            RG   T L  K  G  A     L         R QARAEGIP EMVVIG  SAFTV.LKKAGR  LCG V IH VA AL EAGVG EEIAKQVNV
RAT        E        V      DD            RG   T L  K  G  A     L         M QAKAEGIS EMVVIE  SAFTV.LKKAGR  LCG I IH VA AL EEGMG EEITKKVSV
LL         E        V      DD            RG   T L  K  G  A     L         R MAEMEEIK EQIIVD  IAVENSLYTQGR  VAG V VH IL AA HQEAS DEIKDLADK
3PNL       E        V      DD            RG   T L  K  G  A     L         T LLHDSGVK TTVVID  VAVKDSLYTAGR  VAN V IE LV AA ERGDS DACAELGRK
pneumoniae  E        V      DD            RG   T L  K  G  A     L         T LLHESGIK TTVVVD  VAVKDSLYTAGR  VAN V IE LV AA ERGDS EACAELGRR
                                                               1UN9      
      190       200       210       220       230       240    
1UN9              G  L     P              E G GIH E G                    AASNTFSL VA SSCHL QETDAAPRHHPGHA L M   G P ASVIDTQNSAQVVNLMVDKL
HUMAN             G  L     P              E G GIH E G                    VAKAMGTL VS SSCSV .GSKPTFELSADEV L L   G A VRRIKMATADEIVKLMLDHM
RAT               G  L     P              E G GIH E G                    IAKAIGTL VS SPCSV .GTKPTFELAADEM L L   G A VRRIKLVPVDQIVTLMLDHM
LL                G  L     P              E G GIH E G                    VVKNIKTI LA SAATV EVGKPGFVLDDNEI Y V   S P YRREKMKTSYELATELVGKL
3PNL              G  L     P              E G GIH E G                    LNNQGHSI IA GACTV AAGKPSFTLADNEM F V   G P IDRRPFSSLDQTVDEMFDTL
pneumoniae         G  L     P              E G GIH E G                    LNNLGHSI IA GACTV AAGQPSFTLKDDEM F V   G P IDRRRFSSLDQTVDEMFDTL
                                                               1UN9      
                      250              260       270       280 
1UN9                                              N  G     E             LAALP...................ETGR.......LAVMI NL GVSVA MAIITRELASSPL
HUMAN                                             N  G     E             TNTTN...................ASHVPVQPGSSVVMMV NL GLSFL LGIIADATVRSLE
RAT                                               N  G     E             TDTSN...................ISHVPVKSGSSVVLMV NL GLSFL LGIIADAAIRLLE
LL                                                N  G     E             KE........................EFKFEAGQKYGILV GM ATPLM QFIFMNDVAKLLT
3PNL                                              N  G     E             LVNGSYHRTLRFWDYQQGSWQEEQQTKQPLQSGDRVIALV NL ATPLS LYGVYNRLTTRCQ
pneumoniae                                         N  G     E             LENGAYSRTLRQWDTVKGAWQEVKQSKTALQNGDRVIALV NL ATPLS LYGVYHRLAQRCE
                                                               1UN9      
      290        300       310       320           330         
1UN9                         M G S T                                     HSRIDWLIGPA.SLVTALD K F L AIVLEESIEKALLTEVETSNWP....TPVPPREITCV
HUMAN                        M G S T                                     GRGVKIARALVGTFMSALE P I L LLLVDEPLLKLIDAETTAAAWPNVAAVSITGRKRSRV
RAT                          M G S T                                     GRGVKVARALVGTFMSALE R V L LMLVDEPLLKLIDAETNAKAWPHMSKVSVTGRNRIRA
LL                           M G S T                                     EENIEILFKKVGNYMTSID A L L MIKLEDD.QWLKNLNEDVKTISWG...LLTIDT....
3PNL                         M G S T                                     QAGLTIERNLIGAYCTSLD T F I LLKVDDETLALWDAPVHTPALNWGKGSSLSRTQ....
pneumoniae                    M G S T                                     ASGIIIERNLIGSYCTSLD S F I LLKVDDETLTLWDAPVHTPALNWG..NSLNRTQ....
                                                               1UN9      
340       350          360       370       380       390         
1UN9                                             L  LD   GD D G          VSSHASARVEFQPS...ANALVAGIVELVTATLSDLETH NA  AKV  G T STFAAAAREI
HUMAN                                            L  LD   GD D G          APAEPQEAPDSTAAGGSASKRMALVLERVCSTLLGLEEH NA  RAA  G C TTHSRAARAI
RAT                                              L  LD   GD D G          APTEPAEAPEATAAGGVASKQMTLVLDRISTTLIGLEEH NA  RAA  G C STHSRAAKAI
LL                                               L  LD   GD D G          .....................TIEWLGKFNEKIQENKAY SE  GPI  G H ANMARGMSET
3PNL                                             L  LD   GD D G          .....................IVNWLTRCGDIFSTESEY TG  REI  A H LNMNRGFSKV
pneumoniae                                        L  LD   GD D G          .....................IVDWLYRCGDIFTKESDF TG  KEI  A H LNMHRGFSKV
                                          ..            ...    1UN9      
400       410       420       430       440         450          
1UN9         L                    L    GG SG L        A                  ASL HRQQLPLNNLATLFALIGER TVVM  S  V MSIFFT.. AGQKLEQGANV...VEAL
HUMAN        L                    L    GG SG L        A                  QEW KEGPPPAS.PAQLLSKLSVL LEKM  S  A YGLFLT.. AAQPLKAKTSLPAWSAAM
RAT          L                    L    GG SG L        A                  QGW KEGPTPAS.PAQVLSKLSVL LEKM  S  A YGLFLT.. AAQPLKANTDLPAWSAAM
LL           L                    L    GG SG L        A                  MKA E..VSNFGNVSEIFKKVAMT MSKV  A  P YGSAFL.. MSKTAIETLDTSEL...I
3PNL         L                    L    GG SG L        A                  VEK P..AIADKDIGFILKNTGMT LSSV  A  P FGTFFIRA QATQARQSLTLEELYQMF
pneumoniae    L                    L   GG SG L        A                  VEK P..SIADKDIGFILKNTGMT LSNV  A  P FGTFFIRA QVTQAHQSLTLDELYLMI
                                                               1UN9      
460       470       480       490          500       510       
1UN9        G       G A  G  TM D        L                     E          NT LAQMKFY G DE DR  I ALQPALTS LAQPK...NLQAAFDAAQAGA RTCLSSK...
HUMAN       G       G A  G  TM D        L                     E          DA LEAMQKY K AP DR  L SLWAAGQE QAWKSPGADLLQVLTKAVKSA AAAEATKNME
RAT         G       G A  G  TM D        L                     E          DA LKAMQKY K AP DR  L SLWAAAQE QAWKSPGASLLPVLTKAVKSA AAAEATKNME
LL          G       G A  G  TM D        L                     E          YA LEAIQKR K QV EK  V IWSAFLND QTDS...........ASKDNL KVVKASAGLL
3PNL        G       G A  G  TM D        L                     E          RD ADGVISR K EP DK  C VWVPVVES RQSSEQNLSVPVALEAASSIA SAAQSTITMQ
pneumoniae   G       G A  G  TM D        L                     E          RE ADGVVNR K EP DK  C VWLPVADS RQSSEQHLSIAAALDAACEVA RAAHATITMQ
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!2 #4 "2 #5 "3 
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             1UN9      
 1       10        20        30        40          50        60
1 N9 .A QFFF QRTHLVS VID AIIAS WNNLAR ESDPAI IVV R N.. NN VI
HUMAN T L A D L N H
RAT SK MV SVEGCAGDA A FVACNP LQLLQGYRVALRSDLDSLK R L
LL  MSDE I QP VS M D TY YGD IEKVPDFEIIQRKS KS V
3PNL      GS D Q D A S V A
pneumoniae        N           G                                 VA  SGGGSG...KKLI RVEDVLNEQLQ LAKAHPQ......LTLHQDPLYVTRTDAPVAGK  LL      
               1UN9      
        70        80        90         100       110       120 
1 N9 V AAVC D A S DAV T Q T.. EA C
HUMAN T V
RAT E I K TGVIA V A AVGS LA RAVAQAGT T V T RL GL
LL  K A A FV E A VC A Q Y AIKSA E A L VM M
3PNL      I V
pneumoniae H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKMFECAMQID..GGE V   I   T  IL  ET 
                  1UN9      
      130       140          150       160       170       180 
1 N9 A K RL YN LIV ISLPD N HP.. IA I V I YF R YN ATVLREAQY
HUMAN R R P G V A V A Q N
RAT M Q KA G S MVVIE S FTV. KKA LC I I VA L EEGMG E TKKVSV
LL  R MAEMEEI EQIIV I EN Q G VH IL HQEA EIKD AD
3PNL      D V I D K
pneumoniae  E        V      DD            RG   T L  K  G  A     L         T LLHESGIK TTVVVD  VAVKDSLYTAGR  VAN V IE LV AA ERGDS EACAELGRR
                  1UN9      
      190       200       210       220       230       240    
1 N9 A SNTFS A HL QETDAAPRHHPGHA M P ASV DTQNSAQV N V KL
HUMAN V M S S S V MATA E K
RAT IA A G L VS PCS .GT T E AAD M L L G A V I LVPVDQIV LMLDHM
LL  VVKNIKT L S A EV G V D I Y S YR EKMKTSYELAT LVGK
3PNL      Q K A N P
pneumoniae         G  L     P              E G GIH E G                    LNNLGHSI IA GACTV AAGQPSFTLKDDEM F V   G P IDRRRFSSLDQTVDEMFDTL
            1UN9      
                      250              260       270       280 
1 N9 LAALP ETGR.......LAV I V VA MA TRELAS PL
HUMAN N T A QP M TV S
RAT TDTSN ISHVPVKS SSVVLM NL GLSFL LG IADAAIR E
LL  KE........................EFKFEA QKYGI GM M QFIFM DVAKLLT
3PNL      V S H F YQQ S EQ T QP S N TT Q
pneumoniae                                         N  G     E             LENGAYSRTLRQWDTVKGAWQEVKQSKTALQNGDRVIALV NL ATPLS LYGVYHRLAQRCE
               1UN9      
      290        300       310       320           330         
1 N9 HSRIDWLIGPA.SLVT D K F AIVLE SIE ALLT VETSN ....TPVPP EITC
HUMAN I P I L T A NVAA I K S V
RAT GRGVKVARAL TF SALE R V LMLVDEPLLK IDAETNA AWPHMSKVSV GRNRIRA
LL  EENIE LFKKV N M I A L L MI LE D.QW KNLNEDVKTIS ...L TIDT
3PNL      QA LT A T A KGS S
pneumoniae                    M G S T                                     ASGIIIERNLIGSYCTSLD S F I LLKVDDETLTLWDAPVHTPALNWG..NSLNRTQ....
                1UN9      
340       350          360       370       380       390         
1 N9 VSSHASARVEFQPS... NALV GIV L TA SD T AKV T S FAA E
HUMAN A Q DS S R A E VCS L T R
RAT APTEPAEAPEATAAGGVASKQMTLV DRISTTLIGLEEH NA RAA C STHS AAKAI
LL  TIE GKFNEKIQENKA SE GP G A A M ET
3PNL      N T ST EY R N
pneumoniae                                        L  LD   GD D G          .....................IVDWLYRCGDIFTKESDF TG  KEI  A H LNMHRGFSKV
             ..    ...1UN9      
400       410       420       430       440         450          
1 N9 ASL HRQQL LNNL T FALIGER TVV V MSI F G K EQGANV...VE L
HUMAN E P L K S
RAT QGW KEGPTPAS.PAQVLS LSVL LE M S A LFLT AAQPLKANT LPAWSAAM
LL  MKA E VSNFGNVSE F KVA M K Y SA L.. MSKT IET DTS ...I
3PNL      A S A R E Q F
pneumoniae    L                    L    GG SG L        A                  VEK P..SIADKDIGFILKNTGMT LSNV  A  P FGTFFIRA QVTQAHQSLTLDELYLMI
                  1UN9      
460       470       480       490          500       510       
1 N9 NT AQ KF G DE I A QP LTS L QPK...N QAAFDA QAG RTCLSS ...
HUMAN E G D Q
RAT D K M Y AP DR L SLW AAQE AWKSPGASLLPVLTKAVKSA AAAE TKNME
LL  YA LEAIQK QV E V I SAFLND QTD ........... SKDNL KVVKASAGLL
3PNL      D IS V VE N VPV E SSI S QS
pneumoniae   G       G A  G  TM D        L                     E          RE ADGVVNR K EP DK  C VWLPVADS RQSSEQHLSIAAALDAACEVA RAAHATITMQ
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#6 "4 "5 
#7 #8 #9 "6 
#10 "7 
!3 #11 #12 "8 #13 
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U             N           G                                 VA  SGGGSGS  D  P L R R DL K         
            N           G                                 VA  SGGGSGM SKK V SV GCA DALA VACNP .....LQLLQG RVALRSDLDSLKGR  LL      
              N           G                                 VA  SGGGSGMS K  L  D..... G   L       
             N           G                                 VA  SGGGSGK I QDV E L  L A ......L P GK  L       
       N           G                                 VA  SGGGSG. KKLI V DVL EQL  LAKAHP ......LTLHQDP YVTR DAPVAGK  LL      
                                                
U      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A  FI K   T  V   V L AI AV G     V   T  RL  GL 
     H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A A FI K   TGVIA AV   AVGSILAAIRAVAQAGT  T   V   T  RL  GL 
       H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A  A A F      A    I AI A            
      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A        S A  I T  TPD I E D.. G  V   I       E  
H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDK FECAMQ D..GGE V   I   T  IL  ET 
                                             
U       E        V      DD            RG   T L  K  G  A     L          AR G  EM G  . K   G  H A  E G  
      E        V      DD            RG   T L  K  G  A     L          QA AEGI  EMVVI   SAFTV.LKKAGR  LCG  IH VA AL E G G EEI K V V
        E        V      DD            RG   T L  K  G  A     L          A E I  E   A L GR  G  H  A   EI
       E        V      DD            RG   T L  K  G  A     L          K D  AV SLYT GR  VA  V   AA S D L K
 E        V      DD            RG   T L  K  G  A     L         T LLH SG K TTVV D  VAVKDSLYTAGR  VAN V IE LV AA ERGDS ACAELGR
                                             
U              G  L     P              E G GIH E G                    A L V  SSC   L    G  I V LM D
             G  L     P              E G GIH E G                    AKA GTL VS S CSV .G KPTFEL ADE  L L   G A VRRIK D IV LMLDHM
               G  L     P              E G GIH E G                    K I T   S V KP F L E        RR K T
              G  L     P              E G GIH E G                    I A A TV GKP F L DNE   V    P R E L
        G  L     P              E G GIH E G                    LNN GHSI IA GACTV AAG PSFTL D EM F V   G P IDRR FSSLDQTVDEMFDTL
                                                   
U                                              N  G     E             ................... M  NL G S  II S
                                             N  G     E             T T N................... SHVPV GSSVV MV NL GLSFL LGIIADA R LE
                                               N  G     E             ................... G V   I LL
                                              N  G     E             G LV  ATPL  N
                                        N  G     E             L NG Y RTLR WD G WQE Q K LQ GDRVIALV NL ATPLS LYGVY RL RC
                                                
U                         M G S T                                     AL    L E K E WP R V
                        M G S T                                     GRGVK ARALVGTFMSALE   L L LVDEPLLKLIDAET A AWP VS TGR R R
                          M G S T                                     VG M    L L K T
                         M G S T                                     I G Y TS D    K D L WG L ....
                   M G S T                                     G IERNLIG YCTSLD  F I LLKVDDETL LWDAPVHTPALNWG SL RTQ....
                                               
U                                             L  LD   GD D G          A A E V TL LE H NA    G  T AAR I
                                            L  LD   GD D G          AP EP EAP TAAGG ASK M LVL R TL GLEEH NA  RAA  G C THSRAA AI
                                              L  LD   GD D G          L      G  R
                                             L  LD   GD D G          ..................... WL Y   I   H NM RG S
                                       L  LD   GD D G          .....................IV WL RCGDIF ES  TG  EI  A H LNM RGFSKV
                                          
U         L                    L    GG SG L        A                   P A L  M  S   F T.. A Q L A
        L                    L    GG SG L        A                  Q W KEGP PAS.PAQ LSKLSVL LEKM  S  A YGLFLT.. AAQPLKA T LPAWSAAM
          L                    L    GG SG L        A                   K  K      YG .. D
         L                    L    GG SG L        A                   .. I K MT S V  A  P G F  A L EL
   L                    L    GG SG L        A                  VEK P.. IADKDIGFILKNTGMT LS V  A  P FGTFFIRA Q TQA QSLTL ELY M
                                             
U        G       G A  G  TM D        L                     E           L M Y   DR   L A  A L A A K
       G       G A  G  TM D        L                     E          DA L AMQKY K AP DR  L SLWAA QE QAWKSPGA LL VLTKAVKSA AAAEATKNME
         G       G A  G  TM D        L                     E          A L A QK  K     A  Q  A
        G       G A  G  TM D        L                     E           R K  K   W  S A  
3PNL        G       G A  G  TM D        L                     E          RD ADGVISR K EP DK  C VWVPVVES RQSSEQNLSVPVALEAASSIA SAAQSTITMQ
pneumoniae   G       G A  G  TM D        L                     E          RE ADGVVNR K EP DK  C VWLPVADS RQSSEQHLSIAAALDAACEVA RAAHATITMQ
     
     
   
    
  
     
  
  
    
                                                               1UN9      
1 10 20 30 40 50 60
1 N9 .A QFFF QRTHLVS VID AIIAS WNNLAR ESDPAI IVV R N.. NN VI
HUMAN T L A D L N H
RAT SK MV SVEGCAGDA A FVACNP LQLLQGYRVALRSDLDSLK R L
LL  MSDE I QP VS M D TY YGD IEKVPDFEIIQRKS KS V
3PNL      GS D Q D A S V A
pneumoniae        N           G                                 VA  SGGGSG...KKLI RVEDVLNEQLQ LAKAHPQ......LTLHQDPLYVTRTDAPVAGK  LL      
                                                               1UN9      
70 80 90 100 110 120
1 N9 V AAVC D A S DAV T Q T.. EA C
HUMAN T V
RAT E I K TGVIA V A AVGS LA RAVAQAGT T V T RL GL
LL  K A A FV E A VC A Q Y AIKSA E A L VM M
3PNL      I V
pneumoniae H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKMFECAMQID..GGE V   I   T  IL  ET 
                                                               1UN9      
130 140 150 160 170 180
1 N9 A K RL YN LIV ISLPD N HP.. IA I V I YF R YN ATVLREAQY
HUMAN R R P G V A V A Q N
RAT M Q KA G S MVVIE S FTV. KKA LC I I VA L EEGMG E TKKVSV
LL  R MAEMEEI EQIIV I EN Q G VH IL HQEA EIKD AD
3PNL      D V I D K
pneumoniae  E        V      DD            RG   T L  K  G  A     L         T LLHESGIK TTVVVD  VAVKDSLYTAGR  VAN V IE LV AA ERGDS EACAELGRR
                                                               1UN9      
190 200 210 220 230 240
1 N9 A SNTFS A HL QETDAAPRHHPGHA M P ASV DTQNSAQV N V KL
HUMAN V M S S S V MATA E K
RAT IA A G L VS PCS .GT T E AAD M L L G A V I LVPVDQIV LMLDHM
LL  VVKNIKT L S A EV G V D I Y S YR EKMKTSYELAT LVGK
3PNL      Q K A N P
pneumoniae         G  L     P              E G GIH E G                    LNNLGHSI IA GACTV AAGQPSFTLKDDEM F V   G P IDRRRFSSLDQTVDEMFDTL
                                                               1UN9      
250 260 270 280
1 N9 LAALP ETGR.......LAV I V VA MA TRELAS PL
HUMAN N T A QP M TV S
RAT TDTSN ISHVPVKS SSVVLM NL GLSFL LG IADAAIR E
LL  KE........................EFKFEA QKYGI GM M QFIFM DVAKLLT
3PNL      V S H F YQQ S EQ T QP S N TT Q
pneumoniae                                         N  G     E             LENGAYSRTLRQWDTVKGAWQEVKQSKTALQNGDRVIALV NL ATPLS LYGVYHRLAQRCE
                                                               1UN9      
290 300 310 320 330
1 N9 HSRIDWLIGPA.SLVT D K F AIVLE SIE ALLT VETSN ....TPVPP EITC
HUMAN I P I L T A NVAA I K S V
RAT GRGVKVARAL TF SALE R V LMLVDEPLLK IDAETNA AWPHMSKVSV GRNRIRA
LL  EENIE LFKKV N M I A L L MI LE D.QW KNLNEDVKTIS ...L TIDT
3PNL      QA LT A T A KGS S
pneumoniae                    M G S T                                     ASGIIIERNLIGSYCTSLD S F I LLKVDDETLTLWDAPVHTPALNWG..NSLNRTQ....
                                                               1UN9      
340 350 360 370 380 390
1 N9 VSSHASARVEFQPS... NALV GIV L TA SD T AKV T S FAA E
HUMAN A Q DS S R A E VCS L T R
RAT APTEPAEAPEATAAGGVASKQMTLV DRISTTLIGLEEH NA RAA C STHS AAKAI
LL  TIE GKFNEKIQENKA SE GP G A A M ET
3PNL      N T ST EY R N
pneumoniae                                        L  LD   GD D G          .....................IVDWLYRCGDIFTKESDF TG  KEI  A H LNMHRGFSKV
                                          ..            ...    1UN9      
400 410 420 430 440 450
1 N9 ASL HRQQL LNNL T FALIGER TVV V MSI F G K EQGANV...VE L
HUMAN E P L K S
RAT QGW KEGPTPAS.PAQVLS LSVL LE M S A LFLT AAQPLKANT LPAWSAAM
LL  MKA E VSNFGNVSE F KVA M K Y SA L.. MSKT IET DTS ...I
3PNL      A S A R E Q F
pneumoniae    L                    L    GG SG L        A                  VEK P..SIADKDIGFILKNTGMT LSNV  A  P FGTFFIRA QVTQAHQSLTLDELYLMI
                                                               1UN9      
460 470 480 490 500 510
1 N9 NT AQ KF G DE I A QP LTS L QPK...N QAAFDA QAG RTCLSS ...
HUMAN E G D Q
RAT D K M Y AP DR L SLW AAQE AWKSPGASLLPVLTKAVKSA AAAE TKNME
LL  YA LEAIQK QV E V I SAFLND QTD ........... SKDNL KVVKASAGLL
3PNL      D IS V VE N VPV E SSI S QS
pneumoniae   G       G A  G  TM D        L                     E          RE ADGVVNR K EP DK  C VWLPVADS RQSSEQHLSIAAALDAACEVA RAAHATITMQ
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Figure 1.6. Sequence alignment of current available Dha kinase structures and some 
representative unpublished Dha kinases.  
C. freundii DAK, H. sapiens DAK (Q3LXA3) and Rat DAK (Q4KLZ6) (top three rows) represent the 
ATP-dependent DAK family, and their sequences have been divided into N-terminal (A) and C-
terminal domains (B) (represented by N- or C- in the front of the species name). The N- and C-terminal 
domains respectively are aligned with DhaK and DhaL from PEP-dependent DAK. Kinases from L. 
lactis, E. coli and Klebsiella. pneumoniae (bottom three rows) represent PEP-dependent DAK. 
Additionally, L. lactis represents Gram-positive bacteria, and E. coli and K. pneumoniae represent 
Gram-negative bacteria.  The region framed yellow is the disordered region of the C-terminal domain 
of C. freundii DAK. The region framed green is the extra β-ribbon and the TrpZip indicated with the 
green triangles, which has been reported only present in Gram-negative bacteria Dha kinase. The blue 
triangle indicates the charged residues of the edge strand, which is only present in Gram-positive 
bacteria Dha kinase. The black stars indicate the residues that are involved in the kinase activity. 
Strictly conserved residues have a red background with white letters. Sequence alignment was done 
with Clustal W (Larkin et al., 2007) and the picture was generated with ESPript (Gouet et al., 2003).  
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1UN9             N           G                                 VA  SGGGSG.ASQFFF QRTHLVSDVID AIIASPWNNLARLESDPAIRIVVRRDLN..KNN  VI      
HUMAN            N           G                                 VA  SGGGSGMTSKKLV SVAGCADDALA LVACNPN.....LQLLQGHRVALRSDLDSLKGR  LL      
RAT              N           G                                 VA  SGGGSGMSSKKMV SVEGCAGDALA FVACNPD.....LQLLQGYRVALRSDLDSLKGR  LL      
LL               N           G                                 VA  SGGGSGMSDEKII QPQDVVSEMLD LTYAYGD......LIEKVPDFEIIQRKSPKSGK  LV      
3PNL             N           G                                 VA  SGGGSG.GSKKLI DVQDVLDEQLA LAKAHPS......LTLHQDPVYVTRADAPVAGK  LL      
pneumoniae        N           G                                 VA  SGGGSG...KKLI RVEDVLNEQLQ LAKAHPQ......LTLHQDPLYVTRTDAPVAGK  LL      
                                                               1UN9      
        70        80        90         100       110       120 
1UN9      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A V FI K   TAAVC DV A  SVDAVLTAIQAVT..GEA C   V   T  RL  GL 
HUMAN     H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A A FI K   TGVIA AV T  AVGSILAAIRAVAQAGTV T   V   T  RL  GL 
RAT       H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A A FI K   TGVIA AV A  AVGSILAAIRAVAQAGTA T   V   T  RL  GL 
LL        H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A K A A FV E   SAAVC AI T  TPDQIYEAIKSAD..EGA V   I   L  VM  EM 
3PNL      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKIFECAMQVD..GGE V   I   T  IL  ET 
pneumoniae H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKMFECAMQID..GGE V   I   T  IL  ET 
                                                               1UN9      
      130       140          150       160       170       180 
1UN9       E        V      DD            RG   T L  K  G  A     L         A KARRLGYN EMLIVG  ISLPD.NKHP..  IAG I VH IA YF ERGYN ATVLREAQY
HUMAN      E        V      DD            RG   T L  K  G  A     L         R QARAEGIP EMVVIG  SAFTV.LKKAGR  LCG V IH VA AL EAGVG EEIAKQVNV
RAT        E        V      DD            RG   T L  K  G  A     L         M QAKAEGIS EMVVIE  SAFTV.LKKAGR  LCG I IH VA AL EEGMG EEITKKVSV
LL         E        V      DD            RG   T L  K  G  A     L         R MAEMEEIK EQIIVD  IAVENSLYTQGR  VAG V VH IL AA HQEAS DEIKDLADK
3PNL       E        V      DD            RG   T L  K  G  A     L         T LLHDSGVK TTVVID  VAVKDSLYTAGR  VAN V IE LV AA ERGDS DACAELGRK
pneumoniae  E        V      DD            RG   T L  K  G  A     L         T LLHESGIK TTVVVD  VAVKDSLYTAGR  VAN V IE LV AA ERGDS EACAELGRR
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1UN9              G  L     P              E G GIH E G                    AASNTFSL VA SSCHL QETDAAPRHHPGHA L M   G P ASVIDTQNSAQVVNLMVDKL
HUMAN             G  L     P              E G GIH E G                    VAKAMGTL VS SSCSV .GSKPTFELSADEV L L   G A VRRIKMATADEIVKLMLDHM
RAT               G  L     P              E G GIH E G                    IAKAIGTL VS SPCSV .GTKPTFELAADEM L L   G A VRRIKLVPVDQIVTLMLDHM
LL                G  L     P              E G GIH E G                    VVKNIKTI LA SAATV EVGKPGFVLDDNEI Y V   S P YRREKMKTSYELATELVGKL
3PNL              G  L     P              E G GIH E G                    LNNQGHSI IA GACTV AAGKPSFTLADNEM F V   G P IDRRPFSSLDQTVDEMFDTL
pneumoniae         G  L     P              E G GIH E G                    LNNLGHSI IA GACTV AAGQPSFTLKDDEM F V   G P IDRRRFSSLDQTVDEMFDTL
                                                               1UN9      
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1UN9                                              N  G     E             LAALP...................ETGR.......LAVMI NL GVSVA MAIITRELASSPL
HUMAN                                             N  G     E             TNTTN...................ASHVPVQPGSSVVMMV NL GLSFL LGIIADATVRSLE
RAT                                               N  G     E             TDTSN...................ISHVPVKSGSSVVLMV NL GLSFL LGIIADAAIRLLE
LL                                                N  G     E             KE........................EFKFEAGQKYGILV GM ATPLM QFIFMNDVAKLLT
3PNL                                              N  G     E             LVNGSYHRTLRFWDYQQGSWQEEQQTKQPLQSGDRVIALV NL ATPLS LYGVYNRLTTRCQ
pneumoniae                                         N  G     E             LENGAYSRTLRQWDTVKGAWQEVKQSKTALQNGDRVIALV NL ATPLS LYGVYHRLAQRCE
                                                               1UN9      
     290        300       310       320           330         
1UN9                         M G S T                                     HSRIDWLIGPA.SLVTALD K F L AIVLEESIEKALLTEVETSNWP....TPVPPREITCV
HUMAN                        M G S T                                     GRGVKIARALVGTFMSALE P I L LLLVDEPLLKLIDAETTAAAWPNVAAVSITGRKRSRV
RAT                          M G S T                                     GRGVKVARALVGTFMSALE R V L LMLVDEPLLKLIDAETNAKAWPHMSKVSVTGRNRIRA
LL                           M G S T                                     EENIEILFKKVGNYMTSID A L L MIKLEDD.QWLKNLNEDVKTISWG...LLTIDT....
3PNL                         M G S T                                     QAGLTIERNLIGAYCTSLD T F I LLKVDDETLALWDAPVHTPALNWGKGSSLSRTQ....
pneumoniae                    M G S T                                     ASGIIIERNLIGSYCTSLD S F I LLKVDDETLTLWDAPVHTPALNWG..NSLNRTQ....
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HUMAN                                            L  LD   GD D G          APAEPQEAPDSTAAGGSASKRMALVLERVCSTLLGLEEH NA  RAA  G C TTHSRAARAI
RAT                                              L  LD   GD D G          APTEPAEAPEATAAGGVASKQMTLVLDRISTTLIGLEEH NA  RAA  G C STHSRAAKAI
LL                                               L  LD   GD D G          .....................TIEWLGKFNEKIQENKAY SE  GPI  G H ANMARGMSET
3PNL                                             L  LD   GD D G          .....................IVNWLTRCGDIFSTESEY TG  REI  A H LNMNRGFSKV
pneumoniae                                        L  LD   GD D G          .....................IVDWLYRCGDIFTKESDF TG  KEI  A H LNMHRGFSKV
                                          ..            ...    1UN9      
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1UN9         L                    L    GG SG L        A                  ASL HRQQLPLNNLATLFALIGER TVVM  S  V MSIFFT.. AGQKLEQGANV...VEAL
HUMAN        L                    L    GG SG L        A                  QEW KEGPPPAS.PAQLLSKLSVL LEKM  S  A YGLFLT.. AAQPLKAKTSLPAWSAAM
RAT          L                    L    GG SG L        A                  QGW KEGPTPAS.PAQVLSKLSVL LEKM  S  A YGLFLT.. AAQPLKANTDLPAWSAAM
LL           L                    L    GG SG L        A                  MKA E..VSNFGNVSEIFKKVAMT MSKV  A  P YGSAFL.. MSKTAIETLDTSEL...I
3PNL         L                    L    GG SG L        A                  VEK P..AIADKDIGFILKNTGMT LSSV  A  P FGTFFIRA QATQARQSLTLEELYQMF
pneumoniae    L                    L    GG SG L        A                  VEK P..SIADKDIGFILKNTGMT LSNV  A  P FGTFFIRA QVTQAHQSLTLDELYLMI
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HUMAN       G       G A  G  TM D        L                     E          DA LEAMQKY K AP DR  L SLWAAGQE QAWKSPGADLLQVLTKAVKSA AAAEATKNME
RAT         G       G A  G  TM D        L                     E          DA LKAMQKY K AP DR  L SLWAAAQE QAWKSPGASLLPVLTKAVKSA AAAEATKNME
LL          G       G A  G  TM D        L                     E          YA LEAIQKR K QV EK  V IWSAFLND QTDS...........ASKDNL KVVKASAGLL
3PNL        G       G A  G  TM D        L                     E          RD ADGVISR K EP DK  C VWVPVVES RQSSEQNLSVPVALEAASSIA SAAQSTITMQ
pneumoniae   G       G A  G  TM D        L                     E          RE ADGVVNR K EP DK  C VWLPVADS RQSSEQHLSIAAALDAACEVA RAAHATITMQ
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HUMAN N T A QP M TV S
RAT TDTSN ISHVPVKS SSVVLM NL GLSFL LG IADAAIR E
LL  KE........................EFKFEA QKYGI GM M QFIFM DVAKLLT
3PNL      V S H F YQQ S EQ T QP S N TT Q
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1 N9             N           G                                 VA  SGGGSG.ASQFFF QRTHLVSDVID AIIASPWNNLARLESDPAIRIVVRRDLN..KNN  VI      
HUMAN            N           G                                 VA  SGGGSGMTSKKL  VA D LA L PN..... L H V G   LL      
RAT              N           G                                 VA  SGGGSGSKKMV SVEGCAGDALA FVACNP .....LQLLQGYRVALRSDLDSLKGR  LL      
LL         N           G                                 VA  SGGGSGMSDEKII QP DVVSEMLD LTYAYGD......LIEKVPDFEIIQRKSPKSGK  LV      
3PNL      GS D Q D A S V A
pneumoniae        N           G                                 VA  SGGGSG...KKLI RVEDVLNEQLQ LAKAHPQ......LTLHQDPLYVTRTDAPVAGK  LL      
               1UN9      
        70        80        90         100       110       120 
1 N9      H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A V FI K   TAAVC DV A  SVDAVLTAIQAVT..GEA C   V   T  RL  GL 
HUMAN     H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E A A FI    G  A  T  I AI V G V       T  L   
RAT       H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E   I K   TGVIA V A  AVGSILA RAVAQAGT  T   V   T  RL  GL 
LL  H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A K A A FV E   SAAVC AI T  TPDQ YEAIKSAD..EGA V   I   L  VM  EM 
3PNL      I V
pneumoniae H P H G  G GML     G  F SP                  G LLI KNY GD  NF  A E M C YI Q   SGACP EI T  TPDKMFECAMQID..GGE V   I   T  IL  ET 
                  1UN9      
      130       140          150       160       170       180 
1 N9       E        V      DD            RG   T L  K  G  A     L         A KA RLGYN EMLIV   ISLPD.NKHP..  IAG I VH IA YF ERGYN ATVLREAQY
HUMAN      E        V      DD            RG   T L  K  G  A     L         R AR EGIP E VVIG  A L AGR  G V IH  A  EAGV  EIA Q N
RAT        E        V      DD            RG   T L  K  G  A     L         M Q KA GIS MVVIE  SAFTV.LKKAGR  LC  I I  VA AL EEGMG E TKKVSV
LL   E        V      DD            RG   T L  K  G  A     L         R MAEMEEIK EQIIVD  IAVENSLYTQGR  VAG V VH IL AA HQEAS EIKDLAD
3PNL      D V I D K
pneumoniae  E        V      DD            RG   T L  K  G  A     L         T LLHESGIK TTVVVD  VAVKDSLYTAGR  VAN V IE LV AA ERGDS EACAELGRR
                  1UN9      
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1 N9              G  L     P              E G GIH E G                    AASNTFSL VA S CHL QETDAAPRHHPGHA L M   G P ASVIDTQNSAQVVNLMVDKL
HUMAN             G  L     P              E G GIH E G                    V K M T   SSC V SKP F LS EV     G  RR KMATADE VK M D
RAT               G  L     P              E G GIH E G                    IA A G L VS PCSV .GTKPTFELAADEM L L   G A V RI LVPVDQIV LMLDHM
LL          G  L     P              E G GIH E G                    VVKNIKTI LA SAATV EVG PGFVLDD EI Y V   S P YRREKMKTSYELATELVGKL
3PNL      Q K A N P
pneumoniae         G  L     P              E G GIH E G                    LNNLGHSI IA GACTV AAGQPSFTLKDDEM F V   G P IDRRRFSSLDQTVDEMFDTL
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LL  EEN E LFKKV N M I A L L MI LE D.QW KNLNEDVKTIS .L TIDT
3PNL      QA LT A T A KGS S
pneumoniae                    M G S T                                     ASGIIIERNLIGSYCTSLD S F I LLKVDDETLTLWDAPVHTPALNWG..NSLNRTQ....
                1UN9      
340       350          360       370       380       390         
1 N9                                             L  LD   GD D G          VSSHASARV FQPS... NALV GIV L TA SD T    AKV  G T FAA E
HUMAN                                            L  LD   GD D G          A Q DS S R A LERVCS L E    R     T R R
RAT                                        L  LD   GD D G          APTEPAEAPEATAAGGVASKQMTLVLDRISTTLIGLE H NA  AA   C STHSRAAKAI
LL  TIE GKFNEKIQENKA SE GP G A A M ET
3PNL      N T ST EY R N
pneumoniae                                        L  LD   GD D G          .....................IVDWLYRCGDIFTKESDF TG  KEI  A H LNMHRGFSKV
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3PNL      A S A R E Q F
pneumoniae    L                    L    GG SG L        A                  VEK P..SIADKDIGFILKNTGMT LSNV  A  P FGTFFIRA QVTQAHQSLTLDELYLMI
                  1UN9      
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1 N9        G       G A  G  TM D        L                     E          NT LAQ KF  G DE   I A QP LTS L QPK...N QAAFDA QAG  RTCLSS ...
HUMAN       G       G A  G  TM D        L                     E            K P D    G  D Q L A A AA T M
RAT   G       G A  G  TM D        L                     E          D  K M Y K AP DR  L SLW AAQE AWKSPGASLLPVLTKAVKSA AAAEATKNME
LL  YA LEAIQK QV E V I SAFLND QTD ........... SKDNL KVVK SAGLL
3PNL      D IS V VE N VPV E SSI S QS
pneumoniae   G       G A  G  TM D        L                     E          RE ADGVVNR K EP DK  C VWLPVADS RQSSEQHLSIAAALDAACEVA RAAHATITMQ
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1.1.4   Structural features of DAKs 
In 2003, the first crystal structure of an ATP-dependent DAK from C. freundii was 
published (Siebold et al., 2003b). This structure revealed a novel folding and domain 
configuration, which is distinct from any other kinases of known structure (Cheek et 
al., 2005). As described above, this protein comprises two domains, which are 
separated by a 30 residue extended linker, and it is assembled as a stable intertwined 
homodimer, i.e. the domains are swapped such that the N-terminal domain of one 
subunit interacts with the C-terminal domain of the other subunit, with the result that 
the two N-terminal domains are gripped by the two C-terminal domains (Figure 1.7). 
The N-terminal substrate-binding domain consists of two α/β regions, which both 
contain six β-strands surrounded by either six or three α-helices, forming two three-
layered mixed α/β sandwiches (Figure 1.8). As the name suggests, this domain is 
responsible for Dha binding and the Dha binding site of this domain occupies a cavity 
between the two α/β regions, which is close to the bottom of the C-terminal domain of 
its homodimer. The C-terminal nucleotide-binding domain is comprised of eight anti-
parallel α-helices which fold with a regular up and down topology, forming a conical 
shaped barrel with a deep hydrophobic interior pocket, which is filled with a 
phospholipid molecule (Figure 1.8). The nucleotide binding-site is located at the 
narrow bottom of the helix barrel, and two Mg2+ ions were determined to coordinate 
with the three phosphates of ANP. In addition, a loop (Asn516-Leu528) between helix 
7 and 8 of the C-terminal domain is disordered, and is assumed to be a flexible cap 
that sits over the nucleotide-binding site, a notion that is supported by the structure of 
E. coli DhaL with which the protein shares high sequence homology in this region 
(Figure 1.6). (Siebold et al., 2003a; Oberholzer et al., 2006).  
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Figure 1.7. The current available DAK structures from different organisms.  
Cartoon representations of known DAK structures with ligands shown as spheres: C. freundii DAK in 
complex with Dha, ANP and Mg2+ (1UN9) (Siebold et al., 2003a); DhaK and DhaL complex from E. 
coli in complex with Dha, ADP and Mg2+ (3PNL) (Shi et al., 2011); DhaM and DhaL complex from L. 
lactis in complex with ADP and Mg2+ (3CR3) (Zurbriggen et al., 2008) and L. lactis DAK in complex 
with Dha (3CT4) (Zurbriggen et al., 2008). 
 
Figure 1.8. Structure of the separated N and C-terminal domains of the C. freundii DAK (1UN9) 
(Siebold et al., 2003a).  
In the N-terminal domain, the α-helices from the first α/β region are shown as violet cylinders, and 
aquamarine cylinders represent the second α/β region. The β-sheets in both regions are represented in 
rainbow colors. In the C-terminal domain, α-helices are shown as rainbow colored cylinders. The 
dashed line represents the disordered region in the C-terminal domain. Dha (yellow), ANP (yellow), 
phospholipid (violet) and two Mg2+ ions (green) are shown in spheres.  
C. freundii DAK (1UN9)  E. coli DhaK and DhaL complex (3PNL) 
L. lactis DhaM and DhaL complex (3CR3)  L. lactis DhaK (3CT4) 
 N-terminal domain of C. freundii DAK  C-terminal domain of C. freundii DAK  
!"
!"
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So far, the C. freundii DAK is the only published ATP-dependent DAK structure. On 
the other hand, crystal structures of the different subunits or complexes of PEP-
dependent DAK from E. coli and Lactococcus lactis have been reported in recent 
years (Figure 1.7) (Shi et al., 2011; Zurbriggen et al., 2008). DhaK and DhaL subunits 
of both organisms are homologous to the N and C-terminal domains respectively of 
the ATP-dependent C. freundii DAK. The topologies of the corresponding 
subunit/domain are very similar to each other. The results of the superimposing of the 
corresponding domains and subunits from these three organisms are shown in Table 
1.1.  
 R.M.S.D NO. of Cα atoms Seq. Identity 
N-C. freundii DAK/ E. coli DhaK 1.32Å 287 35% 
N-C. freundii DAK/ L. lactis DhaK 1.31Å 305 38% 
E. coli DhaK/ L. lactis DhaK 0.95Å 301 46% 
C-C. freundii DAK/ E. coli DhaL 1.77Å 166 25% 
C-C. freundii DAK/ L. lactis DhaL 1.92Å 161 24% 
E. coli DhaL/ L. lactis DhaL 1.77Å 185 35% 
Table 1.1. Comparison of the current available DAK structures in terms of their overall 
structural similarity and percentage sequence identity.  
C. freundii DAK (1UN9) (Siebold et al., 2003a), N-C. freundii DAK represent N-terminal C. freundii 
DAK and C-C. freundii DAK represent C-terminal C. freundii DAK; E. coli DhaK (1OI2) (Siebold et 
al., 2003b); L. lactis DhaK (3CT4) (Zurbriggen et al., 2008); E. coli DhaL (2BTD) (Oberholzer et al., 
2006) and L. lactis DhaL (3CR3) (Zurbriggen et al., 2008). 
There is an extra β-ribbon containing a tryptophan zipper (TrpZip) in E. coli DhaK 
subunit but not in the N-terminal domain of C. freundii DAK and L. lactis DhaK. The 
β-ribbon is inserted between the first α-helix and the second β-strand of the second 
α/β regions, and covers the edge β-strand of the first β-sheet of E. coli DhaK (Figure 
1.9) (Siebold et al., 2003b). It is present only in DhaK of Gram-negative bacteria 
rather than in Gram-positive bacteria and ATP-dependent DAK. This is because the 
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corresponding edge β-strand has a negatively charged glutamic acid residue in both 
Gram-positive bacteria DhaK and ATP-dependent DAK (Figure 1.6). Both β-ribbons 
with TrpZip and edge strands with charged residues were reported to be able to 
protect against aggregation between the edge β-strand and other β-strands they 
encounter (Richardson and Richardson, 2002; Cochran et al., 2001). 
In addition, there is a third subunit of PEP-dependent DAK: the crystal structure of 
the homodimer DhaM from L. lactis was reported five years ago (PDB code: 3CT6) 
(Zurbriggen et al., 2008). The structure comprises a central four-stranded β-sheet that 
is flanked by three and two α-helixes on each side. The four anti-parallel β-strands 
alternate with four α-helixes and the fifth helix forms a helical hairpin with the fourth 
helix, giving a (βα)4α secondary structure arrangement (Zurbriggen et al., 2008).  
The complex structure of the E. coli DhaK with DhaL shows a very similar assembly 
to the C. freundii DAK. However, the binding interface between each subunit or 
domain are altered, bringing the substrate-binding site and the nucleotide binding site 
closer to each other in E. coli Dha kinase compared to C. freundii DAK (Figure 1.7). 
For the L. lactis Dha kinase, the complex structure of DhaL and DhaM also forms a 
dimer, in which the two DhaM subunits are sandwiched by two DhaL subunits. A 
homodimer of the L. lactis DhaK structure shows similar packing to the other 
corresponding subunits/domain (Figure 1.7). 
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Figure 1.9. Structure of DhaK of E. coli (3PNL) (Shi et al., 2011).  
The first α/β region is shown in violet, the second α/β region is shown in aquamarine, and 
corresponding to the coloring of the N-terminal domain of C. freundii DAK in figure 1.8. The extra β-
ribbon is shown in red and the TrpZip (yellow) shown in spheres and sticks.  
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1.1.5   The potential catalytic mechanism for DAKs 
After more structures and research based on DAK from different organisms have been 
published, a three-step catalytic mechanism of E. coli DhaK-DhaL has been proposed 
(Figure 1.10) (Shi et al., 2011). The first step was defined as the formation of the 
covalent intermediate between DhaK and Dha by a nucleophilic addition reaction. 
The nucleophilic, deprotonated NE2 atom of His218K (superscript K represent DhaK) 
attacks the electrophilic carbonyl Cβ atom of Dha. Subsequently, the protonated 
His56K acts as a proton donor, transfering its proton to the negatively charged Oβ of 
Dha forming the β-OH moiety of “Dha” (Figure 1.10a). The second step is the 
phosphoryl transfer. In order that the γ-phosphoryl atom of ATP could successfully 
attack the γ-OH of “Dha”, a target oxyanion at Cγ must be formed. Therefore, the γ-
OH first transfers its proton to Asp109K (the only residue within hydrogen bonding 
distance to γ-OH). As the location of the phosphoryl transfer is mainly negatively 
charged, positively charged groups are required to stabilize the reaction. Indeed, 
Arg178L (superscript L represent DhaL) is within hydrogen bonding distance to γ-OH 
of “Dha” and it is also the only positively charged residue near the negative charges 
surrounding the γ-phosphoryl group of ATP. Therefore, Arg178L coordinates with one 
of the Mg2+ ions to perform the role of stabilizing the γ-phosphoryl group of ATP 
during the phosphoryl transfer. Moreover, the importance of Asp109K and Arg178L 
are supported by mutagenesis studies in which substitution at these positions 
inactivates the enzyme (Figure 1.10b). The final step is DhaP release from DhaK, 
which can be considered as the first step of the reverse reaction. His56K abstracts the 
proton from the β-OH of DhaP, which results in the formation of the carbonyl group 
at Cβ and is followed by breakage of the covalent bond between DhaP and NE2 of 
His218K (Figure 1.10c) (Shi et al., 2011). Moreover, sequence alignment shows that 
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the residues His56K, His218K, Arg178L and Asp109K from E. coli DAK are conserved 
in both bacterial and eukaryotic DAK (Figure 1.6), suggesting that all DAKs may 
share a common catalytic mechanism.  
 
Figure 1.10. Proposed catalytic mechanism for the Dha kinase.  
(a). Initial interaction between kinase and Dha. (b). Phosphoryl transfer from donor to Dha, leading to 
the formation of DhaP. (c). DhaP release from kinase. Adapted from a previously published enzymatic 
mechanism of E. coli DhaK-DhaL (Shi et al., 2011). 
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1.1.6   Immunology function of H. sapiens DAK 
In 2007, Diao et al. reported that H. sapiens DAK could interact with MDA5 under 
physiological conditions, leading to an inactive state of MDA5 in normal cells (Diao 
et al., 2007). 
MDA5 is a member of RIG-I-like receptor (RLR) family, which also contains another 
two family members, namely retinoic acid-inducible gene 1 (RIG-I) and Laboratory 
of genetics and physiology 2 (LGP2). This family is demonstrated to participate in 
distinguishing foreign nucleotides in the cytoplasm, and elicits signalling pathways 
that eventually result in activation of type I interferon (IFN) and NF-κB, which are 
important for evoking an innate immune response in the body (Yoneyama et al., 
2004). MDA5 specifically recognizes long double stranded RNA (>1kb) while RIG-I 
selectively detects short double stranded RNA (<1kb) and single stranded RNA with a 
5’triphosphate group (Kato et al., 2008). 
It has been reported that H. sapiens DAK specifically negatively regulates MDA5-
mediated (but not RIG-I-mediated) antiviral signalling. It is proposed that H. sapiens 
DAK binds to MDA5 N-terminal tandem caspase activation recruitment domains 
(CARD) via its N-terminal domain in the absence of viral stimulation, and that the 
complex separates upon virus infection due to changes in the conformation of MDA5 
(Diao et al., 2007; Takeuchi and Akira, 2009). However, the molecular mechanism of 
how H. sapiens DAK specifically inhibits MDA5 rather than RIG-I is still unclear and 
requires detailed structural studies. At present, no crystal structure of the dual CARD 
domain of MDA5 is available. Therefore, it is of great interest to explore the crystal 
structure of the dual CARD and/or its complex with H. sapiens DAK. 
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1.1.7   Project aims 
The original aim of the project was to determine the crystal structure of H. sapiens 
DAK and its complex with the dual CARD of MDA5 from H. sapiens. The structure 
of WT H. sapiens DAK and the ligand-bound mutated H. sapiens DAK have been 
revealed in the current study, which will be described in Chapter 2 and Chapter 3. 
Unfortunately, it was not possible to form crystals of the H. sapiens DAK in complex 
with the dual CARD of MDA5. Therefore, for further investigation, more associated 
studies between the two proteins are essential. 
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1.2  Introduction to the Streptococcus pneumoniae sialidase A (NanA) 
carbohydrate-binding module (CBM)  
S. pneumoniae is a Gram-positive, alpha-hemolytic bacterium and is also recognized 
as a major human pathogen that habitually colonizes the upper respiratory tract 
(predominantly in the nasopharynx) asymptomatically, and can spread to other organs 
under appropriate conditions. The bacterium causes millions of deaths annually by 
pneumonia, otitis media, bacteraemia, meningitis and haemolytic uraemic syndrome 
(O'Brien et al., 2009; Mitchell, 2003; Janapatla et al., 2013). To date, numerous 
antimicrobial drugs have been developed, however, the mortality and morbidity 
caused by S. pneumoniae infections is still high and it appears that more and more 
pneumococcal strains are resistant to antibiotics, especially in regions of high 
antibiotic use (Peterson, 2006). Therefore, a better understanding of the association 
between pneumococcus and the host cells would be essential for developing novel 
drugs. 
Multivalent capsular polysaccharide vaccines have been widely used for 
pneumococcal disease in recent years, however, the efficacy in high-risk patients 
group is unproven (Butler et al., 1993). It has been identified that there are a number 
of virulence factors that are produced by pneumococci and play critical roles in the 
pathogenesis of infections (Tettelin, 2001; Bergmann and Hammerschmidt, 2006). 
One such common virulence factor, sialidase (also called neuraminidase), has been 
reported to exist in all S. pneumoniae strains and it is capable of catalysing the 
removal of terminal sialic acids from host cell surface glycans. It can damage the host 
cells and alter their glycosylation patterns, leading to more exposure of the host cell 
surface, thereby unmasking potential receptors and facilitating the interaction of the 
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bacteria with the host cell (Kelly et al., 1967; Taylor, 1996). Therefore, sialidases 
could be a potential target for development of novel anti-pneumococci drugs or 
vaccines. 
1.2.1   Sialidases produced by S. pneumoniae 
Sialidases (EC 3.2.1.18) are a superfamily of well-studied glycoside hydrolases, 
which catalyse the hydrolysis of the glycosidic bond to release sialic acid from 
carbohydrate groups of oligosaccharides, glycolipids and glycoproteins on different 
cells (Taylor, 1996). Untill now, 224 types of sialidase have been recorded in the 
SWISS-PROT protein sequence database, which shows sialidases are widely 
distributed in a variety of species in nature (Bairoch and Apweiler, 2000).  
To date, S. pneumoniae has been reported to encode at least three distinct sialidases, 
namely NanA (UniProt: P62575), NanB (Q54727) and NanC (Q97Q99) (Cámara et 
al., 1994; Berry et al., 1996; Xu et al., 2008a). Gene screening studies done by 
Pettigrew et al. showed that the NanA gene is present in all clinical isolated strains, 
NanB gene is present in 96% and NanC gene is identified in 51% of these strains 
(Pettigrew et al., 2006). Functional and structural analysis of these three sialidases 
indicated that they have distinct but cooperative roles in S. pneumoniae infections. 
Generally speaking, NanA acts as a typical exosialidase anchored to the bacterial cell 
outer membrane and performs as a initial virulence factor that is responsible for 
colonization of pneumococci on the nasopharynx by catalysing the removal of N-
acetylneuraminic acid (Neu5Ac) from a range of substrates, including α2,3-, α2,6-, 
and α2,8-linked sialic acids (Xu et al., 2011; Xu et al., 2008b). Indeed, NanA has 
been shown to play a vital role in pneumococcal infection of the nasopharynx and 
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sepsis (Manco et al., 2006), and was recently found to enhance blood-brain barrier 
(BBB) penetration (Uchiyama et al., 2009). NanB is an intramolecular (IT) trans-
sialidase, which indicates it may be involved in providing a nutritional source for the 
metabolic use of bacteria (Xu et al., 2011). NanB was shown to release 2,7-anhydro-
Neu5Ac rather than Neu5Ac, and has a preference for α2,3-linked sialic acids over 
α2,6 and α2,8 linkages (Xu et al., 2008b). NanC, which is a homolog of NanB, may 
act as a regulator for NanA and/or NanB as it can both produce and hydrate 2-deoxy-
2, 3-didehydro-Neu5Ac (DANA/Neu5Ac2en, a general sialidase inhibitor) from α2,3-
linked sialic acids at different phases of pneumococcal infection (Xu et al., 2008b; Xu 
et al., 2011). Moreover, a recent publication determined that NanC plays a critical role 
in haemolytic uraemic syndrome, a severe complication of invasive pneumococcal 
disease (Janapatla et al., 2013). Furthermore, it has been reported that the pH optima 
of each of the three sialidases are distinct: pH6.5-7.0 for NanA, pH4.5-5.0 for NanB 
and pH5.0-6.0 for NanC (Cámara et al., 1994; Berry et al., 1996). Studies using 
inactivation mutants of NanA and NanB in infected mice showed that neither sialidase 
is able to compensate for the absence of the other (Manco et al., 2006). Therefore, all 
the above suggests that these three forms of sialidase have their own distinct 
preferences for different conditions, which may be critical for pneumococcal 
colonization and infection, especially in the alternative environments of the host.  
The molecular masses of NanA, NanB and NanC are 115kDa, 78kDa and 82kDa, 
respectively. Sequence alignment of these three sialidase shows that NanA shares no 
more than 22% amino acid sequence identity with NanB and NanC, while NanB and 
NanC share 48% sequence identity as they are close homologs. Further analysis of the 
sequence shows that they have a very similar domain arrangement (Figure 1.11). They 
all possess an N-terminal signal peptide, which exports the sialidases from the cells 
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(Cámara et al., 1994). A typical carbohydrate-binding module 40 (CBM40, as defined 
by the CAZy database) domain is present downstream of the signal peptide and is 
assumed to recognize and bind sialic acid as seen in some other sialidases, such as 
Vibrio cholerae sialidase and Clostridium perfringens sialidase (Moustafa et al., 
2004; Boraston et al., 2007). In the C-terminus, a catalytic domain is present in all the 
three sialidases, which is of course responsible for removal of the sialic acid from the 
host cells. In addition, the key residues that are involved in sialic acid catalysis are 
conserved in these enzymes. Within the catalytic domain, an extra inserted domain 
with unknown function was shown to be present in these sialidases. This kind of 
inserted domain was previously reported only from C. perfringens and Marobdella 
decora, with no other structurally homologous domain being reported so far 
(Newstead et al., 2008; Luo et al., 1999). Moreover, as the only surface-anchored 
sialidase in S. pneumoniae, NanA has an additional C-terminal domain of over 200 
residues, which is responsible for tethering NanA to the bacterial surface via its 
“LPETGN” anchoring motif in the end of this region. This domain also has 
proline/glycine and threonine/serine rich regions, which may make NanA extremely 
flexible on the surface of pneumococci and therefore facilitate the interaction between 
bacteria and host cells (Cámara et al., 1994).  
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Figure 1.11. The schematics of the three S. pneumoniae sialidases.  
The sequences of NanA, NanB and NanC were annotated via bioinformatics searches. Signal peptide 
domain is shown in yellow, CBM40 domain is shown in green, catalytic domain is shown in blue, 
inserted domain is shown in red, the extra C-terminal domain in NanA is shown in gray and the 
“LPETGN” anchor motif is shown in orange. 
To date, the crystal structures of NanB (residues 39-696) and the catalytic domain 
(residues 322-791) of NanA, either without ligands or in complex with substrate 
analogues and inhibitors have been reported (Xu et al., 2008b; Xu et al., 2008a; Gut 
et al., 2011). However, no structure of NanC has been determined. Similar to the 
previously reported sialidases, both catalytic domains of NanA and NanB exhibit a 
classic six-bladed β-propeller fold, which forms a core catalytic cavity that acts as the 
substrate-binding site. Within each β-propeller, four anti-parallel β-strands are 
arranged such that they span from the central tunnel to the outside of the domain. 
Each β-propeller is connected by a winding loop, which links the fourth β-strand to 
the first β-strand of its adjacent sheet (Figure 1.12). Additionally, the inserted domain 
(83 residues for NanA and 97 residues for NanB) is present between the second and 
third β-strands of the second blade, where it forms a distinct domain adjacent to the β-
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propeller motif of the catalytic domain (Figure 1.12). Superimposition of the two 
catalytic domains gives an r.m.s.d of 1.79Å for 376 Cα atoms. The CBM40 domain of 
NanB forms a typical β-sandwich topology (Figure 1.12). Further details about 
CBM40 are described in the following section and in Chapter 4. 
 
Figure 1.12. The current available sialidase structures of S. pneumoniae.  
Top: Cartoon presentation of NanA catalytic domain structure in complex with Neu5Ac2en 
(PDB:2VVZ) (Xu et al., 2008a). Bottom: NanB structure in complex with Neu5Ac2en (PDB:2VW1) 
(Xu et al., 2008b). CBM40 domain of NanB is shown in green, both β-propeller motifs of the catalytic 
domain are shown in blue and the inserted domains are shown in red. Neu5Ac2en is shown in spheres 
and sticks with yellow carbons. 
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1.2.2   Sialic acid- the substrate of sialidases 
Sialic acids are a large family of negatively charged nine-carbon backbone 
monosaccharides, which are usually located at the distal end of glycan chains and are 
richly present on glycoproteins and glycolipids of all animal species, or as a part of 
polysaccharides in some bacteria, while not normally existent in plants or prokaryotes 
(Kiefel and Itzstein, 2002; Angata and Varki, 2002).  
So far, more than 50 natural derivatives of sialic acids have been defined, which 
mainly consist of single or multiple structural modification such as O-acetylation, O-
lactonization, O-sulfation, O-phosphorylation, and O-methylation at C-4, C-5, C-7, C-
8 and/or C-9 positions (Angata and Varki, 2002). These derivatives of sialic acids are 
predominantly based on three basic sialic acid forms (Figure 1.13): Neu5Ac is the 
most well known sialic acid in human, and therefore it is usually referred to as “sialic 
acid”; N-glycolylneuraminic acid (Neu5Gc), which is expressed in many nonhuman 
mammals; another common deaminated sialic acid is 2-keto-3-deoxy-D-glycero-D-
galacto-nononic acid (KDN), which is more commonly found in lower vertebrates 
and microorganisms (Yu and Chen, 2007). Generally speaking, the sugar ring of most 
sialic acids adopt a 2C5 chair conformation in solution, and a variable glycerol side 
chain moiety extends from the C-6 of the sugar ring. It has been determined that two 
anomeric forms of sialic acid are present in nature. The α-anomer is formed when 
sialic acid is linked with other glycans, and is the ubiquitous form of sialic acid in 
nature. However, when dissolved in solution, about 98% of the free sialic acid forms 
the lower energy β-anomer configuration (Hori et al., 1988; Varki and Varki, 2007). 
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Figure 1.13. Diversity of the sialic acids with modifications at indicated positions.  
The nine carbon atoms of the sialic acid structure starts at the carboxylate carbon and continues around 
the chain. The structure of sialic acid is shown in its α-anomeric configuration. Based on the three 
common sialic acid forms, most of the modifications occur at position C4, 7, 8, 9 in nature. The 
molecules were drawn with ChemDraw (Li et al., 2004). 
In addition to the structural modification of sialic acid on its own, further diversity is 
achieved by the linkage to other sugars via the C2 position of sialic acid. Sialic acids 
can form α2, 3 linkages to galactose (Gal), N-acetylgalactosamine (GalNAc) and N-
acetylglucosamine (GlcNAc), or α2, 6 linkages to Gal and GalNAc, or α2, 8/ α2, 9 
linkages to other sialic acids (Figure 1.14). All of these linkages have been detected 
on human erythrocytes while both α2, 3-linked and α2, 6-linked sialic acids have been 
displayed on the apical membrane of epithelial cells. α2, 8- or α2,9- linked sialic acid 
homopolymers have been found in embryonic neural membranes and certain types of 
bacteria, such as the E. coli K1 strain (Kiefel and Itzstein, 2002; Ulloa and Real, 
2001; Kleene and Schachner, 2004).  
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Figure 1.14. Structure of the linkages of Neu5Ac to other glycans.  
(a) The α2, 3-linkages of Gal (R=OH), GalNAc (R=NHAc)  and GlcNAc (R=NHAc, with OH group at 
Cδ shown in green); (b) the α2,6-linkages of Gal and GalNAc; (c) the α2,8-linkages of Neu5Ac 
homopolymers. 
Such a wide distribution and structural diversity allows sialic acids to play very 
important roles in many physiological and pathological processes. For example, the 
strong negative charge of sialic acids can help the binding and transport of positively 
charged molecules (e.g. Ca2+), and also prevent cell aggregation via attraction and 
repulsion between cells and molecules (Traving and Schauer, 1998). Additionally, the 
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negative charge of sialic acid causes hydrophilicity on some sialic acid-rich cell 
surfaces, which is critical for the protective effect of mucous substances of the human 
body, such as on the surface of the eye or on mucous epithelia (Traving and Schauer, 
1998). Furthermore, it has been reported that large amounts of a variety of sialic acids 
are present in the human brain and human milk, which indicates that sialic acid may 
play roles in neuronal transmission in the central nervous system and infant nutrition 
(Wang and Brand-Miller, 2003). Moreover, as a terminal sugar on glycan chains, 
sialic acids also act as a protective shield to prevent the sub-terminal part of the 
molecule from being degraded by proteases (Traving and Schauer, 1998). In 
pathological processes, sialic acid can coat the host cell surface, acting as a mask that 
can limit the colonization of bacteria. In contrast, sialic acids also serve as receptors 
for certain types of pathogenic viruses and bacteria, such as influenza A viruses and S. 
pneumoniae (Suzuki et al., 2000). Also, the biosynthesis of sialic acid has been 
reported to occur in some pathogenic bacteria (e.g. Aliivibrio salmonicida), thus, they 
could mimic and evade the host immune system without activating the innate immune 
response (Gurung et al., 2013). Additionally, it has been shown that sialic acids also 
participate in other functions, such as glycan and membrane stabilization, organ 
development, biosignal transduction, cell differentiation, proliferation, and apoptosis. 
(Varki, 2010; Wang and Brand-Miller, 2003). 
In the last 20 years, research into sialic acids has intensified, due to the increase in the 
number and distribution of derivatives that have been discovered, particularly in areas 
of important biological processes and many severe diseases. Indeed, as the substrates 
of sialidases, sialic acids are absolutely crucial in the initial interaction between some 
pathogens and host cells. Therefore, novel drug design based on inhibition of this type 
of interaction is an active area of research. 
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1.2.3   The CBM family 
In 1986, CBMs were first reported as non-catalytic cellulose adsorption fragments 
distinct from the enzyme catalytic modules of some carbohydrate-active enzymes 
(Van Tilbeurgh et al., 1986). Two years later, in 1988, two groups published the 
characterization of CBMs and defined them as cellulose-binding domains (CBDs) as 
both of the modules bound crystalline cellulose as their initial ligand (Tomme et al., 
1988; Gilkes et al., 1988). Afterwards, an increasing number of modules in 
carbohydrate-active enzymes were reported. In addition to cellulose, various different 
kinds of carbohydrates (e.g. chitin, xylan, glucan etc.) have been revealed to bind to 
CBDs, and therefore, a reclassification of these non-catalytic sugar-binding modules 
with more inclusive terminology was proposed. Thus, since 1999, the more general 
term CBM is used to describe this class of module (Coutinho and Henrissat, 1999). To 
date, according to the Carbohydrate-Active Enzyme (CAZy) database, over 30,000 
CBMs have been identified, which are currently classified into 67 different families 
based on the amino acid sequence similarity, the conservation of functional residues, 
binding specificity, evolutionary relationships and structural similarity (Cantarel et 
al., 2009; Park et al., 2010).  
CBMs are widely considered as non-catalytic carbohydrate-binding domains 
containing 40 to 200 residues, which are most often connected to a catalytically active 
domain to form a glycoside hydrolase that can degrade different carbohydrates 
(Boraston et al., 1999). Furthermore, it has been reported that CBMs from different 
families can specifically recognize a variety of carbohydrates, ranging from simple 
(e.g. galactose) to complex carbohydrates (e.g. chitin)  (see CAZy for more details). It 
follows that CBMs must play a distinctive role in the interaction of their parental 
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enzyme with the substrate. Indeed, currently three common roles of CBMs have been 
recognized: (i) to increase the effective interaction between enzyme and 
polysaccharide surface via CBM binding to surface polysaccharides adjacent to the 
enzyme substrate (Bolam et al., 1998); (ii) to target the polysaccharides that are the 
substrates of the glycoside hydrolases (Charnock, 2002) and (iii) to disrupt the 
structure of the polysaccharide substrate and therefore improve the degradative ability 
of the catalytic module (Din et al., 1994). Therefore, to better understand the 
mechanisms of these specific roles of CBMs, a great deal of research based on 
structural studies is ongoing. 
To date, over 250 CBMs from 50 families in the CAZy database have had their 
structures determined by either X-ray crystallography or NMR spectroscopy, and 
many of them are also in complex with their ligands (Cantarel et al., 2009). Within 
these structures, many structural similarities in topologic folding were revealed. The 
majority of CBM structures contain a β-sandwich fold (Figure 1.15a), which 
generally consists of two antiparallel β-sheets, each containing three to six β-strands, 
depending on the size of the protein module. In some cases, one or several small α-
helices are also distributed in various locations. In addition, the binding sites are 
present on the surface of the β-sandwich, with the exception of a few structures in 
which the carbohydrate binding site is located at the edge of the β-sandwich (Boraston 
et al., 2004). The CBMs from families 13 and 42 adopt a β-trefoil fold (Figure 1.15b), 
which associates with the ricin toxin B-chain. As the name implies, this fold generally 
consists of three structurally similar sub-domains (normally including two β-hairpin 
and one/two additional small α-helices) which can form a pseudo-three-fold 
symmetry (Notenboom et al., 2002; Miyanaga et al., 2004; Hashimoto, 2006). This 
kind of β-trefoil fold, in which each single subdomain contains a substrate binding 
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site, can significantly enhance the binding affinity of its parental protein due to its 
multiple binding sites (Boraston et al., 2000). Some low molecular weight (30-60 
residues) CBMs from families 1, 5, 10, and 12 assemble with only a small β-sheet and 
coil (Figure 1.15c), this sort of folding limits the diversity of these CBMs, and as a 
result they are specific for cellulose and/or chitin only (Kraulis et al., 1989; Brun et 
al., 1997; Raghothama et al., 2000; Ikegami et al., 2000; Boraston et al., 2004). In 
addition to these typical folds, there are a small number of CBMs families that show 
distinctive folding, such as one β-sheet with an extra small α-helix in CBM14 
(Suetake et al., 2000); a predominantly coiled structure with two small β-sheets 
within a small region of α-helix in CBM18 (Saul et al., 2000) and a two β-strand with 
three helixes in family 50 (Koharudin et al., 2011) (Figure 1.15d).  
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Figure 1.15. Cartoon representations of CBMs grouped as fold families.  
(a). Examples of CBMs with β-sandwich fold. The representative examples also show that the 
carbohydrate-binding site can reside either on the surface of the β-sheet (CBM4 in complex with 
cellopentaose) (Boraston et al., 2002) or at the edge of the β-sandwich (CBM6 in complex with 
xylotriose and Ca2+) (Boraston et al., 2003). (b). The β-trefoil fold CBMs present in CBM13 in 
complex with xylopentaose, glycerol and SO4 (Notenboom et al., 2002) and CBM42 in complex with 
arabinofuranose, glycerol and Cl- (Fujimoto et al., 2010). (c). Examples of CBMs (CBM10 
(Raghothama et al., 2000); CBM1 (Kraulis et al., 1989) and CBM5 (Brun et al., 1997)) that form the 
β-sheet & coil fold. The carbohydrates-binding sites are shown to form a planar platform via aromatic 
side chains (yellow). (d). Other types of fold that are only found in a few CBM families (CBM14 (Rao 
et al., 2005); CBM18 in complex with glucosamine (Saul et al., 2000) and CBM50 (Lytle et al., 2009)). 
Ligands bound to CBMs are shown in blue and the bound metal ions are shown in green.  
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In recent years, another classification of CBMs based on the topology of the binding 
site has also been proposed, in which the protein modules are grouped into three 
different types, namely ‘surface-binding’ CBMs (Type A), ‘glycan-chain-binding’ 
CBMs (Type B) and ‘small-sugar-binding’ CBMs (Type C) (Boraston et al., 2004). 
Currently published Type A CBMs (Figure 1.16a) are predominantly found in families 
1, 2a, 3a, 5, 10, 12 and 63, and specifically bind to insoluble, highly crystalline 
cellulose and/or chitin (Boraston et al., 2004; Georgelis et al., 2012). The binding 
surface of Type A CBMs is generally flat or platform-like, and usually contains 
aromatic residues that form a hydrophobic planar strip suitable for binding the planar 
surface of the associated pyranose rings in crystalline cellulose (Georgelis et al., 
2012). The majority of CBM families belong to Type B CBMs (Figure 1.16b). Unlike 
Type A CBMs, the binding sites of Type B CBMs are usually extended and form a 
groove, which may be a very shallow recess that is enough to hold the surface of the 
polymeric ligand, or a very deep trench to accommodate the whole glycan chain. 
Again, aromatic side chains participate in the recognition of the glycan chain, and 
form a twisted or sandwich platform rather than the planar platform seen in type A 
(Figure 1.17). Compared with Type A and Type B CBMs, Type C CBMs (Figure 
1.16c) possess carbohydrate binding sites that form a ‘cave’ rather than a planar 
surface or a extended groove, and are specific to mono-, di-, or trisaccharides due to 
the spatial restriction of the binding site (Boraston et al., 2004). In the last decade, 
more Type C CBM structures have been reported and, to date, modules from 12 
different families have been shown to have the properties of Type C CBMs. 
Additionally, besides the aromatic residues, some polar residues are reported to 
interact with the substrate, improving the affinity of the modules (Notenboom et al., 
2001).  
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Figure 1.16. Solvent-accessible surface representations of CBMs grouped as functional types.  
(a). Example of a cellohexaose molecule binding to the “flat” surface of CBM63 (Georgelis et al., 
2012). (b). Example of a cellopentaose molecule occupying a deep binding trench in CBM4 (Boraston 
et al., 2002) and also a cellotetraose molecule occupying a shallow binding recess in CBM29 (Flint et 
al., 2005) (c). Example of a cellobiose molecule binding to the cavity of CBM9 (Notenboom et al., 
2001). The surfaces created by the aromatic side chains involved in binding are shown in yellow. 
Ligands bound to CBMs are shown in blue. 
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Figure 1.17. Ribbon and stick representation of the three types of binding-site ‘platforms’ 
formed by aromatic residues.  
(a). Example of a cellohexaose molecule binding to the ‘planar’ platform-like Type A CBM from 
family 63 (4FER) (Georgelis et al., 2012). The same planar binding-site of CBMs are also shown in 
Figure 1.15C. (b). Example of a cellopentaose molecule binding to the ‘sandwich’ platform-like Type 
B CBM from family 4 (1GU3) (Boraston et al., 2002). (c). Example of a cellotetraose molecule 
binding to the ‘twisted’ platform-like binding-site of Type B CBM from family 29 (1W8T) (Flint et al., 
2005). Aromatic side chains involved in binding are shown in yellow (sticks). Ligands bound to CBMs 
are shown in blue. 
The ability of CBMs to recognize such a wide ranges of polysaccharides make CBMs 
an excellent system for studying the mechanisms of the protein-carbohydrate 
interaction, particularly with the use of structural studies. For example, the design of 
ligands that can act as agonists/antagonists or the synthesis of multivalent CBMs to 
enhance binding affinity will have a number of applications, for example in plant 
development, novel drug biosynthesis, nutritional improvement (Connaris et al., 
2009; Shoseyov et al., 2006). Although hundreds of structures of CBMs have been 
determined, the majority of CBM structures are still unknown, making it very difficult 
to understand the molecular mechanisms of how CBMs bind and act on the 
corresponding polysaccharides. Therefore, in the future, research focusing on the 
structural studies of CBMs is potentially important.  
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1.2.4   Project aims 
The aim of the current project is to determine the crystal structure of the CBM domain 
of NanA from S. pneumoniae. The X-ray structure of this domain, which belongs to 
CBM family 40, has been determined in both its apo- and holo-forms. The structure 
reveals typical β-sandwich folding and classifies the protein as a Type C CBM. Here 
it is shown, for the first time, that this domain of NanA recognizes sialic acid, as 
previous reports concerning this domain with respect to studies on its role in invading 
the BBB had described it broadly as a ‘lectin-like domain’ with ‘laminin-G homology’ 
(Uchiyama et al., 2009; Banerjee et al., 2010).These studies on BBB invasion showed 
that the CBM domain of NanA is the critical determinant in this activity, hence the 
importance of studying this domain in detail. Details about the protein production and 
structure determination are presented in Chapter 4. 
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Chapter 2: Crystal structure of the full-
length H. sapiens DAK 
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2.1  Summary 
MDA5 is a cytoplasmically expressed protein, and has been shown to recognize 
foreign double stranded RNA, resulting in the activation of the innate immune 
response (Kato et al., 2008, Yoneyama et al., 2004). It was also reported that H. 
sapiens DAK is able to interact with the N-terminal CARD domain of MDA5 in a 
non-virus environment, and that this interaction is disrupted by activations of MDA5 
by foreign nucleotides, which causes conformational changes in MDA5 (Diao et al., 
2007). The mechanism of the interaction between DAK and MDA5-CARD is still 
unclear and therefore, structural studies of DAK and MDA5-CARD are essential. 
In this chapter, the structure and biochemical studies of wild-type DAK from H. 
sapiens are reported.  
Both full-length DAK (designated FL-DAK) (575 residues, ~59 kDa) and N-terminal 
DAK (designated N-DAK) (327 residues, ~34 kDa) were successfully cloned. 
Purified FL-DAK exhibits kinase activity, and the 2.5 Å structure shows a very 
similar structural framework to the C. freundii DAK (PDB code: 1UN9) (Siebold et 
al., 2003a). The crystals of FL-DAK contained eight monomers per asymmetric unit. 
The electron density map of the N-terminal domain was very well defined, whereas 
various regions of the C-terminal domain were disordered. Complexes of FL-DAK 
with various analogues of ATP failed to co-crystallize and could also not be achieved 
by soaking the crystals with ligands. Attempts to co-crystallize N-DAK with the 
CARD domains of MDA5 were unsuccessful. Indeed, further experimental results 
indicated that there was no interaction between the two proteins. 
The structure of FL-DAK provided detailed information about the crystal packing, 
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which could be exploited to improve crystal quality (discussed in Chapter 3). The 
entire experimental procedure from protein expression to structure determination will 
be divided into eight sections (from section 2.2 to section 2.9). More details about the 
experimental procedures are shown separately in Appendix I Materials and Methods.   
2.2  Prediction of the disordered regions of FL-DAK and 
identification of the sequence coverage of the N-DAK 
The FL-DAK sequence (UniProt: Q3LXA3) was submitted to Phyre2 for prediction of 
the secondary structure and the disordered regions (Kelley and Sternberg, 2009) (The 
program is described in more detail in chapter 4, where it was used for homology 
modeling). It was revealed that most of the protein is predicted to be well ordered, 
except three regions that are identified as disordered by the program (Figure 2.1). 
Based on the output of Phyre2, the first disordered region (residues 142-152) is 
present towards the N-terminus, another disordered region is from residues 340 to 
370, involving the linker between the N- and C-terminal domains, and the third 
disordered region is towards the C-terminus and includes residues 537-549. 
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Figure 2.1. The secondary structure and disorder prediction of FL-DAK.  
Predicted by the Phyre2 server. The predicted presence of α-helices, β-strands and disordered regions is 
shown graphically together with a color-coded confidence bar. The residues with “?” underneath are 
predicted to be disordered regions, which include regions 142-152, 340-370 and 537-549.  
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In order to ascertain which region of the sequence corresponds to the N-terminal 
domain, the output PDB model from Phyre2 was superposed with the C. freundii 
DAK, and a sequence alignment of the two DAK sequences was performed via 
Clustal W (Larkin et al., 2007) (Figure 2.2). Together these results showed the linker 
between the two domains is likely to span residues 327 to 367. Therefore, N-terminal 
DAK constructs that contained residues 1 to 327 were sub-cloned. 
 
Figure 2.2. Sequence alignments of H. sapiens DAK and C. freundii DAK.  
Sequence alignment was done with Clustal W (Larkin et al., 2007). The region-framed red is the linker 
between the N- and C-terminal domains of C. freundii DAK. (Identical residues are indicated by an 
asterisk; two dots represent highly conserved residues and weakly conserved residues are indicated by 
a sigle dot) 
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2.3  Cloning, expression and purification of WT DAK and MDA5-
CARD 
The target sequences for H. sapiens DAK (FL-DAK and N-DAK) were successfully 
amplified from pCMV-SPORT6 vector containing cDNA encoding target proteins 
(purchased from Source BioScience LifeSciences) by the polymerase chain reaction 
(PCR) using standard protocols. The primer pairs that were used are shown in Table 
2.1 and the amplified sequences were identified by agarose gel electrophoresis as 
shown in Figure 2.3a.  
Target 
protein 
Primer 
name 
Primer sequence (5’-3’) 
Restriction 
enzyme 
FL-DAK 
(1725bp) 
DAK_1_F CCACATCATGACCTCCAAGAAGCTG PagI (BspHI) 
DAK_575_R GGGAGGCAGTCGACCACCTTAGC SalI 
N-DAK 
(981bp) 
DAK_1_F CCACATCATGACCTCCAAGAAGCTG PagI (BspHI) 
DAK_327_R AGTGGTCGACGCATCTTACAGTTTCAG SalI 
Table 2.1. Primers for gene cloning of FL-DAK and N-DAK. 
 Restriction enzyme sites are shown in bold.  
The PCR product was then cloned into a modified pMAL-c2X vector (New England 
BioLabs) (designated pLOU3) and positive colonies were identified by colony PCR 
(Figure 2.3b). The construct included an N-terminal six-histidine tag, Maltose-
Binding Protein (MBP) tag followed by a Tobacco Etch Virus (TEV) cleavage site 
between the MBP tag and the protein-coding sequence (Figure 2.4). The presence of 
both a histidine and an MBP affinity tag in one construct can significantly improve the 
purity of the target protein during the purification. In addition, MBP can often greatly 
improve the solubility and stability of the fused protein of interest. A highly specific 
TEV protease recognition site also allows the tag to be cleaved after purification. The 
correct sequences were confirmed by the DNA sequencing service at the School of 
Life Sciences, University of Dundee, Scotland. 
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Figure 2.3. Analysis of target genes using DNA agarose gels.  
 (a) PCR result of amplified DAK genes. (b) Colony PCR of DAK with negative (lanes 2,3,5) and 
positive (lanes 4, 6) colonies. The DNA size marker (M) is a commercial 1kbp ladder.  
 
Figure 2.4. The schematics of the constructs.  
All constructs include a N-terminal 6-His tag, MBP tag and a TEV cleavage site. 
In order to optimize protein production, various conditions of small-scale expression 
trials were performed after the plasmid was transformed into E. coli Rosetta (DE3) 
cells (Novagen). A number of variables were tested such as: type of media (LB or 
TPB), OD600 at induction (0.6 or 1.0), temperature after induction (15/25/30/37oC), 
induction time (3h or overnight) and with or without cold shock. Both proteins (FL-
DAK and N-DAK) were extracted from the whole cell lysates and supernatants were 
analysed by SDS-PAGE gel (Invitrogen). The results showed that both constructs of 
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DAK were most soluble when the cells were grown from 1:100 dilutions of overnight 
cultures in Luria Broth (LB) medium with a final ampicillin and chloramphenicol 
concentration of 50µg ml-1 and 34µg ml-1, respectively in an orbital shaker at 200rpm 
at 37oC for 2-3 hours. Once the culture reached an OD600 of 0.6, the culture was cold 
shocked at 4oC for 30min. After that, IPTG was added to a final concentration of 
0.4mM, and expression was performed at 15oC for 16-20 hours. Approximately 15g 
of FL-DAK and 25g of N-DAK cell pellets were harvested from each 5 litre culture.  
For the MDA5-CARD domain, the gene had been sub-cloned into the pLOU3 vector 
by a previous member of the group (Dr C. Ryan), and the plasmid was transformed 
into E. coli Rosetta (DE3) cells (Novagen). Similar expression conditions were used 
except the cold shock was omitted and induction was carried out at 22oC overnight 
instead of 15 oC. Approximately 25g of cell pellets would be harvested from a 5 litre 
culture. 
To obtain high-purity protein, a five-step purification strategy was performed for all 
three proteins. The cell-free supernatant containing the target protein was first purified 
by nickel affinity chromatography (Ni2+-nitrilotriacetic acid resin); the first eluted 
protein solution was then additionally purified by amylose affinity chromatography 
(amylose resin); the second eluted protein solution was mixed with TEV protease 
(10:1 molar ratio target protein to TEV), which was then dialysed overnight at 4oC. A 
second nickel affinity chromatography (HisTrap) step was employed to remove the 
protease and the uncleaved proteins after TEV protease treatment, and a size 
exclusion chromatography (gel filtration) was used as the final purification step 
(Figure 2.5&2.6&2.7). The whole purification procedure was carried out at 4oC due to 
the poor stability of the proteins at room temperature. Approximately 20-25mg of FL-
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DAK, 5-6mg of N-DAK and 1.5-2mg of MDA5-CARD were obtained from each 5L 
cell culture. Protein identity and integrity were confirmed by mass spectrometry 
(BSRC Mass Spectrometry and Proteomics Facility, University of St Andrews). 
 
Figure 2.5. FL-DAK purification.  
(a). An SDS-PAGE gel showing fractions collected from nickel and MBP affinity purification; the 
main band in lane 7 is FL-DAK with MBP tag and 6-Histidine tag, 104kDa in total. MBP eluted 
sample was collected and digested by TEV protease. Lane 1, Pre Ni2+ column; Lane 2, Ni2+ column 
flow through; Lane 3, Ni2+ column wash; Lane 4, Ni2+ column elute; Lane 5, MBP column flow 
through; Lane 6, MBP column wash; Lane 7, MBP column elute and Lane M, Protein Marker. (b). An 
SDS-PAGE gel showing fractions collected from the second nickel affinity purification after TEV 
cleavage. The red asterisk indicates FL-DAK (59kDa), the green asterisk indicates MBP tag plus 6-
Histidine tag (45kDa), and the blue asterisk indicates TEV protease (27kDa). Lane 1, Pre Ni2+ column 
after TEV cleavage; Lane 2, Ni2+ column flow through; Lane 3&4, Ni2+ column wash; Lane 5, Ni2+ 
column elute; Lane 6, TEV control and Lane M, Protein Marker. (c). Elution profiles of FL-DAK after 
gel filtration column (HiPrep 16/60, Sephacryl S-200) (GE Healthcare). The blue line indicates the 
absorbance at 280nm. Inset shows SDS-PAGE analysis of the main peak fractions (indicated by the 
green horizontal bar).  
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Figure 2.6. N-DAK purification.  
(a). An SDS-PAGE gel showing fractions collected from nickel and MBP affinity purification; the 
main band with black asterisk indicates N-DAK with MBP tag and 6-Histidine tag, 79kDa in total. 
MBP eluted sample was collected and digested by TEV protease. Lane 1, Pre Ni2+ column; Lane 2, 
Ni2+ column flow through; Lane 3, Ni2+ column wash; Lane 4, Ni2+ column elute; Lane 5, MBP column 
flow through; Lane 6, MBP column wash; Lane 7, MBP column elute and Lane M, Protein Marker. (b). 
An SDS-PAGE gel showing fractions collected from the second nickel affinity purification after TEV 
cleavage. The red asterisk indicates N-DAK (34kDa), the green asterisk indicates MBP tag plus 6-
Histidine tag (45kDa), and the blue asterisk indicates TEV protease (27kDa). Lane 1, Pre Ni2+ column 
after TEV cleavage; Lane 2, Ni2+ column flow through; Lane 3&4, Ni2+ column wash; Lane 5, Ni2+ 
column elute and Lane M, Protein Marker. (c). Gel filtration elutes of N-DAK. The main band of the 
SDS-PAGE gel indicates N-DAK (34kDa).  
 
Figure 2.7. MDA5-CARD purification.  
(a). An SDS-PAGE gel showing fractions collected from nickel and MBP affinity purification; the 
main band with black asterisk indicates MDA5-CARD with MBP tag and 6-Histidine tag, 66.8kDa in 
total. MBP eluted sample was collected and digested by TEV protease. Lane 1, Pre Ni2+ column; Lane 
2, Ni2+ column flow through; Lane 3, Ni2+ column wash; Lane 4, Ni2+ column elute; Lane 5, MBP 
column flow through; Lane 6, MBP column wash; Lane 7, MBP column elute and Lane M, Protein 
Marker. (b). An SDS-PAGE gel showing fractions collected from the second nickel affinity 
purification after TEV cleavage. The red asterisk indicates MDA5-CARD (21.8kDa), the green asterisk 
indicates MBP tag plus 6-Histidine tag (45kDa), and the blue asterisk indicates TEV protease (27kDa). 
Lane 1, Pre Ni2+ column after TEV cleavage; Lane 2, Ni2+ column flow through; Lane 3&4, Ni2+ 
column wash; Lane 5, Ni2+ column elute and Lane M, Protein Marker. (c). Gel filtration elutes of 
MDA5-CARD. The main band from the SDS-PAGE gel indicates MDA5-CARD (21.8kDa).  
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2.4  Analysis of complex formation between DAK and MDA5-CARD 
To explore whether MDA5-CARD interacted with FL-DAK or N-DAK, both amylose 
pull downs and size exclusion chromatography were performed. For the amylose pull 
downs experiment, MDA5-CARD with tags was first bound to the amylose resin, then 
FL-DAK or N-DAK was loaded into the columns. However, both FL-DAK and N-
DAK passed through during the first wash step (Figure 2.8a&b). For the size 
exclusion chromatography experiment, the elution peaks of (i) FL-DAK only, (ii) 
MDA5-CARD only and (iii) a mixture of the two were compared by SuperdexTM 200 
10/300 GL column (GE Healthcare) (Figure 2.8c), and N-DAK, MDA5-CARD and 
their mixture were compared (SuperdexTM 75 10/300 GL column (GE Healthcare)) 
(Figure 2.8d). However, the peak positions of the proteins when loaded as a mixture 
were the same as the individual protein elution profiles. This indicates that the 
proteins did not form a complex under these conditions. 
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Figure 2.8. Pull down amylose affinity chromatography and size exclusion chromatography to 
test the interaction between MDA5-CARD and DAKs.  
(a). Amylose resin pull down experiment shows that FL-DAK was not binding to the column that 
contained MDA5-CARD protein. An SDS-PAGE gel showing fractions collected from MBP affinity 
chromatography. Lane 1, Pre MBP column of MDA5-CARD; Lane 2, MBP column flow through; 
Lane 3, MBP column first wash; Lane 4, flow through after FL-DAK loaded; Lane 5, first wash after 
FL-DAK loaded (all FL-DAK protein went through); Lane 6, second wash after FL-DAK protein 
loaded; Lane 7, MBP column elute (MDA5-CARD with tags were eluted); lane 8, FL-DAK protein 
control and Lane M, Protein Marker. The black asterisk indicates FL-DAK and the red asterisk 
indicates MDA5-CARD with tags (b) Amylose resin pull down experiment shows that N-DAK was 
also not binding to the column that contained MDA5-CARD protein. An SDS-PAGE gel showing 
fractions collected from MBP affinity chromatography. Same lane number showed as (a) except lane 
5&8 are N-DAK instead of FL-DAK. The black asterisk indicates N-DAK and the red asterisk 
indicates MDA5-CARD with tags (c). Size exclusion chromatography with an analytical SuperdexTM 
200 10/300 GL column (GE Healthcare) showed that the mixed MDA5-CARD and FL-DAK eluted in 
different peaks (shown in red). MDA5-CARD only (21.8kDa) shown in green and FL-DAK only 
(59kDa) shown in purple. (d). Size exclusion chromatography with an analytical SuperdexTM 75 10/300 
GL column (GE Healthcare) showed that the mixed MDA5-CARD and N-DAK eluted in different 
peaks (shown in red). MDA5-CARD only (21.8kDa) shown in green and N-DAK only (34kDa) shown 
in purple. All the peaks are performed at 280nm absorbance. 
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2.5  Determination of the activity of DAK 
As one of the members of the dihydroxyacetone kinase family, it is expected that H. 
sapiens DAK is capable of utilizing ATP as a high-energy donor to phosphorylate 
dihydroxyacetone (Dha) to produce dihydroxyacetone phosphate (DhaP). In the 
meantime, ADP molecules are released from dephosphorylated ATP (Gutknecht et al., 
2001). Therefore, a coupled enzyme assay was performed, modified from Wu and Hill 
(Wu and Hill 1993). The principle of the assay is based on coupling the liberation of 
ADP to the lactate dehydrogenase (LDH) oxidation of nicotinamide adenine 
dinucleotide (NADH) to NAD+, as shown in Figure 2.9. Initially, ADP molecules are 
liberated from the dephosphorylation of ATP by DAK, after which newly created ATP 
molecules are regenerated by pyruvate kinase (PK), which also catalyses the 
dephosphorylation of PEP into pyruvate. In the final reaction, NADH is oxidized by 
LDH, accompanied by the reduction of pyruvate to lactate. To monitor the decreasing 
levels of NADH, fluorescence spectroscopy at 376nm excitation wavelength (Ex) and 
462nm emission wavelength (Em) was employed. The results indicate that the DAK 
enzyme assay is concentration dependent as shown in Figure 2.10. A protein 
concentration of 2µM was selected for further enzyme activity tests.  
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Figure 2.9. Flowchart for ADP activity assay for detecting DAK enzyme activity.  
As a starting substrate in the enzyme-coupling reaction, ADP molecules are liberated from DAK 
reaction. Therein, PEP and NADH are consumed, and the oxidation level of NADH can be monitored 
by fluorescence. Abbreviations: PEP: phosphoenolpyruvate; NADH/NAD+: reduced and oxidized form 
of nicotinamide adenine dinucleotide.  
 
Figure 2.10. Activity assay result of FL-DAK.  
Various concentrations of DAK were tested, 2µM of protein as the highest concentration, and 50nM as 
the lowest concentration to be used. In addition, n protein was used as the negative control, which 
resulted in no decrease of NADH.  
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2.6  Crystallization of FL-DAK 
Initial crystallization trials for FL-DAK were performed using a Honeybee 963 robot 
system (Genomic Solutions) with commercially available screens. For each of the 96-
well sitting-drop vapour-diffusion screens (MRC plates, Greiner), 150 nl of protein 
solution (9mg ml-1 and 18mg ml-1) was mixed with 150 nl of precipitant and 
equilibrated against a reservoir of 75 µl precipitant. The sealed plates were then 
incubated at both 20oC and 4oC.  
Initial star shape crystals of FL-DAK were obtained from the condition 49 (200mM 
NaF and 20%(w/v) PEG 3350) of the PACT Suite screen (Qiagen) and were further 
optimized using the Additive Screen (Hampton Research) and several rounds of 
stochastic optimizations in a 96 well format where precipitant concentration and pH 
were varied. The best crystals were obtained in 200mM KF, 5mM MgCl2, 18%(w/v) 
PEG 3350, 6%(w/v) MPD and 25mM glycine with equal amounts of protein solution 
(18mg ml-1) and reservoir solution (1µl each). Crystals (>0.3mm) usually appeared 
after 5 days at 20oC (Figure 2.11a&b). Prior to flash freezing in liquid nitrogen for 
data collection, the crystals were cryoprotected by transferring them to mother liquor 
supplemented with 10% PEG 400.  
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Figure 2.11. FL-DAK crystals and its diffraction patterns.  
Crystals of FL-DAK obtained from 200mM KF, 5mM MgCl2, 18% PEG 3350, 6% MPD and 25mM 
glycine. (a) Irregular crystal shape with the appearance of several thin plates stacked together. The 
scale bar represents 0.3mm. (b) Individual crystal after separation from the cluster shown in (a). (c) X-
ray diffraction pattern. From this angle, the reflections could be identified very well. (d) After the 
crystal is rotated by 90 degrees, the pattern looks very smeary, and it is difficult to distinguish 
individual reflections.  
Attempts were made to produce crystals of FL-DAK in complex with cofactor 
analogues by pre-incubating FL-DAK with Dha and ATP analogues at 4oC for 30min 
prior to crystallizations trials. Unfortunately, no crystals were formed. Furthermore, 
soaking the crystals of FL-DAK with the analogues of ATP and Dha was also 
attempted, however, the crystal dissolved directly after transfer into the mother liquor 
supplemented with ligands, even at very low ligand concentration. No crystals of the 
N-DAK and MDA5-CARD “complex” were formed, which was not unexpected given 
that the experimental results indicated that the proteins did not interact. 
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2.7  Data collection and structure determination 
The FL-DAK crystals diffracted to 2.5Å resolution (Figure 2.11 c&d). A single crystal 
was used to collect X-ray diffraction data over a range of 164o (0.25o steps) on the I03 
beamline (λ = 0.9763 Å) at the Diamond Light Source (Didcot, England), which is 
equipped with an area detector systems corporation (ADSC) Q315 detector. The 
crystal belongs to the space group P21, with unit cell parameters of a=136.1Å, 
b=90.4Å, c=177.8Å and α=γ=90.0o, β=92.9o. Data collection and processing statistics 
are summarized in Table 2.2. The Matthews coefficient, calculated using the CCP4 
suite (Winn et al., 2011) suggested that each asymmetric unit contained 8 molecules.  
Data collection FL-DAK 
Beamline  I03 Diamond 
Wavelength (Å) 0.9763 
Unit-cell parameters 
a (Å) 
b (Å) 
c (Å) 
α (°)  
β (°)  
γ (°) 
 
136.09 
90.42 
177.82 
90.00 
92.87 
90.00 
Space group P21 
Molecules per asymmetric unit 8 
Resolution (Å) 90.54-2.52(2.58-2.52) 
Unique reflections 156285 
Redundancya  3.4(3.4) 
Completeness%a 99.1(98.8) 
Rmerge (%)a,b 6.1(62.5) 
<I/σIa> 11.2(2.0) 
Wilson B-factor (Å2) 42.6 
Matthews coefficient 2.3 
Solvent (%) 47 
Table 2.2. Data collection and processing statistics of FL-DAK.  
a. Values in parentheses correspond to the highest resolution shell. 
b. Rmerge=Σhkl Σi |Ii(hkl)-<I(hkl)>|/ Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity for all observations i 
of reflection hkl, and <I (hkl)> is the weighted average intensity for all observations i of reflection hkl. 
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Sequence alignment indicated that H. sapiens FL-DAK shares 39% amino acid 
sequence identity with the C. freundii DAK (Siebold et al., 2003a), therefore, 
molecular replacement (MR) was employed to solve the structure. The 2.5Å data were 
indexed, integrated and scaled using HKL-2000 (Otwinowski & Minor, 1997), and 
the structure was phased by MR with the PHASER program (McCoy et al., 2007) 
from the CCP4 suite (Winn et al., 2011). Refinement was carried out with the 
program REFMAC5 (Vagin et al., 2004) from the CCP4 suite and the refined model 
was manually adjusted in Coot (Emsley et al., 2004). The final structure had an Rfactor 
and Rfree of 22.6% and 29.7%, respectively. Structure refinement statistics are 
summarized in Table 2.3 
Refinement  FL-DAK 
Resolution range (Å) 30.0-2.5 
Mean B-factor (Å2) 52.8 
Rfactor (%)a 22.6 
Rfree (%)b 29.7 
r.m.s.d. bond lengths (Å)c 0.01 
r.m.s.d. bond angles (°)c 1.74 
Number of reflections 147517 
Protein atoms 31888 
Water molecules 0 
Table 2.3. FL-DAK data refinement statistics.  
a. Rfactor and Rfree = (Σ| |Fo| - |Fc| |)/(Σ |Fo|). 
b. Rfree was calculated for a 5% set of reflections excluded from the refinement. 
c. r.m.s.d. is the root-mean-square deviation from ideal geometry. 
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2.8  Overall structure of FL-DAK 
The two domains of the FL-DAK structure are separated by a long extended linker 
(Figure 2.12a), in agreement with the sequence analysis and structure prediction. A 
monomer of FL-DAK consists of 555 residues from Lys4 to Leu574. The N-terminal 
domain runs from Lys4 to Arg347, the C-terminal domain runs from residues Thr364 
to Leu574 with the linker (residues from Lys348 to Ser363) between them. 
Interestingly, the FL-DAK structure forms a homodimer (shown as Figure 2.12b), 
which is highly similar to C. freundii DAK. Domains are swapped such that the C-
terminal domain of one monomer is bound to the N-terminal domain of the other. 
Superimposition of the two monomers gives an r.m.s.d. of 1.84Å for 500 Cα atoms. 
However, superimposition of each N-terminal domain gives an r.m.s.d. of 0.51Å for 
357 Cα atoms, and the C-terminal domains gives an r.m.s.d. of 0.88Å for 194 Cα 
atoms. Analysis of the interface between the two N-terminal domains using the PISA 
(Protein interfaces surfaces and assemblies) server (rissinel and Henrick, 2007) 
suggests an extensive interaction involving more than 70 residues, which together 
bury an area of 2339Å2. 
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Figure 2.12. Cartoon representation of FL-DAK.  
(a) Monomer shown in green (N-terminal domain) and blue (C-terminal domain), which are connected 
by a long linker. (b) Dimer form. The second monomer is shown in grey. The two monomers swap 
domains: the two N-terminal domains are in the middle of the dimer while their respective C-termini 
are positioned adjacent to the other N-terminal domain.  
Like C. freundii DAK, the N-terminal domain of H. sapiens FL-DAK exhibits the 
characteristic two α/β-folds, each of which contains a six stranded mixed β-sheet, one 
surrounded by six helices and the other surrounded by three helices. Superimposition 
of this region onto the N-terminal domain of C. freundii DAK gives an r.m.s.d. of 
1.30Å over 313 Cα atoms. Several regions of the C-terminal domain are relatively 
disordered compared with the N-terminal domain (Figure 2.13) (the average B factor 
of the N- and C-terminal domains are 44Å2 and 67Å2, respectively). However, an eight 
antiparallel α-helices model of the C-terminal domain was manually built based on 
the structure of C. freundii DAK and the poor electron density map. Superimposition 
of the final refined C-terminal domain with C. freundii DAK gives an r.m.s.d of 1.66Å 
over 172 Cα atoms. As in C. freundii DAK, residues 538-553 were completely 
disordered and could not be modelled.  
!" #"
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Figure 2.13. 2Fo-Fc electron density map (contoured at 1.5σ level) in parts of the N- and C-
terminal domains of FL-DAK.  
(a). The electron density map is very clear in most regions of the N-terminal domain. (b). The electron 
density map shows that most regions of the C-terminus are relatively disordered. Figures were prepared 
with Coot (Emsley et al., 2004). 
Eight monomers were present in the asymmetric unit of the crystal, which formed 4 
close packing dimers (Figure 2.14). However, the interaction between the dimers are 
much less extensive than between monomers, so it is likely that the dimer represents 
the biological unit of the protein.  
  
a, N-terminus site b, C-terminus site 
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Figure 2.14. Overall structure of the asymmetric unit contents of H. sapiens FL-DAK.  
(a) Cartoon representation of FL-DAK in the asymmetric unit, which contained 4 close-packing dimers. 
Each dimer is displayed with a different colour. (b) The view after a 90o rotation from (a).  
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2.9  Protein methylation 
In order to try to improve crystal packing and obtain better diffracting crystals, 
chemical modification of the protein was attempted. As one of the most useful 
biochemical tools for the study of protein structure and function, reductive 
methylation of lysine residues of the target protein has been widely used (Rypniewski 
et al., 1993). FL-DAK contains 25 lysines, therefore the effect of methylating their 
side chains (JBS Methylation kit) was investigated. The methylated protein showed a 
complete loss of enzymatic activity (Figure 2.15). This was found to be due to loss of 
tertiary structure during methylation, as demonstrated by circular dichroism (CD) 
spectropolarimetry (JASCO UK) (Figure 2.16). The presence of peaks in the near UV 
region of the CD spectrum indicates the presence of aromatic residues in a folded, 
asymmetric environment. Loss of these peaks shows that the protein was unfolded 
after the methylation process.  
 
Figure 2.15. Activity assay result of the methylated DAK.  
Methylated DAK lost all the enzyme activity. 2µM apo FL-DAK was used as the positive control and n 
protein was used as the negative control. 
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Figure 2.16. CD result of Methylated DAK.  
Methylated DAK lost the tertiary structure (shown in green), apo DAK was used as the positive control 
(shown in blue). 1ml of 1mg ml-1 of each sample were tested.  
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2.10  Discussion and conclusion 
The purified H. sapiens FL-DAK displays the characteristics of a member of the 
dihydroxyacetone kinase family. FL-DAK can utilize ATP as the source for high-
energy phosphate, thereby phosphorylating Dha to DhaP, as confirmed by the enzyme 
activity assay. Indeed, the X-ray structure of WT H. sapiens FL-DAK also shows high 
structural similarity to C. freundii DAK. The quality of the electron density map 
towards the C-terminus is very poor, Figure 2.11d, and this is reflected in the fact that 
the Rfactor/Rfree are relatively high. This indicates that the C-terminus is disordered in 
this crystal form. 
Although the structure of FL-DAK has been solved, it is difficult to study the 
structure-function relationship under these conditions. Hundreds of crystals were 
tested, among which, crystal annealing (Heras and Martin, 2005), dehydration (Heras 
and Martin, 2005) and crystal seeding (Bergfors, 2003) were attempted, but no 
improvement in diffraction was seen. This is likely due to the crystal packing 
arrangement or protein disorder such that some regions are too flexible and hinder the 
growth of more ordered, better diffracting crystals. Therefore, protein surface 
engineering was considered as an approach to improve the crystals.  
Protein methylation was performed on the purified protein. Unfortunately, the protein 
lost all enzyme activity due to its loss of tertiary structure (as shown by CD). 
Additionally, limited proteolysis of the protein was carried out using trypsin. The 
proteolysis produced a variety of cleaved products of different sites. However, mass 
spectrometry results indicated that no stable versions of the C-terminus were 
produced.  
This initial structure, although of poor quality, provided valuable information about 
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the residues involved in crystal packing. This allowed the design of surface mutations 
which dramatically improved crystal quality. More details will be described in 
Chapter 3.  
Attempts were made to produce a complex of DAK protein with MDA5-CARD, 
however, no crystals were formed after several rounds of crystal trials. Not only that, I 
failed to prove that there is any interaction between the proteins, either by pull down 
experiment or size exclusion chromatography. However, this does not mean there is 
definitely no interaction between the proteins as Diao et al. has identified that N-DAK 
and MDA5-CARD are binding to each other in cell biology (Diao et al., 2007). They 
transfected 293 cells with expression plasmids for different tagged DAK and MDA5 
and performed co-immunoprecipitation experiments, which showed that the two 
proteins interacted. One possibility is that the 293 cells, which are human embryonic 
kidney cells, mimic the inner environment of the human cell and allow protein post-
translation modifications. Therefore, we may be able to conclude that either DAK or 
MAD5-CARD or both are post-translationally modified when transfected into 293 
cells, a characteristic which is not expressed in E. coli. Indeed, without this 
modification, they may not bind to each other. Thus, for further work, co-transfection 
of the mammalian cells with the appropriate plasmids could be performed. 
Alternatively, co-expression of DAK protein with MDA5-CARD could also be 
considered. However, it is somewhat surprising, given the importance of MDA5 in 
innate immunity, that there have been no follow-up publications to the MDA5-DAK 
work. The yeast-2 hybrid system carries a high rate of false positives (Deane et al., 
2002) and while the work by Diao et al. clearly identifies an important effect on 
MDA5-mediated antiviral activity, it is possible that the specific interaction between 
the N-terminal DAK domain and the MDA5-CARD may not occur in vivo. 
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3.1  Summary 
This chapter presents the structural studies of mutated full-length H. sapiens DAK 
(designated MU-DAK) with Dha and analogues of ATP. 
The existing structure of apo DAK was not good enough for structure-function studies, 
since large parts of it were disordered. Therefore, in order to obtain better diffracting 
crystals, surface mutations were introduced. Three amino acids on the surface of the 
N-terminal domain of the protein were mutated, in order to alter the packing pattern in 
the crystal. It was confirmed that MU-DAK still retains the full activity of the WT. 
Several very different shapes of crystals were obtained after optimization. Eventually, 
a 1.4Å resolution dataset was collected, and the structure had a final Rfactor/Rfree of 
13.7% and 17.3%, respectively. In the structure, over 95% of the sequence was clearly 
defined in the electron density and the final refined structure showed high similarity to 
apo DAK. Moreover, instead of eight monomers, only one monomer was present per 
asymmetric unit of the crystal of MU-DAK, which made the structure building more 
manageable.  
In addition, co-crystallization of MU-DAK with Dha and two analogues of ATP was 
also performed, the complex structure showed that the ATP binding site and the 
substrate-binding site are in a similar position to those in C. freundii DAK, whereas 
only one Mg2+ ion was found near the ATP binding site. Moreover, a phospholipid 
containing two 16 carbon tails was also found in the middle of the C-terminal domain. 
On the other hand, no crystals could be obtained for the complex of MU-DAK with 
FAD/FMN.  
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3.2  Production of the protein 
The current structure of apo DAK reveals the important crystal contacts between the 
symmetry related molecules. Position A and B in Figure 3.1 respectively highlight the 
areas of the molecule that make the closest contacts with symmetry related molecules. 
As shown in Figure 3.2A (which corresponds to position A in Figure 3.1), there are 
two small molecular weight residues (Gly47 and Val102), which are both within 4Å of 
the symmetry related molecules. If these were mutated into higher molecular weight 
residues (Gly47Tyr and Val102Lys), then there would not be enough space for the 
residues, as shown in Figure 3.2C, and additionally Val102Lys will be in close contact 
to a positively charged patch on the symmetry mate. This will disrupt interactions with 
the symmetry related molecules, which may result in different kinds of packing in the 
crystal. Similarly, mutation of Gly12 to Arg (Figure 3.1 and Figure 3.2B) on the other 
side of the molecule would also be expected to the alter crystal packing.  
 
Figure 3.1. Cartoon representation of the symmetry related molecules of apo DAK.  
Dimer shown in colour, two symmetry related molecules shown in grey. Positions A and B highlight 
areas on opposite sides of DAK that make close interactions with symmetry related molecules.  
!""
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Figure 3.2. Cartoon and sticks representation of potential mutation sites.  
(A) An enlarged view of position A in Figure 3.1. Both Gly47 and Val102 are very close to the upper 
symmetry related molecule. (B) An enlarged view of position B in Figure 3.1. On the other side of the 
molecule, Gly12 is near to another symmetry related molecule. (C) and (D). The modelled mutations 
indicate that these substitutions are likely to alter the crystal packing. Mutated residues showed in 
yellow and symmetry-related residues are shown in grey.  
The mutations of the DAK gene (G12R/G47Y/V102K) were prepared using the 
QuikChange Multi Site-Directed Mutagenesis Kit (Stratagene) and the 
oligonucleotides provided by Operon are shown in Table 3.1. Extracted plasmids were 
sequenced to confirm the mutation sites by the DNA sequencing service at the School 
of Life Sciences, University of Dundee, Scotland. 
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Mutations Primer sequences 
DAK_G12R 5′-GTGAACTCGGTGGCTCGCTGTGCTGATGACGC-3′ 
DAK_G47Y 5′-CCTGGACAGCCTCAAGTATCGGGTGGCACTGCT-3′ 
DAK_V102K  5′-GCCCAGGCCGGCACAAAGGGGACGCTCCTTATC-3′ 
Table 3.1. Primers used in multi site-mutagenesis of MU-DAK genes.  
Nucleotide codons for aimed site mutations are shown in bold. 
The successfully mutated DAK gene was also cloned into the pLOU3 vector, and the 
same expression conditions as for FL-DAK were employed (0.4 mM IPTG induction 
after cold shock, express at 15 oC for 16-20 hours). Approximately 17g of MU-DAK 
cell pellets were harvested from each 5 litre culture.  
The main purification steps for over-expressed MU-DAK were carried out using the 
same procedure as FL-DAK (nickel affinity, amylose affinity, TEV cleavage, second 
nickel affinity) except that a HiPrep 26/10 desalting column (GE Healthcare) was used 
instead of the gel-filtration column, because there were no obvious contaminants 
visible on SDS-PAGE gels after the second nickel column. This also reduced the 
exposure of the protein to room temperature during the purification (Figure 3.3). 
Approximately 3mg of protein was obtained from each 5L cell culture. It was 
confirmed that purified MU-DAK retained the full enzyme activity of the WT. 
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Figure 3.3. MU-DAK purification.  
(a). An SDS-PAGE gel showing fractions collected from nickel and MBP affinity purification; the main 
band with black asterisk indicates MU-DAK with MBP tag and 6-Histidine tag, 104kDa in total. MBP 
eluted sample was collected and digested by TEV protease. Lane 1, Pre Ni2+ column; Lane 2, Ni column 
flow through; Lane 3, Ni2+ column wash; Lane 4, Ni2+ column elute; Lane 5, MBP column flow through; 
Lane 6, MBP column wash; Lane 7, MBP column elute and Lane M, Protein Marker. (b). An SDS-
PAGE gel showing fractions collected from the second nickel affinity purification after TEV cleavage 
and desalt column. The red asterisk indicates MU-DAK (59kDa), the green asterisk indicates MBP tag 
plus 6-Histidine tag (45kDa), and the blue asterisk indicates TEV protease (27kDa). Lane 1, Pre Ni2+ 
column after TEV cleavage; Lane 2, Ni2+ column flow through; Lane 3&4, Ni2+ column wash; Lane 5, 
Ni2+ column elute; Lane 6&7, desalting column elute and Lane M, Protein Marker. 
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3.3  Crystallization of MU-DAK 
Initial crystallization trials for MU-DAK were carried out using the same method as 
described in chapter 2. The pre-crystallization test (PCT) kit (Hampton research) was 
used to optimize the protein concentration for the screen. A mixture of 0.5μl	  protein	  (various	  concentrations)	  and	  0.5μl	  PCT	  reagent	  was	  applied	  for	  30min	  on	  a	  glass	  cover	  slide.	  The	  presence	  of	  heavy	  precipitate	  or	  a	  clear	  drop	  would	  indicate	  that	  the	   protein	   concentration	   was	   too	   high	   or	   low	   respectively.	   A	   protein	  concentration	  of 10mg ml-1 produced a light, granular precipitate, suggesting that this 
was a good starting concentration for screening. Two different shapes of crystals were 
obtained in two different conditions: long rods and broken, hollow shaped crystals 
were obtained in the original FL-DAK crystallization condition (200mM KF, 5mM 
MgCl2, 18%(w/v) PEG 3350, 6%(w/v) MPD and 25mM glycine) (picture not shown) 
and long triangular crystals (Figure 3.4b) were obtained in condition 54 (200mM 
sodium formate and 20%(w/v) PEG3350) of the PACT Suite screen (Qiagen). 
However, the data collected from the crystals shown in Figure 3.4b were not 
processable due to overlapping spots with poor quality diffraction (Figure 3.4d). 
Therefore, the original FL-DAK crystallization condition was selected for crystal 
optimization. After several rounds of stochastic optimizations that were based on the 
original FL-DAK crystallization condition, the best crystals were obtained using 1µl of 
10mg ml-1 protein mixed with 1µl reservoir solution (140mM KF, 14%(w/v) PEG 
3350, 5mM MgCl2 and 6%(w/v) MPD) using sitting drop vapor diffusion. Crystals 
usually appeared on the second day and reached their maximum size (>0.6mm) (Figure 
3.4a) in 3-4 days at 20oC. Mother liquor supplemented with 10% PEG 400 was 
selected as the cryoprotection condition.  
  
Chapter 3: Crystal structure of the mutated H. sapiens DAK in complex with analogues of ATP 
 74 
 
Figure 3.4. Two different types of MU-DAK crystals obtained from different conditions and their 
respective diffraction patterns.  
(a) MU-DAK crystals obtained from 140mM KF, 5mM MgCl2, 14% (w/v) PEG3350 and 6% (w/v) 
MPD. (b) MU-DAK crystals obtained from 200mM sodium formate and 20% (w/v) PEG3350. The 
scale bar represents 0.3 mm. (c) X-ray diffraction pattern of one of the crystals shown in (a). (d) X-ray 
diffraction pattern of one of the crystals shown in (b). 
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3.4  Data collection and structure determination of MU-DAK  
MU-DAK crystals diffracted to 1.4Å resolution (Figure 3.4c). The data were collected 
from a single crystal at the European Synchrotron Radiation Facility (ESRF) 
(Grenoble, France) over a range of 180o (0.5o steps) on the ID23 beamline (λ = 0.9763 
Å), which is equipped with the MarMOSAIC detector. The data were indexed and 
processed in the monoclinic space-group C2 using HKL-2000 (Otwinowski & Minor, 
1997), which gave unit cell parameters of a=148.7Å, b=50.0Å, c=78.5Å and 
α=γ=90.0o, β=105.9o. As judged by the calculation of Matthews coefficient from the 
CCP4 suite (Winn et al., 2011), this crystal form contained a single molecule of MU-
DAK in each asymmetric unit. Data collection and processing statistics are listed in 
Table 3.2 
Data collection MU-DAK 
Beamline ID23 Grenoble 
Wavelength(Å) 0.9763 
Unit-cell parameters 
a (Å) 
b (Å) 
c (Å) 
α (°) 
β (°) 
γ (°) 
 
148.72 
49.96 
78.45 
90.00 
105.87 
90.00 
Space group C2 
Molecules per asymmetric unit 1 
Resolution (Å) 75.43-1.40(1.44-1.40) 
Unique reflections 109534 
Redundancya 4.1(3.6) 
Completeness%a 100.0(100.0) 
Rmerge (%)a,b 7.7(70.7) 
<I/σIa> 11.4(2.2) 
Wilson B-factor (Å2) 17.4 
Matthews coefficient 2.4 
Solvent (%) 47 
Table 3.2. Data collection and processing statistics of MU-DAK.  
a. Values in parentheses correspond to the highest resolution shell. 
b. Rmerge=Σhkl Σi |Ii(hkl)-<I(hkl)>|/ Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity for all observations i of reflection 
hkl, and <I (hkl)> is the weighted average intensity for all observations i of reflection hkl. 
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For the structure determination, the current FL-DAK structure was used as the search 
model. The structure was phased by MR with the PHASER program (McCoy et al., 
2007) from the CCP4 suite (Winn et al., 2011) using data from 75.5-2.1Å, which gave 
a single solution with a TFZ-score of 54.8 and LLG of 3492. REFMAC5 (Vagin et al., 
2004) from the CCP4 suite (Winn et al., 2011) was used for subsequent rigid body and 
restrained refinement and calculation of the electron density maps. The refined 
structure was then manually adjusted according to the 2Fo-Fc and Fo-Fc maps by Coot 
(Emsley et al., 2004). The final Rfactor and Rfree of the structure dropped to 13.7% and 
17.3%, respectively. Structure refinement statistics are summarized in Table 3.3 
Refinement  MU-DAK 
Resolution range (Å) 75.5-1.4 
Mean B-factor (Å2)  
                       Protein 19.5 
                       Ligands  35.0 
                       Water 32.3 
Rfactor (%)a 13.7 
Rfree (%)b 17.3 
r.m.s.d. bond lengths (Å)c 0.02 
r.m.s.d. bond angles (°)c 1.91 
Number of reflections 104045 
No. of atoms  
                   Protein atoms 4345 
                   Ligands  84 
                   Water molecules 442 
Validationd   
Clashscoree  2.5 
Rotamer outliers (%) 1.0 
Cβ deviations >0.25Å 0 
Residues with bad bonds/angles (%) 0.0/0.0 
MolProbity Scoref 1.1 (98th percentile) 
Ramachandran favoured/outliers (%) 97.6/0.0 
Table 3.3. MU-DAK data refinement statistics.  
a. Rfactor and Rfree = (Σ| |Fo| - |Fc| |)/(Σ |Fo|). 
b. Rfree was calculated for a 5% set of reflections excluded from the refinement. 
c. r.m.s.d. is the root-mean-square deviation from ideal geometry. 
d. Values were calculated using Molprobity (Chen, et al. 2010). 
e. Clash score is the number of serious steric overlaps (>0.4Å) per 100 atoms. 
f. MolProbity score combines the clashscore, rotamer and ramachandran evalutions into a single score, normalized 
to be on the same scale as X-ray resolution. 
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3.5  Overall structure of MU-DAK 
Compared with FL-DAK, the structure of MU-DAK is very well ordered in both the 
N- and C-terminal domains. In particular, the electron density map in the C-terminal 
domains is much clearer than before and it is much easier to identify the positions of 
the side chains, as shown in Figure 3.5.  
 
Figure 3.5. Comparison of the 2Fo-Fc electron density map (contoured at 1.5σ level) in parts of the 
C-terminal domain of FL-DAK and MU-DAK.  
(a). Same view as Figure 2.13b. (b) Greatly improved electron density map of the same region after 
mutation.  
For the new crystal form, only one monomer is present in the asymmetric unit. Indeed, 
the crystal packing between the symmetry-related molecules (Figure 3.6) is very 
different compared with the crystal packing of FL-DAK (Figure 3.1). Analyzing the 
interface between the two monomers in the dimer using the PISA server (Krissinel and 
Henrick, 2007), suggests an extensive interaction involving over 130 residues (25% of 
all residues) with a buried area of 4709Å2 (19% of the total surface area). 
a, FL-DAK structure, C-terminal domain b, MU-DAK structure, C-terminal domain 
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Figure 3.6. Cartoon representation of the symmetry related molecules of MU-DAK.  
One “monomer” is present in an asymmetric unit (shown in green), which is formed by the N-terminal 
domain of one monomer and the C-terminal domain of another monomer. A and B indicate the mutation 
positions also shown in Figure 3.1. The mutations result in different crystal packing pattern compared 
with the WT Figure 3.1  
MU-DAK provided a much more ordered structure than the WT. Superimposition of 
MU-DAK and FL-DAK (both as dimers) (Figure 3.7) shows that the two structures are 
very similar except for a loop between strands 7 and 8, where residues 200-212 are 
shifted by approximately 9Å. This was found to be caused by an MPD molecule 
binding very close to the loop (Figure 3.13), and this altered the original position of the 
loop. However, this shift did not affect the enzyme activity.  
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Figure 3.7. Cartoon representation of the superimposition of MU-DAK and FL-DAK.  
MU-DAK is shown in colour, in which the two N-terminal domains in the middle are shown in green 
and the two C-terminal domains on each side are shown in blue. FL-DAK is shown in grey. The loop of 
MU-DAK (shifted relative to FL-DAK) is shown in red.  
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As described in the last chapter, two α/β-folds form the N-terminal domain, which 
consists of a core structure of a six-stranded mixed β-sheet (β1- β6) surrounded by six 
helices (αA- αF), and another six-stranded mixed β-sheet (β7- β12) surrounded by 
three helices (αG- αI) (Figure 3.8). This typical configuration is very similar to C. 
freundii DAK (PDB code: 1UN9) (Siebold et al., 2003a) and E. coli DAK (PDB code: 
1OI2) (Siebold et al., 2003b). Indeed, superimposition of these three structures shows 
that three highly conserved residues (His220, His61 and Asp114 of C. freundii DAK; 
His218K, His56K and Asp109K of E. coli DAK and His221, His59 and Asp114 of H. 
sapiens DAK) are present in the substrate-binding site (Figure 3.9). This confirms the 
position of the substrate-binding site of H. sapiens DAK. The C-terminal domain 
consists of eight antiparallel α-helices, arranged as a barrel enclosing a deep pocket 
(Figure 3.10), all the residues are well defined with the exception of the loop between 
helix 7 and 8 where residues 538-553 are not visible in the map. ATP binding sites of 
both C. freundii DAK and E. coli DAK are in the bottom of the pocket of the C-
terminal domain, therefore, superimposition of all three C-terminal domains of DAK 
show that the ATP binding site of H. sapiens MU-DAK is likely to be in the same 
position as others (Figure 3.11). Indeed, a co-purified phospholipid with very strong 
electron density was identified in the middle of the pocket of the C-terminal domain 
(Figure 3.12). The phosphate head group of the phospholipid is exposed at the entrance 
of the pocket and the two palmitic acid tails extend 14.9Å and 17.8Å into the pocket, 
respectively. Furthermore, five MPDs were also found to have co-crystallized with the 
protein (Figure 3.13), four of which were bound to the N-terminal domain and one that 
was bound to the C-terminal domain. The linker between two domains is well ordered 
with the exception of residues 359 to 367, which are disordered.  
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Figure 3.8. Structure of the N-terminal domain of MU-DAK. 
 (a) Cartoon presentation of the N-terminal domain of MU-DAK. (b) Topological diagram of the N-
terminal domain and each colour corresponding to the respective α-helices/β-strands of (a). The number 
of the residues in each α-helices/β-sheet is also displayed. Figures were prepared with PyMol 
(http://pymol.org) and Microsoft PowerPoint 2011.  
 
Figure 3.9. Stereo view of the cartoon representation of the superimposition of H. sapiens MU-
DAK, C. freundii DAK and E. coli DAK in the substrate binding site.  
C. freundii DAK is shown in blue, E. coli DAK is shown in magenta and H. sapiens MU-DAK is shown 
in green. The substrate binding sites of C. freundii DAK and E. coli DAK are in the same position, and 
the three conserved residues (His, His and Asp shown as sticks) that surround Dha are also present in 
the H. sapiens MU-DAK. The name and the number of each residue are labelled in the relevant colour.  
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Figure 3.10. Structure of the C-terminal domain of MU-DAK.  
(a) Cartoon presentation of the C-terminal domain of MU-DAK, which consists of eight antiparallel α-
helices. (b) Topological diagram of the C-terminal domain in which each colour corresponds to the 
respective α-helix of (a). The number of the residues in each α-helix is also displayed.  
 
Figure 3.11. Stereo view of the cartoon representation of the superimposition of H. sapiens MU-
DAK, C. freundii DAK and E. coli DAK in the ATP binding site. 
C. freundii DAK is shown in blue, E. coli DAK is shown in magenta and H. sapiens MU-DAK is shown 
in green. The ATP binding sites of C. freundii DAK (ANP) and E. coli DAK (ADP) are in the same 
position.  
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Figure 3.12. Stereo view of the phospholipid binding in the pocket of the C-terminal domain of 
MU-DAK.  
The lipid is shown in sticks with Fo-Fc electron density (contoured at 2.5σ level).  
 
Figure 3.13. Fo-Fc electron density map (contoured at 2.5σ level) of MPD.  
Two MPDs were found on each side of the N-terminal domain and one was present at the bottom of the 
pocket in the C-terminal domain.  
90o 
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3.6  Complex formations of MU-DAK with Dha and ATP analogues 
Attempts to obtain a structure of MU-DAK in complex with both Dha and ATP 
analogues (ADP, ANP, AMP, CTP and APC) were made using the same crystallization 
condition as Figure 3.4a. However, although crystals grew, none of these ligands were 
present in the structure. Soaking MU-DAK crystals with these ligands made them 
malleable and was detrimental to the diffraction pattern; reflections were no longer 
observed, which suggests that these ligands were harmful to the crystal packing. 
Another possible problem was the presence of MPD in the assumed ATP binding site 
(as shown in Figure 3.13), which might prevent formation of the complex. Therefore, 
in an attempt to find a replacement for MPD as crystallization additive, the Additive 
screen (Hampton research) and Silver Bullet screen (Hampton research) were used. 
However, all the crystals diffracted much worse than before. On the other hand, further 
optimization of the alternative condition (Figure 3.4b) was carried out using the 
Additive Screen and several rounds of stochastic optimizations, which yielded a new 
crystal in 140mM sodium formate, 5mM MgCl2, 14% (w/v) PEG3350 and 6% (w/v) 
1,6-hexanediol with the protein concentration of 10mg ml-1. These crystals could 
diffract to 2.2Å in house, and no obvious additional electronic density was visible near 
the ATP binding site. After that, co-crystallization of the protein with Dha and ATP 
analogues was then performed. Dramatically, both Dha (5mM) and APC (5mM)/CTP 
(5mM) were successfully bound to the protein. 
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3.7  Data collection and structure determination of complexes of MU-
DAK with Dha and APC/CTP 
Crystals of all of the complexes belonged to space group C2, and single crystals 
diffracted to 2.2Å resolution (for MU-DAK only), 1.9Å resolution (APC complex) and 
2.4Å resolution (CTP complex). Data were collected over a range of 180o (0.1o steps) 
in house with a Rigaku 007HFM (Cu anode, λ = 1.54178) X-ray generator, with a 
Saturn 944CCD detector. HKL2000 (Otwinowski & Minor, 1997) was employed for 
data indexing and processing. For the structure determination, the same protocols were 
applied as described above. All data collection and structure refinement statistics are 
summarised in Table 3.4. 
Data collection MU-DAK-1.6-Hexanediol complex 
MU-DAK-APC/Dha 
complex 
MU-DAK-CTP/Dha 
complex 
Beamline  In-house In-house In-house 
Wavelength (Å) 1.54178 1.54178 1.54178 
Unit-cell parameters (Å) 
a (Å) 
b (Å) 
c (Å) 
α (°)  
β (°)  
γ (°) 
 
149.00 
50.01 
78.63 
90.00 
106.10 
90.00 
 
149.07 
50.21 
78.68 
90.00 
105.95 
90.00 
 
149.02 
49.95 
78.58 
90.00 
106.16 
90.00 
Space group C2 C2 C2 
Molecules per asymmetric unit 1 1 1 
Resolution (Å) 50.00-2.23(2.27-2.23) 50.00-1.85(1.88-1.85) 50.00-2.36 (2.40-2.36) 
Unique reflections 27240 45766 21863 
Redundancya  3.6(2.8) 3.3(2.6) 2.5(2.0) 
Completeness%a 99.2(91.3) 95.0(88.8) 94.3(82.1) 
Rmerge (%)a,b 4.6(17.7) 4.3(19.6) 3.8(14.7) 
<I/σIa> 38.7(8.3) 40.32(6.1) 34.67(6.9) 
Wilson B-factor (Å) 20.7 21.8 39.2 
Matthews coefficient 2.3 2.4 2.4 
Solvent (%) 49 49 48 
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Refinement  MU-DAK-1.6-Hexanediol complex 
MU-DAK-APC/Dha 
complex 
MU-DAK-CTP/Dha 
complex 
Resolution range (Å) 75.5-2.2 75.7-1.9 75.5-2.4 
Mean B-factor (Å2)    
                   Protein 35.9 28.9 48.5 
                   Ligands  44.9 40.4 63.5 
                   Water  39.2 37.2 41.4 
Rfactor (%)c 18.6 18.6 20.9 
Rfree (%)d 25.2 23.6 28.1 
r.m.s.d. bond lengths (Å)e 0.02 0.02 0.01 
r.m.s.d. bond angles (°)e 1.79 2.02 1.68 
Number of reflections 25806 43234 20674 
No. of atoms    
                   Protein atoms 4293 4258 4150 
                   Ligands 68 105 95 
                   Water molecules 208 386 51 
Mg2+ ions 0 1 0 
1-6 Hexanediol molecules 3 3 2 
Dha molecules 0 1 1 
APC molecules 0 1 0 
CTP molecules 0 0 1 
Validationf     
Clashscoreg  5.5 4.8 4.7 
Rotamer outliers (%) 1.7 2.7 3.7 
Cβ deviations >0.25Å 0 4 2 
Residues with bad bonds/angles (%) 0.0/0.1 0.1/0.1 0.0/0.0 
MolProbity Scoreh 1.8 1.8 2.2 
 (94th percentile) (79th percentile) (87th percentile) 
Ramachandran favoured/outliers (%) 95.3/0.4 96.83/0.56 91.8/0.4 
Table 3.4. Data collection and refinement statistics of the complex of MU-DAK with Dha and ATP 
analogues.  
a. Values in parentheses correspond to the highest resolution shell. 
b. Rmerge=Σhkl Σi |Ii(hkl)-<I(hkl)>|/ Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity for all observations i of reflection 
hkl, and <I (hkl)> is the weighted average intensity for all observations i of reflection hkl. 
c. Rfactor and Rfree = (Σ| |Fo| - |Fc| |)/(Σ |Fo|). 
d. Rfree was calculated for a 5% set of reflections excluded from the refinement. 
e. r.m.s.d. is the root-mean-square deviation from ideal geometry. 
f. Values were calculated using Molprobity (Chen, et al. 2010). 
g. Clash score is the number of serious steric overlaps (>0.4Å) per 100 atoms. 
h. MolProbity score combines the clashscore, rotamer and ramachandran evalutions into a single score, normalized 
to be on the same scale as X-ray resolution. 
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3.8  Overview of the active site of MU-DAK 
Comparing the crystal structure of MU-DAK with and without the ligands, it is shown 
that the MU-DAK structure does not undergo significant conformational changes upon 
ligand binding. The r.m.s.d value of superimposition of the two structures is only 
0.26Å over all of the Cα atoms. The σA-weighted Fo-Fc electron-density maps of Dha 
and APC/CTP molecules in the complexes with MU-DAK are clearly defined (Figure 
3.14).  
  
 
  
a 
b 
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Figure 3.14. Electron density of ligands co-complexed with MU-DAK.  
(a) Stereo view of Fo-Fc map of APC and Mg2+ co-complex contoured at 2.5σ level. (b) Stereo view of 
Fo-Fc map of CTP co-complex contoured at 2.5σ level. (c) Stereo view of Fo-Fc map of Dha co-complex 
contoured at 2.5σ level.  
 
Figure 3.15. APC is shown to indicate H. sapiens DAK active site.  
APC shown in spheres, bound to the bottom of the pocket of the C-terminal domain. A Mg2+ ion is 
shown as a sphere in green. (a) View from the side. (b) View from the bottom.  
Similar to the previously reported homologues, the ATP binding site of H. sapiens 
DAK is also present at the bottom of the pocket of the C-terminal domain, which is 
shown with bound APC in Figure 3.15. There are a number of interactions between 
MU-DAK and its ligands, among which residues Leu450, Thr494, and Met495 interact 
with the adenine base; residues Met495, Asp556 and Pro557 interact with the ribose 
moiety and residues Ser447 and Ser446 are coordinated by α-phosphate and γ-
phosphate, respectively (Figure 3.16a). Additionally, one Mg2+ ion was shown to 
interact with α- and β-phosphate and with Asp396, Asp401 and Asp403 (Figure 3.16a). 
The APC and the phospholipid are separated by four residues (Met443, Tyr451, 
c 
a b 
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Met495 and His408), which form a “wall” between the ligands. Furthermore, Dha is 
bound to the expected site, which is in the N-terminal domain. The Dha forms 
hydrogen bonds with His59 and Asp114, and a covalent bond (hemiaminal structure) 
between the Dha Cβ atom and the His221 NE2 atom (Figure 3.16b). Details of the 
major interactions between MU-DAK and APC/Dha/Mg2+ are listed in Table 3.5. 
 
 
Figure 3.16. Stereo views of the substrate and cofactor binding sites of MU-DAK.  
(a) The complex of MU-DAK with APC/Mg2+ and the residues that are involved in the interactions. 
APC is shown in yellow, Mg2+ in green and waters in magenta. (b) The complex of MU-DAK with Dha 
(yellow) and the residues that are involved in the interactions. Hydrogen bonds are shown as black 
dotted lines. The covalent bond between Dha and His221 is shown. 
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APC/Mg2+ 
 
Protein/ 
Water atoms 
Distance 
(Å) 
Dha Protein/ 
Water atoms 
Distance 
(Å) 
O-1 A Asp396-O-δ2 3.03 O-1 Asp114-O-δ2 2.67 
O-1 A Mg2+ 2.26 O-1 Gly56-N 2.89 
O-1 A Asp403-O-δ1 3.29 O-1 Lys109-N-ζ 3.16 
O-1 B Mg2+ 3.15 O-2 His59-N-ε2 2.78 
O-1 B H2O (W1) 2.52 O-2 His221-N-ε2 3.33 
O-1 G H2O (W1) 2.72 O-3 His59-N-ε2 3.05 
O-1 G Ser446-O-γ 2.84 O-3 Asp114-O-δ1 2.61 
O-2 A Ser447-O-γ 3.18    
O-2 B Mg2+ 2.62    
O-2 B Asp403-O-δ1 2.54    
O-2 B Asp401-O-δ1 2.69    
O-2 G Ser446-N 3.33    
O-2’ Met495-N 2.68    
O-2’ Asp556-O-δ1 2.49    
O-3’ Asp556-O-δ1 3.00    
O-3’ Asp556-O-δ2 2.64    
O-3’ Gly558-N 3.15    
N-1 H2O (W3) 2.65    
N-6 Gly486-O 3.07    
N-7 H2O (W2) 3.00    
Mg2+ Asp403-O-δ1 2.78    
Mg2+ Asp396-O-δ1 3.14    
Mg2+ Asp396-O-δ2 2.18    
Mg2+ Asp401-N 3.38    
H2O (W3) Ala488-N 2.91    
H2O (W3) Met482-O 3.00    
Table 3.5. Interactions between MU-DAK and the ligands. 
Intramolecular hydrogen bonds between MU-DAK and the ligands APC and Dha are listed. Bridging 
interactions made by Mg2+ and water are also detailed.  
Interestingly, the distance between the Cγ of Dha and β-phosphate of APC molecule in 
H. sapiens DAK is 14.2Å, whereas the distance between the corresponding atoms in 
complex of E. coli DAK (PDB code: 1OI2) (Siebold et al., 2003b) with Dha and ADP 
is only 5.9Å, sufficiently close such that an ATP would have its γ–phosphate very near 
Cγ. Comparing the two dimer structures of H. sapiens and E. coli DAK, there are no 
significant conformational changes in the N-terminal domains. However, there is a 
significant shift in the relative orientations of the C-terminal domains with respect to 
the N-termini (Figure 3.17). In E. coli DAK, the two binding sites are brought much 
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closer together. This suggests that the N- and C- domains may undergo changes in 
orientation, which may play a role in its activity as a kinase.  
 
Figure 3.17. Relative positions of the substrate and cofactor binding sites in H. sapiens DAK and E. 
coli DAK.  
(a) APC and Dha are shown in spheres in the complex with MU-DAK, and the distance between the Cγ 
of Dha and β-phosphate of APC is 14.2Å. (b) ADP and Dha are shown in spheres in the complex with E. 
coli DAK, which is shown the N-terminal domains in the same orientation as (a). The distance between 
the Cγ of Dha and β-phosphate of ADP is 5.9Å. 
  
a 
b 
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3.9  Determination of the role of H. sapiens DAK as a lyase 
As a bifunctional enzyme, H. sapiens DAK was reported also to act as an FAD-AMP 
lyase (Cabezas et al., 2005), thus it is predicted that H. sapiens DAK is able to form a 
complex with FAD or cFMN. Accordingly, crystal trials were set-up to obtain a 
complex of DAK with FAD or FMN. However, no crystals were produced in any of 
the crystal trials. 
To confirm an interaction between H. sapiens DAK and FAD, a coupled enzyme assay 
based on a discontinuous colorimetric assay for phosphatase-sensitive Pi liberated from 
AMP was designed (Figure 3.18). Primarily, DAK catalyses the formation of AMP and 
FMN molecules from FAD. The released AMP molecules are then dephosphorylated 
by alkaline phosphatase to form adenosine (ADO) and free Pi. Afterwards, the free Pi 
and ammonium molybdate form phosphomolybdate, which turns blue in the presence 
of ascorbic acid. Indeed, the amount of the blue colored ion liberated is dependent on 
the amount of phosphate present, which can be measured by fluorescence spectroscopy 
at A820. The results displayed that compared with the FAD only, both FL-DAK and 
MU-DAK could catalyse the splitting of FAD into cFMN and AMP (Figure 3.19). 
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Figure 3.18. Flowchart for phosphate discontinuous colorimetric assay.  
AMP molecules, which split from FAD, in a reaction catalysed by DAK, are dephosphorylated by 
alkaline phosphatase and produce free phosphate. The mixture of free phosphate and ammonium 
molybdate can form phosphomolybdate, which will turn blue with ascorbic acid and can be monitored 
by fluorescence at A820. 
 
Figure 3.19. The result of the activity assay of H. sapiens DAK acting as a lyase.  
The absorbance (A.U.) of each reaction is shown under the title of the sample. Different concentrations 
of AMP were used as the positive control; FAD only and protein only were used as the negative control. 
The blue colour is dependent on the amount of phosphate. FAD itself is yellow, therefore the reaction 
with DAK shows as a dark green colour. Assays were performed three times with similar results.  
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3.10  Discussion and conclusion 
As a multifunctional enzyme, H. sapiens DAK has been reported to perform both as an 
ATP-dependent kinase and also a lyase, catalysing the splitting of FAD into cFMN and 
AMP (Cabezas et al., 2005). To further understand these features, a structural study 
was carried out. The initial WT structure was poorly ordered in the C-terminal domain 
and it was not possible to distinguish the details of the whole structure significantly. 
However, based on the structure it was possible to identify three small molecular 
weight amino acids present on the surface of the N-terminal domain that could be 
mutated into longer side chain amino acids. This altered the crystal packing and did 
not affect activity. Dramatically, the newly formed crystals from the mutated protein 
diffracted to 1.4Å. Usually surface mutagenesis is performed when no crystals can be 
obtained. In this case an existing crystal form was deliberately disrupted in order to 
allow the possibility that a crystal with completely different packing might be 
obtained.  
H. sapiens DAK shares 39% and 36% identity with C. freundii DAK and E. coli DAK, 
respectively. The more clear and complete structure shows the common structural 
features of the pre-reported DAKs.  
The C-terminal domain consists of eight α-helices, which form a deep pocket that is 
filled by a phospholipid. Indeed, C. freundii DAK was also reported to form the same 
phospholipid-protein complex in the apo structure form (Siebold et al., 2003). This 
kind of lipid-protein complex often observed in the lipid transfer proteins of plants and 
pollen allergens (Charvolin et al., 1999, Verdino et al., 2002). The lipids in these 
transfer proteins are surrounded either by four amphipathic helices or by two 
intertwined EF-hand-folds, which completely 
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from the medium (Charvolin et al., 1999, Verdino et al., 2002). In contrast, the polar 
head group of the phospholipid from both H. sapiens DAK and C. freundii DAK are 
exposed from the pocket of their C-terminal domain. Phospholipids in this kind of 
configuration have previously only been observed in some membrane proteins and are 
thought to determine the packing of transmembrane helices (Lee 2003). However, the 
function of the phospholipid in the C-terminal domain of DAK is still unclear, and how 
it gets incorporated during protein folding is also not determined. Additionally, the 
lipid-free C. freundii DAK was reported to retain over 80% of the enzyme activity 
after the lipids had been removed from the enzyme by incubation with detergent and 
gel-filtration in a detergent-free buffer, which indicates that the phospholipid is not 
essential for enzyme activity but may function to stabilize the helix barrel in the 
protein. Therefore, more functional studies on the phospholipid from H. sapiens are 
necessary. In the current study, both the ATP and the Dha binding sites adopt the 
positions of classic dihydroxyacetone kinase substrate binding sites. However, none of 
the existing DAK structures have FAD or FAD analogues bound, so the structural basis 
for the DAK lyase activity requires further crystallographic study.  
The previously published C. freundii DAK structure in complex with ANP and Dha 
was achieved by soaking the crystal with the ligands, and the authors believed that the 
conformation of the protein would be changed upon co-crystallization of the protein 
with the ligands, but they failed to obtain any crystals at that stage (Siebold et al., 
2003a). In the current study, the complex structure of the H. sapiens MU-DAK with 
ligands was carried out by co-crystallization, and the structure does not undergo 
significant conformational changes compared with C. freundii DAK. The C. freundii 
DAK structure has the same orientation of N- and C-terminal domains as the H. 
sapiens DAK, with the unexpectedly large distance between the Dha and ATP binding 
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sites. The authors of the C. freundii DAK structure suggest that this may be a 
crystallization artifact. However, the fact that H. sapiens DAK adopts a very similar 
conformation (with a completely different set of crystal contacts) strongly suggests 
that this conformation is not a crystallization artifact, but may instead represent a 
physiologically relevant state of the protein.  
On the other hand, compared with the H. sapiens DAK, the previously reported DAK 
structure from E. coli shows a different conformation, in which the C-terminal 
domains on each side are rotated with respect to the N-terminal domains, bringing the 
two substrate binding sites closer to each other (Figure 3.17). Additionally, DAK from 
E. coli utilizes PTS (phosphoenolpyruvate: sugar phosphotransferase system) to 
provide the phosphoryl group, and consists of two sub-units called DhaK and DhaL, 
which correspond to the N-terminal domain and the C-terminal domain of H. sapiens 
DAK, respectively (Shi et al., 2011). The presence of two polypeptide chains (E. coli 
DhaK, DhaL) rather than one (H. sapiens DAK) may account for the difference in 
conformation. The N- and C-terminal domains of MU-DAK have very similar overall 
structures to E. coli DhaK (r.m.s.d of 1.24Å; 310 Cα atoms) and DhaL (r.m.s.d of 
1.59Å; 186 Cα atoms), respectively. Although H. sapiens DAK and E. coli DAK 
utilize different sources to provide the phosphoryl group, the mechanisms of the kinase 
are almost identical (Shi et al., 2011). Therefore, I may make the tentative assumption 
that the C-terminal domains in H. sapiens DAK are flexible in solution and the protein 
undergoes a large conformational change, bringing the substrate and cofactor binding 
sites together to allow the kinase reaction to occur. Further evidence to prove this 
assumption is essential.  
In the current study, the first crystal structure of a eukaryotic DAK in complex with its 
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substrates has been solved, revealing details of the kinase active site. How the protein 
performs as a lyase to catalyse the FAD into cFMN and AMP, and how the protein can 
interact with MDA5 is still not clear. Therefore, further studies on these targets are 
necessary.  
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4.1  Summary 
Streptococcus pneumoniae NanA is an important sialidase, present in all clinical 
strains (Pettigrew et al., 2006). In addition, it has been indicated that NanA could 
mediate S. pneumoniae adherence to and invasion of human brain microvascular 
endothelial cells (hBMECs) (Uchiyama et al., 2009). Isogenic bacteria with a 
mutation that eliminates NanA expression show a significant decrease in adherence 
and invasion of hBMECs, and pretreatment of hBMECs with recombinant NanA 
protein significantly increased bacterial invasion (Uchiyama et al., 2009, Banerjee et 
al., 2010). It has also been determined that the sialidase catalytic activity makes only 
a limited contribution to the ability of NanA to mediate this invasion, which indicated 
that the N-terminal CBM domain of NanA plays a very critical role (Banerjee et al., 
2010). Therefore, it will be an essential advantage for novel drug design if the 
structure and function of NanA are fully understood. At present, only the structure of 
the catalytic domain of NanA has been reported as published by Xu et al. (Xu et al., 
2008a), thus, there is a need to understand the structure of the N-terminal CBM 
domain of NanA to gain a more complete understanding of the enzyme.  
In the current chapter, the crystal structure of the S. pneumoniae NanA CBM domain 
(residues 121-305, ~21kDa, designated NanA-CBM) and the structures of complexes 
of NanA-CBM with Neu5Ac and its derivatives will be described. 
The CBM domain from S. pneumoniae NanA was successfully sub-cloned. The 
purified protein was subsequently analysed by HSQC NMR to determine the level of 
disorder in the protein as initial structural analysis suggested that there may have been 
disordered regions. Crystallization trials of apo NanA-CBM and NanA-CBM with 
substrates were carried out. Diffracting crystals were obtained using seeding 
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techniques. The apo structure was determined to 1.84Å with final Rfactor/Rfree of 16.3% 
and 21.8%, respectively. The structure exists as two monomers in one asymmetric 
unit, which adopt a β-sandwich fold that is structurally homologous to other members 
of the reported family 40 CBM (CBM40) modules. For the complex structures, data 
to the same resolution were obtained, however, only one monomer was present in 
each asymmetric unit, as a result of the altered crystal packing compared to the apo 
structure. Nevertheless, comparison of apo and holo structures show that NanA-CBM 
does not undergo any conformational changes upon ligand binding. Unlike other 
CBM40 structures, a distinct negatively charged pocket with a positively charged rim 
is present next to the substrate-binding site, which is filled by a lysine side chain that 
belongs to a symmetry-related molecule. This pocket could play an essential role for 
NanA not only in recognition of the sialic acid, but also in promoting S. pneumoniae 
adherence to human brain microvascular endothelial cells (Uchiyama et al., 2009). 
Therefore, further study on the potential ligands that could bind to the substrate-
binding site, and/or the negatively charged pocket is imperative.  
The experimental procedures are described below, and more details about the 
materials and methods are given in Appendix I.  
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4.2  NanA-CBM production  
The gene encoding NanA-CBM that had been amplified from S. pneumoniae NanA 
genomic DNA (UniProt: P62575) was sub-cloned into the pEHISGFPTEV vector 
(Liu and Naismith, 2009) by a member of the group (Dr H. Connaris). The construct 
comprises an N-terminal six-histidine tag and a green fluorescent protein (GFP) tag, 
which is followed by a TEV protease cleavage site (Figure 4.1). The presence of a 
GFP tag has been reported to improve protein folding and increase yields during 
protein expression. Also, the green fluorescence of the construct can be used to easily 
monitor protein expression. In addition, this construct has a histidine tag for affinity 
purification and a TEV protease recognition for efficient tag removal. The plasmid 
was transformed into E. coli BL21 (DE3) cells (Life Technologies). In order to obtain 
a higher yield of soluble protein, auto-induction media was selected for the protein 
expression (Studier, 2005). A 10ml overnight culture was inoculated into 500ml auto-
induction media (pre-warmed at 37oC) containing 100µg ml-1 kanamycin (Sigma), 
shaken at 250rpm for 3h at 37oC, which was followed by further shaking for 48h at 
18oC. Around 20g of cell pellets would be obtained from a 2L culture.  
 
Figure 4.1. The schematics of NanA-CBM construct.  
For protein purification, soluble protein extract was initially purified by nickel affinity 
chromatography (20ml HisPrep, GE Healthcare) (Figure 4.2a); the eluted protein 
solution was then digested by TEV protease in order to separate the GFP tag from the 
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protein; a second nickel affinity chromatography step (20ml HisPrep, GE Healthcare) 
was then employed to remove the protease and the cleaved GFP tag portion of the 
protein (Figure 4.2b); in the final step, a HiPrep 26/60 S-200 column (GE Healthcare) 
was used for gel-filtration purification (Figure 4.2c). More than 40mg NanA-CBM 
protein was obtained from a 2L culture.  
 
Figure 4.2. WT NanA-CBM purification.  
(a). An SDS-PAGE gel showing fractions collected from nickel affinity purification; the main band in 
lane 6 is NanA-CBM with GFP tag, 52kDa in total. The eluted sample was collected and digested by 
TEV protease. Lane 1, Pre Ni2+ column; Lane 2, Ni2+ column flow through; Lane 3&4&5, Ni2+ column 
wash; Lane 6, Ni2+ column elute and Lane M, Protein Marker. (b). An SDS-PAGE gel showing 
fractions collected from the second nickel affinity purification after TEV cleavage. The red asterisk 
indicates NanA-CBM (21kDa), the green asterisk indicates GFP tag (31kDa), and the blue asterisk 
indicates TEV protease (27kDa). Lane 1, Pre Ni2+ column after TEV cleavage; Lane 2, Ni2+ column 
flow through; Lane 3&4, Ni2+ column wash; Lane 5, Ni2+ column elute and Lane M, Protein Marker. 
(c). Elution profiles of NanA-CBM after gel filtration column (HiPrep 26/60, Sephacryl S-200) (GE 
Healthcare). The blue line indicates the absorbance at 280nm. Inset shows SDS-PAGE analysis of the 
main peak fractions (indicated by the green horizontal bar). 
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4.3  Crystallization of NanA-CBM 
For NanA-CBM crystallization trials, 20mg ml-1 protein concentration, as suggested 
by the pre-crystallization test (PCT) was chosen as the starting point of the crystal 
trials. The initial crystal trials were carried out with the commercial screens following 
the same protocols described in chapter 2. Crystals appeared after four weeks in 
condition 44 (0.1M Tris-HCl pH8.5, 25% (w/v) PEG4000) and condition 45 (0.1M 
Tris-HCl pH8.5, 25% (w/v) PEG6000) of the PEGs Suite (Qiagen). Crystals formed 
as a thin sheet-like square shape (Figure 4.3a), that either stuck to a skin that 
repeatedly formed on the surface of the crystallization drops or to the bottom of the 
crystallization wells, which made crystal harvesting extremely troublesome. After 
several rounds of optimization, the crystals did not diffract better than 4Å (Figure 
4.3c). Further optimizations were carried out using a higher concentration of the 
protein (up to 33mg ml-1) and re-screening. Surprisingly, besides the original 
conditions, several new forms of crystals were grown in conditions including: 17 
(0.1M MIB (molar ratios 2: 3: 3 of sodium malonate: imidazole: boric acid) buffer 
pH8, 25% (w/v) PEG1500), 18 (0.1M MIB buffer pH9, 25% (w/v) PEG1500), 41 
(0.1M MMT (molar ratios 1: 2: 2 of DL-malic acid: MES: Tris Base) buffer pH8, 25% 
(w/v) PEG1500) and 42 (0.1M MMT buffer pH9, 25% (w/v) PEG1500) of the PACT 
screen; condition 11 (0.1M MES pH6.0, 0.2M Li2SO4 and 20% (w/v) 1,4-butanediol) 
of the Wizard screen. After several rounds of optimizations, the best crystals were 
obtained using seeding (Bergfors, 2003) in 120mM MMT pH9.0, 25% (w/v) 
PEG1500 and 300mM valine (reservoir solution). To make the seeds stocks, 0.5µl 
protein was mixed with 0.5µl reservoir solution and set up in sitting drop vapor 
diffusion plates. The initial crystals appeared after two weeks. Drops containing 
crystals were placed into a 1.5ml eppendorf containing a seed bead (Hampton 
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Research) followed by vortexing, removal of the seed bead and dilution of the seed 
suspension in different concentrations for further use. For crystal seeding, the same 
method was performed to set up the plates and a cat whisker (kindly provided by Dr 
M. Taylor’s cat) was used to streak seed from the seed stock to a fresh crystallization 
drop the day after the plates were setup. Usually, the seeded crystals appeared the next 
day and reached their maximum size within a week, and a 1.84Å dataset was collected 
from the seeded crystal. (Figure 4.3b&d).  
 
Figure 4.3. NanA-CBM crystals and their respective diffraction patterns.  
(a). NanA-CBM crystals obtained from a concentration of 20mg ml-1. (b). NanA-CBM crystals 
obtained from a concentration of 33mg ml-1 by seeding. (c). X-ray diffraction pattern of one of the 
crystals shown in (a). (d). X-ray diffraction pattern of one of the crystals shown in (b).  
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4.4  Data collection and structure determination of NanA-CBM 
A 1.84Å (maximum resolution for in-house) dataset was collected with the collection 
strategy of over a range of 180o (0.1o steps), 40mm between crystal and detector, 
10sec exposure per image. The dataset was then processed using the HKL2000 
program (Otwinowski & Minor, 1997). However, for the MR, there was no available 
protein in PDB library sharing more than 25% amino acid sequence identity with 
NanA-CBM, therefore, the sequence of NanA-CBM was submitted to Phyre2 to 
produce a potential model. Phyre uses PSI-Blast to compare the query sequence to a 
library of known structures, which has been converted into a fold library. To allow 
identification of distant homologs, PSI-Blast generates profiles for both the query 
sequence and the sequences of known structure. These profiles include conservation 
scores for each amino acid in the sequence. Next, secondary structure is predicted 
using Psi-Pred, SSPro and JNet, and the disordered regions are predicted by Disopred. 
For homology modeling, the profile and secondary structure predictions are then 
searched against the fold library profiles and the top ten hits are used for 3D model 
construction (Kelley and Sternberg, 2009). The output model was based on the 
structure of the CBM domain of the trans-sialidase NanL (PDB code: 2SLI) (Luo et 
al., 1999) from M. decora, which shares 25% amino acid sequence identity with 
NanA-CBM. The output structure was then used as the MR search model. The 
structure was phased by MR with the PHASER program (McCoy et al., 2007) from 
the CCP4 suite (Winn et al., 2011) using data from 67.0-2.5Å, which gave a single 
solution with a TFZ-score of 21.2 and LLG of 669. The refinement was carried out 
using the same methods as described in chapter 2. However, after several rounds of 
refinement, while most regions of the structure could be identified very well, some 
discontinuous regions (over 30 amino acid in total) were very poorly defined and the 
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Rfactor/Rfree of the structure remained at around 38.9/44.0%. Initially, it was thought 
that the protein was disordered or unstable in these regions, therefore, 15N NMR was 
carried out to assess the state of the protein stability and folding. Surprisingly, the 
NMR result showed that the protein was highly ordered (described in section 4.5). 
Subsequently, the sequence register errors were recognized in theses regions and 
manually rebuilt followed by further refinement. Eventually, the completed structure 
was refined with final Rfactor/Rfree values of 16.3% and 21.8%, respectively. All data 
collection and structure refinement statistics are summarized in Table 4.1 
Data collection NanA-CBM Refinement  NanA-CBM 
Beamline  In-house Resolution range (Å) 67.0-1.8 
Wavelength (Å) 1.54178 Mean B-factor (Å2)  
Unit-cell parameters 
a (Å) 
b (Å) 
c (Å) 
α (°)  
β (°)  
γ (°) 
 
39.23 
66.98 
66.79 
90.00 
92.43 
90.00 
                       Protein 
                       Ligands 
                       Water 
Rfactor (%)c 
Rfree (%)d 
r.m.s.d. bond lengths (Å)e 
r.m.s.d. bond angles (°)e 
16.3 
0 
28.5 
16.3 
21.8 
0.02 
2.10 
Space group P21 Number of reflections 27743 
Molecules per asymmetric unit 2 No. of atoms  
Resolution (Å) 50.00-1.84(1.87-1.84)                    Protein atoms 2986 
Unique reflections 29236                    Ligands 0 
Redundancya  2.5(2.0)                    Water molecules 403 
Completeness (%)a 96.8(73.9)   
Rmerge (%)a,b 3.2(7.2)   
<I/σIa> 43.9(22.7)   
Wilson B-factor (Å) 13.9   
Matthews coefficient 2.1   
Solvent (%) 41   
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Validationf    
Clashscoreg 3.9   
Rotamer outliers (%) 4.0   
Cβ deviations >0.25Å 4   
Residues with bad bonds/angles 
(%) 
0.1/0.1   
MolProbity Scoreh 1.8 (76
th percentile)  
Ramachandran 
favoured/outliers (%) 
96.7/0.0   
Table 4.1. Data collection, refinement and validation statistics of NanA-CBM. 
a. Values in parentheses correspond to the highest resolution shell. 
b. Rmerge=Σhkl Σi |Ii(hkl)-<I(hkl)>|/ Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity for all observations i 
of reflection hkl, and <I (hkl)> is the weighted average intensity for all observations i of reflection hkl. 
c. Rfactor and Rfree = (Σ| |Fo| - |Fc| |)/(Σ |Fo|). 
d. Rfree was calculated for a 5% set of reflections excluded from the refinement. 
e. r.m.s.d. is the root-mean-square deviation from ideal geometry. 
f. Values were calculated using Molprobity (Chen, et al. 2010). 
g. Clash score is the number of serious steric overlaps (>0.4Å) per 100 atoms. 
h. MolProbity score combines the clashscore, rotamer and ramachandran evalutions into a single score, 
normalized to be on the same scale as X-ray resolution. 
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4.5  15N NMR HSQC analysis of the level of disorder of NanA-CBM 
NanA-CBM was thought to be partially disordered due to difficulties encountered in 
building the structure in some regions. This assumption required further investigation 
and, as the protein is relatively small (21kDa), NMR was used to assess the extent of 
the order of the protein structure. Therefore, 15N labeled protein was analysed by 
NMR in both 1D (Dimension) 1H and 2D HSQC spectra.  
For 15N-labelled NanA-CBM protein expression, minimal medium containing 1mg 
ml-1 15NH4Cl was used for the protein expression. An overnight LB medium culture 
was centrifuged and resuspended with minimal medium to replace the LB medium. 
The suspension was then inoculated into 0.5L minimal medium containing 50µg ml-1 
kanamycin followed by incubation at 250rpm for 4-5h at 37oC until OD600 reached 
0.5-0.6. Prior to IPTG induction (0.5mM) for protein expression, the cultures were 
heat shocked in a 42oC water bath for 30min. Cultures were then left in a shaking 
incubator at 18oC overnight. About 6g of cell pellets were harvested from a 2L 
culture.  
15N labeled protein was purified as described in section 4.2. The purified protein was 
diluted to 0.76mM (16mg ml-1) in 50mM NaCl, 20mM sodium citrate, pH 6.0. In each 
600µl sample solution, 550µl 0.7mM 15N labeled protein and 50µl deuterated water 
(D2O, 99.9%, Sigma) were mixed. The mixture was then transferred into a 5mm 
NMR tube (Bruker) and measured on a 500MHz triple channel solution-state NMR 
spectrometer. The experiment was carried out and NMR data processed and analysed 
by Dr U. Schwarz-Linek (School of Biology, University of St Andrews).  
Basically, the spectrum shows a very good spectral dispersion in both dimensions, 
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mostly uniform cross-peak intensities and line-widths typical for a ~25 kDa protein at 
the magnetic field strength used. This indicates that the protein is well folded and 
monomeric in solution. There are no signs of unfolded or highly flexible regions, 
which would give rise to intense, narrow, overlapped cross-peaks in the central region 
of the spectrum. In the 1D 1H spectrum (Figure 4.4a), each signal corresponds to an 
functional group and the peaks show very good chemical shift dispersion, which 
illustrates the protein is properly folded, otherwise the peaks would be much broader 
with poor chemical shift dispersion in unfolded or partially folded regions. 
Additionally, the 2D HSQC spectrum (Figure 4.4b) also shows the protein is well-
ordered according to the good chemical shift dispersion (each cross-peak corresponds 
to an amino acid), otherwise most of the spots would be very close to each other in the 
spectrum due to the free protons in unfolded or partially folded protein.  
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Figure 4.4. The result of 15N NMR analysis of NanA-CBM.  
(a). 1D 1H spectrum. Peaks from water and citrate are labeled. (b). 2D HSQC spectrum. Blue contours 
represent cross-peaks that are aliased (folded) in the 15N dimension (i.e. their true 15N resonance 
frequencies lie out with the spectral boundaries).  
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4.6  Overall structure of NanA-CBM and comparison with other 
related CBMs 
All residues (from Val121 to Ser305) of the sequence of the expressed CBM were 
clearly identifiable in the complete NanA-CBM crystal structure. As shown in Figure 
4.5, the structure constituted a central β-sandwich (comprising an antiparallel β-sheet 
containing five-strands opposing an antiparallel β-sheet containing six-strands), a β-
hairpin (β11- β12 shown in orange) on the top and generally perpendicular to the β-
sheets, an α-helix (αA shown in blue) present between the β-sheets, and a C-terminal 
α-helix (αB shown in red) packing against the β-sandwich.  
 
Figure 4.5. Overall structure of the NanA-CBM.  
(a). Cartoon presentation of the NanA-CBM in two orientations. (b). Topological diagram of the 
NanA-CBM structure wherein each colour corresponds to the respective α-helices/β-strands of (a). The 
number of the residues in each α-helix/β-strand is also displayed. 
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Currently, there are no available CBM structures that share a high percentage of 
amino acid sequence identity with NanA-CBM. The structure of NanA-CBM exhibits 
a typical CBM β-sandwich fold, which is structurally homologous to CBM40 
modules from S. pneumoniae NanB (PDB code: 2VW0) (Xu et al., 2008b), M. decora 
NanL (PDB code: 2SLI) (Luo et al., 1999), C. perfringens NanJ (PDB code: 2V73) 
(Boraston et al., 2007) and V. cholerae NanH (PDB code: 1W0P) (Moustafa et al., 
2004). To compare the amino acid sequence identity and the structural similarity 
between these five CBM40 family members, PDBeFold (Krissinel and Henrick, 2005) 
was used for the calculation. The result shows that although they do not share high 
sequence identity, they are very similar structurally, except for the CBM domain of 
NanH (NanH-CBM) from V. cholerae, which gives a higher RMSD for a relatively 
low number of Cα compared with the other CBM modules (Table 4.2). Furthermore, 
superimposition of NanA-CBM, NanB-CBM, NanJ-CBM and NanL-CBM (Figure 
4.6a) shows that all of these CBM structures are very comparable in that they share 
the same topology. On the other hand, superimposition of NanA-CBM with NanH-
CBM (Figure 4.6b) reveals that they share a similar framework configuration but the 
different topology leads to the higher RMSD relative to the other CBMs.  
 NanA-CBM NanB-CBM NanJ-CBM NanL-CBM NanH-CBM 
NanA-CBM  2.01Å/170 1.73Å/169 1.93Å/176 3.12Å/134 
NanB-CBM 21%  1.62Å/168 1.31Å/178 2.89Å/132 
NanJ-CBM 20% 26%  1.49Å/170 3.12Å/123 
NanL-CBM 25% 29% 26%  2.72Å/127 
NanH-CBM 9% 8% 11% 12%  
Table 4.2. Comparison of the five CBM40 family members in terms of their percentage sequence 
identity (lime) and overall structural similarity (aquamarine) indicated with RMSD/Cα atoms.  
NanB-CBM indicates S. pneumoniae sialidase B CBM domain (185aa); NanJ-CBM indicates C. 
perfringens sialidase CBM domain (183aa); NanL-CBM indicates M. decora sialidase Leech CBM 
domain (193aa) and NanH-CBM indicates V. cholerae sialidase CBM domain (195aa). The colour used 
for each CBM corresponds to the respective structure in Figure 4.6. Sequence identity and structural 
similarity were calculated using PDBeFold (Krissinel and Henrick, 2005). 
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Figure 4.6. Stereo view of the cartoon representation of the superimposition of NanA-CBM with 
other CBM40 family members.  
(a). The topology displayed by the CBM40 family members are highly structural similar to each other, 
in agreement with the results in Table 4.2. NanA-CBM is shown in green, NanB-CBM is shown in 
blue, NanJ-CBM is shown in yellow and NanL-CBM is shown in salmon. (b). Superimposition of 
NanA-CBM with NanH-CBM. NanH-CBM is shown in gray. 
Two NanA-CBM molecules were present in the asymmetric unit of the crystal (Figure 
4.7). Superimposition of the two monomers gives an r.m.s.d of 0.2Å over all Cα 
atoms. However, as seen from the structure, there are few interactions between them 
and there are no previous reports that indicate that NanA-CBM functions as a dimer, 
which is supported by the gel filtration results. Therefore, this is likely to be an 
artifact of crystal packing.  
a 
b 
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Figure 4.7. Overall structure of the asymmetric unit contents of NanA-CBM. 
(a). Cartoon representation of NanA-CBM in the asymmetric unit, which contained two molecules 
displayed as green and blue. (b). The view after a 90o rotation from (a).  
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4.7  Complex formations of NanA-CBM with 3’-SL & 6’-SL 
The proposed function of CBM40 is binding with Neu5Ac, and it has been reported 
that Neu5Ac is bound to both NanJ-CBM (Boraston et al., 2007) and NanH-CBM 
(Moustafa et al., 2004) in crystal structures. Recently, a glycan array screen assay 
(performed by group member Dr H. Connaris) further revealed that certain derivatives 
of Neu5Ac could bind to NanA-CBM (unpublished data). Moreover, a fluorescence-
based thermal shift assay also showed that NanA-CBM is more stable with the 
derivatives of Neu5Ac than protein only (Figure 4.8). Therefore, crystallographic 
studies were carried out to determine the details of the interaction between NanA-
CBM and the Neu5Ac derivatives. As the most common derivatives of Neu5Ac, both 
3’-SL (α2, 3-sialyllactose, Sigma) and 6’-SL (α2, 6-sialyllactose, Sigma) (Figure 4.9) 
were selected for co-crystallization trials with NanA-CBM. For the crystallization 
trials, 0.5µl 33mg ml-1 protein solution containing 5mM ligand was incubated at 4oC 
for 30min followed by mixing with 0.5µl reservoir solution (100mM MMT pH9.0 and 
28% (w/v) PEG1500), which was optimized from the original NanA-CBM 
crystallization condition. The same seeding technique was applied and the seeded 
crystals appeared the next day and reached maximum size in 3-4 days. Most of those 
crystals could diffract to 1.84Å (Figure 4.10). 
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Figure 4.8. The result of the fluorescence-based thermal shift assay.  
The thermal unfolding curve of NanA-CBM is shown in blue, and the protein with added compounds 
are shown in green (Neu5Ac2en), red (3’-SL) and purple (6’-SL), respectively. The shift in the 
midpoint temperatures (Tm) of the protein unfolding with and without 3’-SL is shown by the black 
arrow.  
 
Figure 4.9. The structure of 3’-SL and 6’-SL.  
3’-SL is the α2,3-linkage of Neu5Ac to lactose and 6’-SL is the α2,6-linkage of Neu5Ac to lactose. 
Structures are from the website (www.acesobio.com). 
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Figure 4.10. The crystals of NanA-CBM with 3’SL and its diffraction pattern.  
(a). The crystal of NanA-CBM in complex with 3’SL, which was obtained in 100mM MMT pH9.0 and 
28% PEG1500. (b). X-ray diffraction pattern of crystal from (a). 
1.84Å datasets of NanA-CBM in complex with both 3’-SL and 6’-SL were collected 
in-house with the same strategies as described in section 4.4. Data collection and 
structure refinement statistics are summarized in Table 4.3 
Data collection 3’-SL 6’-SL 
Beamline  In-house In-house 
Wavelength (Å) 1.54178 1.54178 
Unit-cell parameters 
a (Å) 
b (Å) 
c (Å) 
α (°)  
β (°)  
γ (°) 
 
42.57 
44.52 
42.99 
90.00 
97.00 
90.00 
 
42.54 
44.55 
43.00 
90.00 
97.00 
90.00 
Space group P21 P21 
Molecules per asymmetric unit 1 1 
Resolution (Å) 50.00-1.84(1.87-1.84) 50.00-1.84(1.87-1.84) 
Unique reflections 12926 13634 
Redundancya  2.4(1.7) 3.0(2.2) 
Completeness (%)a 92.0(75.6) 97.2(82.6) 
Rmerge (%)a,b 7.8(10.5) 5.5(9.6) 
<I/σIa> 38.7(16.8) 44.2(9.6) 
Wilson B-factor (Å) 13.1 13.9 
Matthews coefficient 1.93 1.93 
Solvent (%) 36 37 
!
!
!
!
!
!
!
!
!
!
!
a b 
0.05mm 
3.84 
2.71 
2.22 
1.92 
1.72 
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Refinement  3’-SL 6’-SL 
Resolution range (Å) 44.5-1.8 44.6-1.8 
Mean B-factor (Å2)   
                       Protein 15.2 15.9 
                       Ligands  27.8 32.4 
                       Water 27.8 26.4 
Rfactor (%)c 14.3 15.0 
Rfree (%)d 19.8 19.5 
r.m.s.d. bond lengths (Å)e 0.02 0.02 
r.m.s.d. bond angles (°)e 2.04 2.08 
Number of reflections 12277 12950 
No. of atoms   
                   Protein atoms 1532 1528 
                   Ligands 3’-SL 
43 
6’-SL 
43 
                   Water molecules 166 148 
Validationf   
Clashscoreg 1.3 2.5 
Rotamer outliers (%) 2.5 1.8 
Cβ deviations >0.25Å 0 0 
Residues with bad bonds/angles (%) 0.3/0.2 0.1/0.3 
MolProbity Scoreh 1.2 1.4 
 (99
th percentile) (96th percentile) 
Ramachandran favoured/outliers (%) 97.9/0.0 96.8/0.0 
Table 4.3. Data collection, refinement and validation statistics of NanA-CBM in complex with 3’-
SL & 6’-SL. 
a. Values in parentheses correspond to the highest resolution shell. 
b. Rmerge=Σhkl Σi |Ii(hkl)-<I(hkl)>|/ Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity for all observations i 
of reflection hkl, and <I (hkl)> is the weighted average intensity for all observations i of reflection hkl. 
c. Rfactor and Rfree = (Σ| |Fo| - |Fc| |)/(Σ |Fo|). 
d. Rfree was calculated for a 5% set of reflections excluded from the refinement. 
e. r.m.s.d. is the root-mean-square deviation from ideal geometry. 
f. Values were calculated using Molprobity (Chen, et al. 2010). 
g. Clash score is the number of serious steric overlaps (>0.4Å) per 100 atoms. 
h. MolProbity score combines the clashscore, rotamer and ramachandran evalutions into a single score, 
normalized to be on the same scale as X-ray resolution. 
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4.8  Substrate binding site of NanA-CBM and comparison with other 
CBM40 
For the complex structures, the crystals belong to the same space group (P21) as the 
apo NanA-CBM, however the volume of the unit cell is half that of the apo NanA-
CBM, which indicated that only one molecule is present in an asymmetric unit. This 
must be due to the effect of the substrate on crystal packing. Despite this, there is no 
obvious conformational change between the apo NanA-CBM structure and the 
complex structure, and superimposition of the two structures gives an r.m.s.d of 0.48Å 
(both 3’-SL and 6’-SL) for all of the Cα atoms. The σA-weighted Fo-Fc electron-
density maps of both 3’-SL and 6’-SL molecules, in complex with NanA-CBM, are 
clearly defined (Figure 4.11), particularly with the sialic acid moiety of each sialoside. 
This may be due to the greater number of interactions that the sialic acid group makes 
with the protein compared to the lactose moiety, which is freely mobile. Moreover, 
superimposition of the structure in complex with 3’-SL and 6’-SL gives an r.m.s.d of 
0.06Å for all of the Cα atoms, and the sialic acid moiety of both are completely 
overlapped. Due to the fact that all of the interactions of the complexes occur via the 
sialic acid moiety, and both ligands make the same interactions with the protein, 3’-SL 
in complex with NanA-CBM will be used in the following description. 
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Figure 4.11. 3’-SL and 6’-SL co-complexed with NanA-CBM.  
(a) Stereo view of Fo-Fc map of 3’-SL co-complex contoured at 2.5σ level. (b) Stereo view of Fo-Fc 
map of 6’-SL co-complex contoured at 2.5σ level. (c) Stereo view of 3’-SL (shown in spheres) bound 
to the NanA-CBM substrate binding site.  
a 
b 
c 
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Based on the complex structure, only the sialic acid part of 3’-SL makes interactions 
with the protein. The residues that are involved in the interaction are mainly from the 
concave surface donated by two loops and β-strand 6 (β-6) and β-11. As shown in 
Figure 4.12, Asn209 in the loop between β-6 and β-7 forms a hydrogen bond with the 
carbonyl oxygen of the acetamido group (O-10 atom) of Neu5Ac, Glu195 in β-6 
forms direct hydrogen bonds with the N-5 (acetamido nitrogen) and the hydroxyl 
group at C-4 (O-4 atom) of Neu5Ac. Arg197 in β-6 interacts with the carboxylate 
group of Neu5Ac, as does Arg274 in β-11. Trp280 in the loop between β-12 and β-13 
forms a hydrogen bond with the C-7 hydroxyl (O-8 atom) of Neu5Ac. In addition, 
Tyr182 in β-5 may interact with the pyranose ring of Neu5Ac as they are only 3.7Å 
apart, and Phe167 in β-4 may also interact with Neu5Ac as its side chain is relatively 
close and almost parallel with the glycerol group of Neu5Ac. Moreover, four water 
molecules are involved in the interaction of ligand and the protein, in which W-1 
interacts with Arg197 and O-1A of Neu5Ac, W-2 interacts with O-8 and O-9 of 
Neu5Ac, W-3 bonds with C-4 hydroxyl (O-4 atom) and W-4 forms a hydrogen bond 
with Asn209 and also interacts with C-11 of Neu5Ac. Details of the major interactions 
between NanA-CBM and ligand are listed in Table 4.4. 
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Figure 4.12. Stereo view of Neu5Ac binding sites of NanA-CBM.  
3’-SL is shown in yellow and waters in magenta. The relevant residues that involved in the interaction 
are shown in stick representation, their name and the number are also labelled. Hydrogen bonds are 
shown as black dotted lines. 
 
 
3’-SL/ 
 
Protein/ 
Water atoms 
Distance 
(Å) 
O-1 A Arg274-N-η2 2.88 
O-1 A Arg197-N-η1 3.15 
O-1 A H2O (W1) 2.74 
O-1 B Arg274-N-η1 2.90 
O-4 Glu195-O-ε1 2.71 
O-4 Glu195-O-ε2 3.39 
O-4 H2O (W3) 2.66 
O-8 Trp280-N-ε1 2.87 
O-8 H2O (W2) 3.15 
O-9 H2O (W2) 2.87 
O-10 Asn209-N-δ2 2.79 
N-5 Glu195-O-ε1 3.39 
N-5 Glu195-O-ε2 2.77 
Table 4.4. Interactions between NanA-CBM and 3’-SL.  
Intramolecular hydrogen bonds between NanA-CBM and 3’-SL are listed. Water molecules bound to 
3’-SL are also detailed. 
  
E195 E195 Y182 Y182 
R197 R197 
N209 N209 
R274 R274 
W280 W280 
W1 W1 
W2 W2 
W3 W3 
W4 W4 
F167 F167 
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Of the current available structures from CBM40 family members, only NanJ-CBM 
from C. perfringens and NanH-CBM from V. cholerae have been determined in 
complex with Neu5Ac. Comparisons of the complex structure of NanA-CBM with the 
complex structures of NanJ-CBM and NanH-CBM were carried out. Ostensibly, all of 
the substrate binding sites of these CBMs are on the concave surface of the structures, 
however, superimposing the structures shows that the substrate binding sites of NanA-
CBM and NanJ-CBM are located in relatively similar positions (Figure 4.13a), 
whereas the substrate binding site of NanH-CBM is in a very different position 
(Figure 4.13b). Additionally, superimposition of the binding sites of the three 
structures revealed that there is some structural conservation in the substrate binding 
site between NanA-CBM and NanJ-CBM, however, NanH-CBM has little to no 
structural conservation in the substrate binding site compared with the others (Figure 
4.14). This also corresponds to the sequence alignment, as shown in Figure 4.15. 
Chapter 4: Crystal structure of the S. pneumoniae NanA CBM in complex with Neu5Ac and its 
derivatives 
 124 
 
Figure 4.13. Structural overlap of NanA-CBM with NanJ-CBM and NanH-CBM, respectively.  
(a) Structural superposition of the NanA-CBM 3’-SL complex (green) and the NanJ-CBM Neu5Ac 
complex (yellow). The proteins and ligands are shown in cartoon and stick form, respectively (b) 
Superposition of the NanA-CBM 3’-SL complex (green) and the NanH-CBM Neu5Ac complex (gray). 
The proteins and ligands are shown in cartoon and stick form, respectively.  
a 
b 
90o 
90o 
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Figure 4.14. Stereo view of the structural overlap of the sialic acid binding sites from NanA-CBM, 
NanJ-CBM and NanH-CBM.  
The overlay was produced by overlapping equivalent atoms in the bound sialic acid residues. Relevant 
amino acids involved in coordinating the sugars are shown in stick representation. For clarity, only 
Neu5Ac (yellow) is shown, rather than 3’-SL. Residues from NanA-CBM are shown in green, residues 
from NanJ-CBM are shown in blue and residues from NanH-CBM are shown in gray. The name and 
the number of each residue are labeled in the relevant colour.  
NanB-CBM from S. pneumoniae and NanL-CBM from M. decora have not been 
demonstrated to bind to Neu5Ac by any structural study. However, superimposition of 
these structures with NanA-CBM reveals that most of the residues in NanA-CBM 
involved in the substrate-binding site are also present in NanB-CBM and NanL-CBM 
(Figure 4.16). Moreover, sequence alignment also suggests that the residues that 
interact with Neu5Ac are conserved in NanB-CBM and NanL-CBM (Figure 4.15). 
Therefore, this is further evidence to indicate that CBM40 could specifically 
recognize and bind sialylated substrates. However, for NanB-CBM and NanL-CBM, 
Neu5Ac binding needs to be further confirmed by structural studies.  
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Figure 4.15. Sequence alignment of all of the CBM40s of known structure using NanA-CBM as a 
reference structure.  
Strictly conserved residues have a red background with white letters. NanA-CBM residues that are 
involved in sialic acid recognition are indicated with black asterisks, and are highly conserved within 
all these CBM40s except NanH-CBM (black boxes). Blue triangles indicate the residues that interact 
with sialic acid in NanH-CBM. Sequence alignment was done with Clustal W (Larkin et al., 2007) and 
the picture was generated with ESPript (Gouet et al., 2003). 
 
Figure 4.16. Putative sialic acid binding site in NanB-CBM and NanL-CBM by superimposition 
onto NanA-CBM complex structure. 
The conserved residues present in all of these CBMs are shown in stick representation. Residues from 
NanA-CBM are shown in green, residues from NanB-CBM are shown in blue and residues from 
NanL-CBM are shown in salmon. Only the sialic acid moiety of 3’-SL (yellow) is shown.  
  
                                                                NanA_CBM
       130       140       150       160       170       180    
NanA_CBM                                                  L              VIEKEDVETNASNGQRVDLSSELDKLKKLENATVHMEFKPDAKAPAFYN FSVSSATKKDE..Y
NanB_CBM                                                  L              IFQGGSYQLNNKSI...DISSLLLDKLSGESQTVVMKFKAD.KPNSLQA FGLSNSKAGFKNNY
NanL_CBM                                                  L              LMEKNNVDIAEGQGYSLDQEAGAKYVKAMTQGTIILSYKST.SENGIQS FSVGNSTAGNQDRH
NanJ_CBM                                                  L              IANYGNLKI.TKEEERLNITGDLEKFSSLDEGTIVTRFNMN..DTSIQS IGLSDGNKANN..Y
NanH_CBM                                                  L              TGDTEFDSPAKQGWMQDNTNNGSGVLTNADGMPAWLVQGIGGRAQWTYS STNQHAQASSFGWR
                                                                NanA_CBM
      190       200        210       220       230       240    
NanA_CBM FTMAVY.NNTATLEGRGSDGKQ.FYNNYNDAPLKVKPGQWNSVTFTVEKPTAELPKGRVRLYVN
NanB_CBM FSIFMRDSGEIGVEIRDAQKGI..NYLFSRPASLWGKHKGQAVENTLVFV.SDSKDKTYTMYVN
NanL_CBM FHIYITNSGGIGIELRNTDGVF..NYTLDRPASVRALYKGERVFNTVALK.ADAANKQCRLFAN
NanJ_CBM FSLYVS.GGKVGYELRRQEGNGDFNVHHSADVTFNKG......INTLALK.IEKGVG.AKIFLN
NanH_CBM MTTEMKVLSGGMITNYYANGTQRVLPIISLDSSGNLVVEFEGQTGRTVL...ATGTAATEYHKF
  .                               .                             NanA_CBM
    250       260       270        280       290       300      
NanA_CBM GV.LSRTSLRSGNFIKDMPDVTHVQIGATKRANN.TVWGSNLQIRNLTVYNRALTPEEVQKRS 
NanB_CBM GIEVFSETVDTFLPISNINGIDKATLGAVNREGK.EHYLAKGSIDEISLFNKAISDQEVSTIP 
NanL_CBM GELLATLDKDAFKFISDITGVDNVTLGGTKRQGK.IAYPFGGTIGDIKVYSNALSDEELIQAT 
NanJ_CBM GSLVKTVSDPNIKFLNAIN.LNSGFIGKTDRANGYNEYLFRGNIDFMNIYDKPVSDNYLLRKT 
NanH_CBM ELVFLPGSNPSASFYFDGKLIRDNIQPTASKQNMIVWGNGSSNTDGVAAYRDIKFEIQGD... 
!1 "1 !2 "2 #1 !3 !4 
!5 !6 !7 !8 
!9 "3 !10 !11 !12 !13 #2 
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4.9  More Neu5Ac derivatives bound to NanA-CBM 
The above results confirmed that Neu5Ac could bind to NanA-CBM. However, the 
binding site suggested that other analogues of Neu5Ac might be able to bind and form 
a complex with NanA-CBM. NanA-CBM crystals with different compounds were 
obtained under the same crystallization condition as described above. Eventually, 
complexes were obtained with three ligands bound to NanA-CBM: (i) 5-N-Acetyl-9-
O-acetylneuraminic acid (Neu5,9Ac2, Carbosynth) (Figure 4.17), (ii) N-
glycolylneuraminic acid (Neu5Gc, Sigma), which contains an addition hydroxyl 
group at the acetamido group of Neu5Ac (Figure 4.17) and (iii) α-C-sialoside (kindly 
provided by Professor A.J. Bennet, Simon Fraser University, Canada), in which a 4-
piperidinemethanol replaces the O-2 of Neu5Ac (Figure 4.17).  
Data collection, processing, model refinement and validation statistics are 
summarized in Table 4.5 
 
Figure 4.17. The structure of Neu5,9Ac2, Neu5Ac, Neu5Gc and α-C-sialoside.  
Structures adapted from the website (www.hmdb.ca). 
Neu5,9Ac2 Neu5Ac 
Neu5Gc !-C-sialoside  
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Data collection Neu5Ac Neu5Gc α-C-sialoside 
Beamline  In-house In-house In-house 
Wavelength (Å) 1.54178 1.54178 1.54178 
Unit-cell parameters 
a (Å) 
b (Å) 
c (Å) 
α (°)  
β (°)  
γ (°) 
 
42.40 
44.66 
43.07 
90.00 
97.38 
90.00 
 
42.42 
44.75 
43.13 
90.00 
97.00 
90.00 
 
113.26 
41.47 
49.84 
90.00 
97.90 
90.00 
Space group P21 P21 C2 
Molecules per asymmetric unit 1 1 1 
Resolution (Å) 50.00-1.84    
(1.87-1.84) 
50.00-1.84   
(1.87-1.84) 
50.00-1.84   
(1.87-1.84) 
Unique reflections 13701 13965 19031 
Redundancya  2.7(2.0) 3.6(2.8) 3.7(3.3) 
Completeness (%)a 97.6(89.8) 99.3(91.5) 94.3(71.2) 
Rmerge (%)a,b 5.7(7.3) 4.3(8.5) 3.4(8.5) 
<I/σIa> 46(26.2) 58.8(46.3) 50.7(22.5) 
Wilson B-factor (Å) 6.0 8.2 10.7 
Matthews coefficient  1.94 1.93 2.76 
Solvent (%) 36 36 56 
Refinement     
Resolution range (Å) 44.7-1.8 44.8-1.8 56.1-1.8 
Mean B-factor (Å2)    
                       Protein 13.2 9.9 12.9 
                       Ligands  12.8 9.5 12.5 
                       Water 23.0 21.6 23.9 
Rfactor (%)c 15.2 14.9 15.8 
Rfree (%)d 21.1 20.9 19.1 
r.m.s.d. bond lengths (Å)e 0.02 0.02 0.02 
r.m.s.d. bond angles (°)e 1.93 2.07 2.45 
Number of reflections 13009 13260 18061 
No. of atoms    
                     Protein atoms 1502 1520 1539 
                     Ligands Neu5Ac 
21 
Neu5Gc 
22 
2x α-C-sialoside 
56 
                     Water 193 224 224 
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Validationf Neu5Ac Neu5Gc α-C-sialoside 
Clashscoreg 1.3 1.9 1.9 
Rotamer outliers (%) 0.6 0.6 0.6 
Cβ deviations >0.25Å 3 1 1 
Residues with bad bonds/angles (%) 0.0/0.0 0.0/0.0 0.0/0.0 
MolProbity Scoreg 1.0 1.0 1.1 
 (100
th percentile) (100th percentile) (100th percentile) 
Ramachandran favoured/outliers (%) 97.3/0.0 97.8/0.0 97.3/0.0 
Table 4.5. Data collection, refinement and validation statistics of NanA-CBM in complex with 
Neu5Ac, Neu5Gc & α-C-sialoside. 
a. Values in parentheses correspond to the highest resolution shell. 
b. Rmerge=Σhkl Σi |Ii(hkl)-<I(hkl)>|/ Σhkl Σi Ii(hkl), where Ii (hkl) is the intensity for all observations i 
of reflection hkl, and <I (hkl)> is the weighted average intensity for all observations i of reflection hkl. 
c. Rfactor and Rfree = (Σ| |Fo| - |Fc| |)/(Σ |Fo|). 
d. Rfree was calculated for a 5% set of reflections excluded from the refinement. 
e. r.m.s.d. is the root-mean-square deviation from ideal geometry. 
f. Values were calculated using Molprobity (Chen, et al. 2010). 
g. Clash score is the number of serious steric overlaps (>0.4Å) per 100 atoms. 
h. MolProbity score combines the clashscore, rotamer and ramachandran evalutions into a single score, 
normalized to be on the same scale as X-ray resolution. 
Unexpectedly, instead of Neu5,9Ac2, Neu5Ac (with an average B-factor of 12.8Å2) 
was bound to the protein in the substrate binding site, with no evidence of the 
presence of electron density for any part of the acetaldehyde moiety at the 9-position 
(Figure 4.18a). This could either be because this region is disordered or more likely 
that the acetaldehyde had been hydrolyzed during the co-crystallization. Again, there 
is no obvious conformational change compared with the apo NanA-CBM as the 
superimposition of the two structures gives an r.m.s.d of 0.44Å for all the Cα atoms. 
Moreover, the positions of residues in the protein in the substrate binding site are 
identical to those in the complex structure of NanA-CBM with 3’-SL.  
Neu5Gc (with an average B-factor of 9.5Å2) was successfully bound to the active site 
of NanA-CBM in a similar manner to the other complex structures of NanA-CBM 
(Figure 4.18b). Additionally, the extra hydroxyl group of the ligand forms a new 
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hydrogen bond (2.65Å) with the side chain of Asn209 (O-δ1), which may result in a 
higher affinity between the ligand and the protein. 
For the complex structure of α-C-sialoside bound to the protein, data were processed 
in an alternative space group (C2) with different unit cell dimensions. This difference 
is likely due to the binding of two α-C-sialoside molecules to each protein molecule. 
One is bound to the active site in the same way as the other ligands, and another is 
present to one side of the structure (Figure 4.19a), and both of them are identified 
with clear Fo-Fc electron-density maps (Figure 4.18c&d). In addition, the orientations 
of the 4-piperidinemethanol moieties of the two α-C-sialosides are different. In the 
one that binds to the sialic acid binding site, the piperidine group points towards the 
glycerol group and its hydroxyl group points away from the carboxylate group of the 
Neu5Ac (Figure 4.18c). In contrast, the piperidine group in the secondary α-C-
sialoside molecule points in the opposite direction to the carboxylate group, and the 
hydroxyl group from 4-piperidinemethanol moiety is in the same orientation as the 
glycerol group of the Neu5Ac moiety (Figure 4.18d). The extra α-C-sialoside 
molecule mainly interacts with residues present in β-9 (Leu247, Ser248, Arg249 and 
Thr250) as well as six water molecules. Additionally, the 4-piperidinemethanol 
moiety of the α-C-sialoside interacts with the C-terminal region of a symmetry related 
molecule, which causes the side chain of two residues (Lys303 and Arg304) to shift 
4.5Å and 5.5Å to the side, respectively, forming a hydrophobic cavity (Figure 4.19b). 
While it is possible that this represents a functional role of the protein, it is more 
likely to be an artifact of crystal packing.  
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b 
c 
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Figure 4.18. Stereo view of Fo-Fc map of Neu5Ac, Neu5Gc and α-C-sialoside contoured at 2.5σ 
level. 
(a) Stereo view of Fo-Fc map of Neu5Ac. (b) Stereo view of Fo-Fc map of Neu5Gc. (c) Stereo view of 
Fo-Fc map of α-C-sialoside that binds to the binding site of the protein. (d) Stereo view of Fo-Fc map of 
α-C-sialoside that binds in the secondary site.  
 
Figure 4.19. An extra α-C-sialoside molecule interacts with the protein.  
(a) A second α-C-sialoside molecule interacts with the residues (green sticks) that are present in β-9 of 
the protein. Waters are shown as spheres (magenta) and hydrogen bonds are shown as black dotted 
lines. (b) The 4-piperidinemethanol group of the α-C-sialoside occupies a hydrophobic cavity formed 
by a symmetry related molecule (shown with electrostatic surface representation).  
d 
a 
b 
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4.10  Potential function of NanA-CBM 
Besides the classic function of binding to sialic acid, NanA was reported to enhance 
the S. pneumoniae interaction with human brain microvascular endothelial cells 
(hBMECs) via an adhesin function of NanA-CBM, which can potentially facilitate the 
entry of bacterial pathogens into the central nervous system (CNS), even with little 
contribution of the sialidase activity (Uchiyama et al., 2009). However, it is still not 
completely clear which receptor in the hBMECs is important for this process, and 
how it could be recognized by NanA-CBM.  
In the current study, the surface electrostatic view shows that there is a deep 
negatively charged cavity with positively charged surface next to the sialic binding 
site (Figure 4.20a), which is not present in the other family 40 CBMs. Additionally, 
the side chain of a lysine from a symmetry-related molecule points towards and 
occupies the cavity (Figure 4.20b). Moreover, there are four residues (Glu195, 
Gln203, Asn207 and Asn209) that form the cavity and interact with the lysine (Figure 
4.20c). Therefore, it is possible that this region is important for NanA-CBM 
interaction with hBMECs. However, further evidence to prove this hypothesis is 
essential.  
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Figure 4.20. Potential functional cavity of NanA-CBM. 
 (a). The surface electrostatic view from the top of the binding site of NanA-CBM and a cavity adjacent 
to the active site, which is shown by the arrow. (b). A lysine from a symmetry related molecule 
occupying the cavity. (c). Close-up view of the interaction between the lysine and the protein. The 
solvent-accessible surface of NanA-CBM is coloured based on the electrostatic potential from -7 (red) 
to +7 (blue) kT/e, calculated using the APBS tool in PyMol.  
  
N209 
E195 
Q203 
N207 
a 
c b 
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4.11  Discussion and conclusion 
The current study shows that the CBM domain from the S. pneumoniae NanA can be 
successfully isolated from the parent enzyme and retain its ability to recognize sialic 
acid. A large number of crystal trials were carried out, from which a 1.84Å data was 
eventually obtained. The final refined structure shows that all of the residues in the 
sub-cloned gene could be clearly defined. This brings the number of structurally 
determined CBMs from the CBM40 family to five. 
The apo NanA-CBM structure shows that two monomers are present in each 
asymmetric unit. Moreover, the C-terminal catalytic domain of NanA also formed a 
dimer in the crystal (PDB code: 2VVZ) (Xu et al., 2008a). However, analysis of the 
structures with the PISA server (Krissinel and Henrick, 2007) gave a complex 
formation significance sore (CSS) of 0 for both the NanA-CBM and the C-terminal 
catalytic domain, indicating that neither are likely to form a complex in solution. 
Indeed, until now, there have been no reports or evidence that NanA functions as a 
dimer. In addition, the full-length NanA protein containing the catalytic domain and 
CBM domain of NanA was shown to be mainly monomeric in solution via a 
calibrated gel filtration test. Besides that, the substrate-bound NanA-CBM structure 
shows that only one monomer is present in an asymmetric unit. Therefore, until any 
further studies prove this, we may conclude that the polymeric assembly of apo 
NanA-CBM structure in the crystal could be an artificial effect of the crystallization.  
The β-sandwich fold NanA-CBM structure is in keeping with the structural 
homologues of the typical CBM40 family members, among which four of the five 
share similar topology. The exception is the NanH-CBM from V. cholerae, with 
r.m.s.d values of up to 3.12Å compared to the other CBM40 structures. However, 
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another CBM40 family member from Shewanella pealeana sialidase, which shows 
reasonably close sequence identity with NanH-CBM, also possesses the conserved 
residues that are involved in sialic acid recognition by NanH-CBM (Figure 4.21). 
Thus, there might be at least two subfamilies in CBM family 40, which have distinct 
structural differences; one is similar to NanA-CBM while the other resembles NanH-
CBM. Both have the function of binding to sialic acid but they bind the ligand at 
different locations via a completely different set of protein-ligand interactions.  
 
Figure 4.21. Sequence alignment of CBM40 from V. cholerae (shown as NanH-CBM) with related 
modules from S. pealeana.  
Strictly conserved residues have a red background with white letters. NanH-CBM residues that are 
involved in sialic acid recognition are indicated with black asterisk, and are highly conserved with S. 
pealeana CBM.  
The current study shows that NanA-CBM can interact with Neu5Ac and its 
derivatives, and revealed that NanA-CBM specifically recognizes the α-anomer of 
sialic acid due to the greater degree of interactions that this conformation can make 
with the protein. In particular, the carboxylate oxygens at C-1 (O-1A & O-1 B atoms) 
of Neu5Ac are vital for the interaction, forming a salt bridge with Arg274. 
Furthermore, hydroxyl groups at both C2 and C7 point away from the substrate-
binding site without any interaction with the protein, therefore, they are potential 
                                                              NanH-CBM  
        40        50        60        70        80        90  
NanH-CBM   FDS     P   GW  D    G G L N  G  AW   GI GRA W    S      A   E   ..... AKQ  MQ NTNN S V T AD MP  LVQ  G   Q TYSL TNQHAQ SSF
S.pealeana  FDS     P   GW  D    G G L N  G  AW   GI GRA W    S      A   T   NLNTD LLA  TN SVDS A S V EQ QA  QAR  N   E EIQP VQVNRD TTL
                                                              NanH-CBM  
     100       110       120       130       140       150    
NanH-CBM  GW MTT     SG  I  YYANG  R L   S    G LV   EG    T     T A  YH  R   EMKVL  GM TN     TQ V PII LDSS N  VEF  QTGR VLATG A TE  
S.pealeana GW MTT     SG  I  YYANG  R L   S    G LV   EG    T     T A  YH  K   TSRIV  SA SD     NK F ALL INGN D  AAL  GSSH LVPM. G DK  
                                                              NanH-CBM  
   160       170       180       190       200       210      
NanH-CBM    E          A FYFDG  I       A  QN IVWGNGSS T GVA YR   FE  G KF LVFLPGSNPS S     KL RDNIQPT SK  M        N D   A  DIK  IQ D
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!1 !2 "2 "3 "4 "5 #1 
"6 "7 "8 "9 "10 "11 "12 !3 
"13 "14 "15 "16 "17 "18 
Chapter 4: Crystal structure of the S. pneumoniae NanA CBM in complex with Neu5Ac and its 
derivatives 
 137 
modification points of Neu5Ac, which could then be recognized by NanA-CBM. It 
has been reported that the C-terminal catalytic domain of NanA could bind 
Neu5Ac2en, a transition-state analogue/inhibitor of Neu5Ac in a half-chair 
conformation (Xu et al., 2008a). Therefore, to investigate a potential interaction 
between Neu5Ac2en and NanA-CBM, a thermal shift assay was carried out. 
However, the result (Figure 4.8) did not indicate any increase in thermal stability in 
the presence of Neu5Ac2en relative to protein only. Nevertheless, Neu5Ac2en and 
other substrates with half-chair conformations were tested for co-crystallization with 
NanA-CBM, however, no crystals were formed. In particular, the thermofluor results 
indicate that NanA-CBM specifically interacts with Neu5Ac and its derivatives only 
in the chair conformation.  
It has been reported that the NanA protein could not only cleave Neu5Ac from host 
cell-surface glycans, but also promotes pneumococcal invasion into the brain 
endothelial cells even when lacking its sialidase activity, indicating that NanA-CBM 
plays a critical role in adhesin function (Uchiyama et al., 2009). In the current study, 
we determined the structure of NanA-CBM, however, I cannot yet prove that NanA-
CBM can bind any other molecules except Neu5Ac and its derivatives. Nevertheless, 
a negatively charged cavity is present next to the Neu5Ac binding site, which is 
occupied by a lysine from a symmetry related molecule. This feature has not been 
reported in any other CBM modules. Therefore, it may play a functional role in 
recognizing specific molecules, either on its own or synergistically with the 
interaction of Neu5Ac. A search is underway to try to discover other receptors 
recognized by NanA-CBM, and further evidence is required to support this hypothesis 
by crystallography.  
Connaris et al. have reported that artificially generated multivalent polypeptides of the 
NanH-CBM domain can enhance the sialic acid binding affinity (Connaris et al., 
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2009). Therefore, multivalent polypeptides of NanA-CBM are potentially valuable as 
tools for glycobiology and even in novel drug design, further demonstrating the 
importance of this protein. 
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In the current study, crystal structures of both WT and mutated DAK from H. sapiens 
were determined. For the WT, the best crystal diffracted to 2.5Å resolution and the 
initial structure was solved by MR. The N-terminal domain could be identified very 
well, whereas some regions of the C-terminal domain were fairly disordered, which to 
some extent affected the structure-function studies of the protein. Afterwards, based 
on the existing structure, protein surface mutagenesis was introduced. Three residues 
from the N-terminal domain were mutated into higher molecular weight amino acids, 
with the intention of disrupting the original crystal packing pattern. The newly formed 
crystals with an alternative packing pattern gave better diffraction (1.4Å), and resulted 
in a very significant enhancement of the electron density map, especially in the C-
terminal domain. This allowed completion of the structure of the H. sapiens DAK. 
This is the first eukaryotic DAK structure to be determined and the second DAK 
structure that utilizes ATP as the phosphate donor. Its structural framework is 
topologically similar to the C. freundii DAK (Siebold et al., 2003a). The substrate 
(Dha) of the protein, and two ATP analogues (APC and CTP) were successfully bound 
to the mutated DAK structure by co-crystallization. The activity of DAK was 
determined by a coupled enzyme assay, which showed that the mutated DAK still 
maintained the full activity of the WT. A catalytic mechanism for DAK from E. coli 
has been proposed (Shi et al., 2011), and sequence analysis shows that the residues 
involved in the kinase activity are highly conserved. The complex structure of E. coli 
DAK consists of two individual polypeptide chains rather than one, and the distance 
between the substrate and ADP is smaller relative to H. sapiens DAK. Therefore, a 
potential domain movement for H. sapiens DAK catalysis was speculated, although 
further studies to provide more persuasive proof are required. 
The lyase function of DAK was determined by a modified discontinuous colorimetric 
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assay, which showed that both WT and mutated DAK possessed the ability to catalyse 
the cleavage of FAD into cFMN and AMP. However, the crystal trials with these 
compounds did not produce crystals. Therefore, further crystal trials, such as co-
crystallization with different FAD analogues or soaking the crystal with ligands will 
be carried out. Additionally, pull down experiments and size exclusion 
chromatography were performed in an attempt to demonstrate an interaction between 
DAK and MDA5-CARD, as DAK had been reported to negatively regulate the 
function of MDA5 (Diao et al., 2007). However, both experiments failed to show any 
interaction between the two proteins. Therefore, further investigations into 
relationship between the two proteins are ongoing. 
The crystal structure of the NanA-CBM from S. pneumoniae is also described. An 
HSQC NMR study showed that the protein is very well ordered and the fluorescence-
based thermal shift assay revealed that the protein specifically interacts with the 
derivatives of Neu5Ac that are in the chair conformation.  
NanA-CBM is a CBM family 40 protein and the present study shows that the 
structure adopts typical a β-sandwich fold and is identified as a Type C CBM. In 
addition to Neu5Ac, four of its derivatives (3’-SL, 6’-SL, Neu5Gc and α-C-sialoside) 
have also been determined to bind to NanA-CBM. Of the three sialidases from S. 
pneumonia, this is the first time a structural study has revealed that the CBM domain 
could bind to the substrates of sialidase. The ability of NanA-CBM to recognize sialic 
acid opens up the possibility of inhibiting the interaction between the bacterium and 
host cells, and further studies will be carried out in the near future.  
It has been postulated that NanA-CBM could enhance BBB penetration, based on an 
initial interaction between NanA-CBM and a cellular receptor (Uchiyama et al., 2009; 
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Banerjee et al., 2010). However, to date, it is still not clear which receptor, and how it 
can be recognized by NanA-CBM. The current structure shows a potential substrate-
binding site, which is occupied by a side chain of a lysine from a symmetry-related 
molecule. It is proposed that this cavity functions in binding to the potential ligands, 
which may be essential for this recognition. Therefore, further work towards the 
discovery of the potential substrate is under way.  
To date, the structures of most regions of NanA have been revealed, with the 
exception of the N-terminal signal peptide domain (~120 residues) and the additional 
C-terminal fragment (~200 residues), which still require structural determination. 
Also, in order to more fully understand the functions of sialidases as virulence factors, 
and to be able to effectively prevent the colonization of S. pneumoniae, structural 
determination of NanC is also being attempted. 
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I-1. Plasmid construction and site-directed mutagenesis 
The pCMV-SPORT6 vector containing cDNA encoding H. sapiens DAK was 
purchased from Source BioScience LifeSciences, and the DNA was then sub-cloned 
into the pLOU3 vector (the construct was modified from the pMAL-c2X vector (to 
include an N-terminal His tag) by Dr L. Major, University of St. Andrews) (Figure I-
1). The details of the gene cloning procedures are described below.  
The target gene were firstly amplified by PCR using Pfu polymerase (Promega). The 
primer pairs are shown in Table 2.1 (in chapter 2), and the protocols for the reaction 
mix and PCR programs are shown in Table I-1. For a 1% agarose gel electrophoresis, 
1g of agarose was dissolved in 100ml 1x Tris-Acetate-EDTA (TAE) buffer with 0.5µg 
ml-1 ethidium bromide (EB). DNA samples were prepared with 10 µl (6x) of gel 
loading solution (New England BioLabs) being added to 50µl PCR product and 
loaded into wells. 1kb DNA ladder (Promega) was used as a marker. Gels were run at 
80V for 45min. The bands of the expected sizes were excised from the gel and 
purified with QIAquick Gel Extraction Kit (Qiagen). Approximately 500ng of PCR 
product was digested with 1µl SalI, 1µl PagI (due to the presence of two NcoI sites in 
the sequence) and 2µl buffer O in a total volume of 20µl and incubated at 37oC for 3h. 
To digest the vector, about 100ng pLOU3 vector was digested with 1µl SalI, 1µl NcoI 
and 2µl buffer D, 0.3µl of bovine serum albumin (BSA) in a total volume of 20µl and 
incubated at 37oC for 3h. (All restriction enzymes and buffers were purchased from 
Promega). The digested PCR products and vector were further purified using the 
QIAquick Gel Extraction kit (Qiagen). For ligation of the target genes into vector, T4 
DNA ligase (Promega) was used to ligate a 3:1 molar ratio of insert and vector. 
Ligation reactions were performed in 20µl containing 1µl of T4 DNA ligase, 4µl T4 
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ligase buffer (5x) and varying amounts of DNA. Ligations were incubated at 22oC for 
3h. 2µl of ligated DNA was transformed into 50µl of E. coli DH5α competent cells 
(Invitrogen), by cold shock in ice for 30min, followed by a heat shock in 42oC water 
bath for 20sec and cooling in ice for 2min. 950µl of pre-warmed LB media (made by 
media kitchen, University of St. Andrews) was added to the transformation reaction, 
then incubated with shaking at 200rpm for 1h at 37oC. After incubation, the cells were 
spun down at 1,500g for 5min and, following removal of excess LB, cells were 
resuspended with the remaining supernatant. These transformed cells were plated on 
LB agar (made by media kitchen, University of St Andrews) containing ampicillin 
(100µg ml-1) and incubated at 37oC overnight. Colonies containing recombinant 
plasmid were identified using colony PCR screening. 24 colonies were randomly 
picked by sterile toothpick and each resuspended in 10µl water, and then the wet 
toothpick was streaked on LB agar containing ampicillin and allowed to grow at 37oC 
overnight. The remainder of each suspension was heated at 100oC for 5min before cell 
debris was removed by centrifugation. The cell free lysate was amplified by PCR 
using Taq polymerase (Promega); the protocols for reaction mix and PCR programs 
are shown in Table I-2. Colony PCR results were analyzed by agarose gel 
electrophoresis. The transformed colony containing the recombinant vector was 
inoculated in 10ml LB containing ampicillin (50µg ml-1) followed by incubating with 
shaking at 37oC overnight. After incubation, cells were spun down at 3,000g for 
10min at 4oC. The pellet was collected and plasmid DNA was purified by QIAprep 
Spin MiniPrep (Qiagen). For sequencing, 500ng of DNA in 30µl water was sent to the 
sequencing service at the School of Life Sciences, University of Dundee, Scotland 
(www.dnaseq.co.uk). The DNA with the correct sequence was then transformed into 
E. coli Rosetta (DE3) cells (Novagen). 1µl of each plasmid DNA was transformed 
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into 20µl of Rosetta by cold shock in ice for 5min, followed by a heat shock in a 42oC 
water bath for 30sec and cooling in ice for 2min. 80µl of pre-warmed LB media was 
added to the transformation reaction, which was then shaken at 200rpm for 1h at 
37oC. After incubation, these transformed cells were plated on LB agar containing 
ampicillin (100µg ml-1) and incubated at 37oC overnight. 
 
Figure I-1. pLOU3 vector.  
This vector was derived from the NEB vector pMAL-c2X, which has cytoplasmic expression of the 
fusion protein. The vector contains an N-terminal 6xHis tag followed by a MBP tag, and includes a 
TEV protease cleavage site between tags and the protein.  
1
pLou3
6706bp
lacI
malE
lacZ!
q
bla
M13 ori
ori
rop
Ptac
Tev site
XbaI (2767)
PstI (2783)
SalI (2773)
6 x His
PmlI (2751)
EcoRI (2755)
BamHI (2761)
SacI (2680)
HindIII (2787)
ApaI (642)
SwaI (4437)
BglII (1929)
Bpu1102I (2356)
BsmI (2190)
BstEII (612)
DraIII (4662)
Eam1105I (4265)
Tth111I (5864)
Eco56I (4763)
EcoRV (881)
HpaI (937)
MluI (431)MscI (6681)
NaeI (4765)
NdeI (1526)
PflMI (13)
SapI (5765)
ScaI (3784)
SplI (1860)
NdeI (1568)
AvaI (2717)
NcoI (2741)
pLOU3 Tev cleavage site and cloning sites: 
 
AvaI  TEV protease site      NcoI    PmlI    EcoRI   BamHI 
CTC GGG GAA AAC CTG TAT TTT CAG GGC GCC ATG GAT CAC GTG GAA TTC GGA TCC 
 L   G   E   N   L   Y   F   Q   G   A   M   D   H   V   E   F   G   S  
 
 XbaI   SalI     PstI HindIII 
TCT AGA GTC GAC CTG CAG GCA AGC TTG GCA  
 S   R   V   D   L   Q   A   S   L   A    
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a  
Solution Vol  
10x Pfu buffer 5µl 
Forward primer (50µM) 1µl 
Reverse primer (50µM) 1µl 
DNA template (200ng) 0.5µl 
dNTPs (10mM) 1µl 
Pfu polymerase (2.5U µl-1) 0.5µl 
Water 41µl 
Reaction volume  50µl 
 
b    
step  cycle temp. time 
1 1x 95oC 2min 
2 30x 95oC 30sec 
  54oC 30sec 
  72oC 3min 
3 1x 72oC 5min 
  4oC ∞ 
Table I-1. PCR reaction mix and program for the amplification. 
 (a). PCR reaction mix for FL-DAK and N-DAK using Pfu DNA polymerase. (b). Program used for 
PCR amplification.  
 
a  
Solution Vol  
5x Taq buffer 2.8µl 
Forward primer (3.2µM LLMP2) 0.22µl 
Reverse primer (3.2µM LLMP5) 0.22µl 
Lysate 5µl 
dNTPs (10mM) 0.18µl 
Taq polymerase (5U µl-1) 0.18µl 
Water 5.4µl 
Reaction volume  14µl 
 
b    
step  cycle temp. time 
1 1x 95oC 2min 
2 30x 95oC 20sec 
  53oC 50sec 
  72oC 3min 
3 1x 72oC 2min 
  4oC ∞ 
Table I-2. Colony PCR reaction mix and program for the amplification. 
(a). Colony PCR reaction mix for FL-DAK and N-DAK using Taq DNA polymerase. (b). Program 
used for PCR amplification.  
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The site mutations of the DAK gene were performed with the QuikChange Multi Site-
Directed Mutagenesis Kit from Stratagene. The mutations of the gene 
(Gly12Arg/Gly47Tyr/Val102Lys) were obtained using the standard protocol as shown 
in Table I-3, and the primers are listed in Table 3.1. The original DAK gene was used 
as the template for mutation. The PCR products were treated with 1µl of DpnI enzyme 
(10U µl-1, Stratagene) at 37oC for 1h to digest the parental DNA template. DpnI 
treated DNA was then transformed into XL10-Gold Ultracompetent cells: 2µl β-
mercaptoethanol was added into 15µl XL10-Gold cells and incubated in ice for 
10min, followed by the addition of 1.5µl DNA and further incubation in ice for 
30min. After a heat shock at 42oC for 30sec, 0.5ml pre-warmed NYZ+ broth was 
added and the cells were incubated at 200rpm for 1h at 37oC. The incubation was then 
plated on LB agar plates containing ampicillin (100µg ml-1). The process of plasmid 
purification, sequence confirmation and transformation into Rosetta cells was carried 
out following the same procedure described above.  
a  
Solution Vol  
10x Quikchange Multi reaction buffer 2.5µl 
Mutagenic primer (10µM) 1.5µl each 
DNA template (350ng µl-1) 0.5µl 
dNTPs (10mM) 1µl 
Quikchange Multi enzyme blend 1µl 
Water 15.5µl 
Reaction volume  25µl 
 
b    
step  cycle temp. time 
1 1x 95oC 1min 
2 30x 95oC 1min 
  55oC 1min 
  65oC 16min 
3  4oC ∞ 
Table I-3. Mutagenesis reaction mix and program for the amplification. 
 (a). PCR reaction mix for MU-DAK. (b). Program used for PCR amplification.  
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I-2. Protein over-expression in E. coli. 
To optimize the conditions for protein production, various small-scale expression 
trials were carried out. A transformed expression host colony was used to inoculate 
10ml LB medium containing ampicillin (50µg ml-1) and chloramphenicol (34µg ml-1) 
followed by incubation with shaking at 200rpm overnight at 37oC. After incubation, 
2ml culture was inoculated into LB (200ml) or TPB (200ml) containing ampicillin 
(50µg ml-1) and chloramphenicol (34µg ml-1), followed by incubation with shaking at 
37oC until an OD600 of 0.6 or 1.0 was reached. Each culture was split into 2x 50ml 
samples, one of which was cold shocked at 4oC for 30min. The protein expression 
was initiated by adding a final concentration of 0.4mM IPTG to the samples. To 
compare the effects of temperature on the expression yield and protein solubility, the 
samples were each split into 10ml volumes for growth at different temperatures such 
as 15oC, 25oC, 30oC and 37oC for 3h or overnight. After incubation, 1ml of each cell 
culture was spun down at 16,000g for 4min at 4oC. The pellet was resuspended in 
100µl of Bugbuster protein extraction reagent (Novagen) and incubated at room 
temperature for 10-15min. 0.5µl of lysate was added to 10µl loading buffer of 2x 
lithium dodecyl sulfate (LDS) as whole cell samples. The rest of the lysate was spun 
down at 16,000g for 10min at 4oC. Then 3.5µl of supernatant was added to 10µl 
loading buffer of 2x LDS as soluble cell samples. Both whole cell samples and 
soluble cell samples were heated at 100oC for 3min followed by SDS-PAGE gel 
analysis in order to confirm soluble protein expression. The identity of protein bands 
with expected sizes were confirmed by mass spectrometry. 
For large-scale protein over-expression, a transformed expression host colony was 
used to inoculate 100ml LB containing appropriate antibiotic followed by incubation 
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with shaking overnight at 37oC. After incubation, 10ml culture was inoculated in 1L 
LB containing appropriate antibiotics followed by incubation with shaking for 2-3h at 
37oC until the OD600 reached 0.5-0.6. At this point, FL-DAK, N-DAK and MU-DAK 
was cold shocked at 4oC for 30min, then the cells were exposed to 0.4mM of IPTG 
and incubated at 15oC overnight to induce the expression of cloned genes, while for 
MDA5-CARD, no cold shock was conducted and the overnight incubation 
temperature was 22oC.  
In the case of NanA-CBM expression, expression was performed by inoculating a 
starter culture with transformed E. coli cells into 100ml of auto-induction medium 
containing 50µg ml-1 kanamycin and left shaking in an incubator overnight at 37oC. 
The overnight starter culture was then used to inoculate four 2-litre flasks containing 
0.5L of auto-induction medium containing 100µg ml-1 kanamycin (for sustained 
antibiotic resistance), and left to incubate with shaking at 250rpm, for a further 48h at 
18oC.  
For 15N-labelled NanA-CBM protein expression, minimal medium was used for the 
cell culture. To prepare 1L minimal medium, 6g Na2HPO4, 3g KH2PO4, 0.5g NaCl 
and 1g 15NH4Cl were dissolved in water, adjusted to pH7.0 and autoclaved. In the 
meantime, 30ml 20% (w/v) glucose was autoclaved separately. After autoclaving, 
20ml of 20% (w/v) glucose, 1ml of 1M MgSO4, 1ml 0.1M CaCl2, 1ml 50mg ml-1 
kanamycin, and 20ml 8.5% (w/v) yeast nitrogen base were added to the medium 
prepared (all reagents were added via filter-sterilization). An overnight bacterial 
culture was spun down and resuspended with 10ml minimal medium (twice) followed 
by inoculation in 0.5L minimal medium and incubation with shaking at 250rpm for 4-
5h at 37oC until OD600 reached 0.6. The culture medium was then heat shocked in a 
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water bath for 30min at 42oC followed by the addition of 0.5mM IPTG and incubation 
at 250rpm overnight at 18oC.  
After incubation, all cultured cells were spun down at 10,000g for 20 minutes at 4oC. 
The supernatant was discarded and the pellet was transferred into a fresh 50ml 
centrifuge tube and stored at -20oC.  
I-3. Protein purification 
For FL-DAK, N-DAK, MU-DAK and MDA5-CARD protein purification, the 
harvested cell pellets were resuspended in buffer A (20mM HEPES, 100mM NaCl, 
20mM imidazole, pH7.5, all buffers and chemicals were purchased from Sigma) with 
DNase (Sigma, 20µg ml-1) and EDTA free protease inhibitor tablets (1 tablet per 50ml 
extract, Roche Diagnostics). The cell suspension was then disrupted with 10x1min 
sonication on ice followed by centrifugation at 40,000g for 2x30min at 4oC to remove 
the cell debris. The supernatants were collected and filtered with a 0.2µm syringe-
driven filter unit (Millipore) before further protein purification.  
The filtered soluble protein extract was mixed with 10ml Ni2+-nitrilotriacetic acid 
resin (equilibrated in buffer A, Qiagen) and incubated for 1h at 4oC. The mix was then 
loaded on a column and washed with 200ml buffer A before elution with 600mM 
imidazole in buffer A. The eluted fractions were collected and incubated for 1h at 4oC 
with amylose resin (New England BioLabs), which had been equilibrated in buffer B 
(20mM HEPES, 100mM NaCl, pH7.5). The resin was then washed with 100ml buffer 
B and eluted with 10mM maltose in buffer B. The elution fractions were pooled, 
supplemented with TEV protease (1mg protease for 10mg protein) and dialysed in 
buffer B containing 0.5mM DTT overnight at 4oC. The protease and uncleaved 
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proteins were removed by passing over a HisTrap HP column (GE Healthcare) that 
had been equilibrated in buffer B. The flow through was collected and concentrated to 
less than 5ml for further gel-filtration purification. For FL-DAK, N-DAK, and 
MDA5-CARD protein, the concentrated sample was loaded onto a HiPrep 16/60 
Sephacryl S-200 HR gel-filtration column (GE Healthcare), which had been 
equilibrated in buffer C (20mM HEPES, 75mM NaCl, pH7.5). For MU-DAK, the 
concentrated sample was loaded onto a HiPrep 26/10 desalting column (equilibrated 
in buffer C, GE Healthcare) instead of the gel-filtration column. In all cases, fractions 
from the observed peaks were analyzed separately by SDS-PAGE gel. Corresponding 
fractions were collected, concentrated, aliquoted in 40µl per eppendorf, flash-frozen 
in liquid nitrogen and stored at -80oC for future use. 
Similar purification strategies for NanA-CBM and 15N-labelled NanA-CBM were 
used: the cell pellets were resuspended in buffer D (PBS containing 300mM NaCl, 
10mM imidazole) with DNase and EDTA free protease inhibitor tablets, and cell 
disruption was done following the same procedure described above. The soluble 
protein extract was loaded onto a 20ml HisPrep FF 16/10 column (equilibrated in 
buffer D, GE Healthcare). The column was then washed with 100ml buffer D 
followed by further washing with 100ml buffer D containing 20mM imidazole. The 
bound proteins were eluted with 250mM imidazole in buffer D and the eluted 
fractions were then treated by TEV protease overnight. The cleaved proteins were 
further purified by the 20ml HisPrep FF 16/10 column. The collected flow through 
was concentrated for gel-filtration using the HiPrep 26/60 Sephacryl S-200 HR 
column (GE Healthcare), which was pre-equilibrated in buffer E (50mM NaCl, 20mM 
sodium citrate, pH 6.0). The purified proteins were collected, concentrated and stored 
at -80oC for future use. 
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I-4. Pull downs and size exclusion chromatography for protein-
protein interaction experiment 
Pull down experiments were performed for testing the interaction between MDA5-
CARD and FL-DAK/N-DAK. All proteins were purified following the procedure 
described above (section I-3), except for MDA5-CARD which did not undergo TEV 
protease treatment in order that the protein would bind to the amylose resin. 5mg 
MDA5-CARD with tags was pre-loaded onto the amylose resins (equilibrated in 
buffer B) and washed in 100ml buffer B. 5mg FL-DAK/N-DAK was then loaded onto 
the column followed by washing in 100ml buffer B. The bound proteins were then 
eluted with 10mM maltose in buffer B. All fractions were collected and analysed by 
SDS-PAGE gel. 
Size exclusion chromatography was also used for testing the interaction between 
MDA5-CARD and FL-DAK/N-DAK. All proteins were purified following the 
procedure described above (section I-3). SuperdexTM 200 10/300 GL and SuperdexTM 
75 10/300 GL columns (both equilibrated in buffer C, GE Healthcare) were used for 
testing the interaction of MDA5-CARD with FL-DAK and N-DAK, respectively. In 
these experiments, 1mg MDA5-CARD, or 1mg FL-DAK/N-DAK, or a mixture of 
0.5mg MDA5-CARD with 0.5mg FL-DAK/N-DAK was loaded onto the column 
separately, and the interaction status was analysed by superposition of the elution 
peaks. 
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I-5. Determination of DAK as a kinase and lyase 
For the kinase activity assay, a coupled enzyme assay, modified from Wu and Hill 
(Wu and Hill 1993), was performed. The reaction contained 50mM Tris-HCl buffer 
(pH 8.0), 15mM MgCl2, 3mM ATP, 1.5mM PEP, 0.25mM NADH, 8.4 units PK, 12.6 
units LDH, 2mM Dha and various concentrations of protein at a total volume of 140µl 
(all chemicals were purchased from Sigma). The assay was carried out in triplicate 
using a Cary Eclipse spectrometer (Varian) and Perkin-Elmer 1ml cuvettes (Sigma). 
The reaction was started by adding 5µl of various concentrations of FL-DAK and 
MU-DAK. The decrease in NADH fluorescence in real time was monitored. All data 
were processed using Excel2011. 
For the lyase activity assay, a coupled enzyme assay based on a discontinuous 
colorimetric assay was designed. The initial reaction was started with 1.4 units 
alkaline phosphatase (Promega) mixed with 500µM FAD (Sigma), 500µM MnCl2 
(Sigma) and 50µM FL-DAK/MU-DAK in a total volume of 200µl followed by 
incubation at 37oC for 30min. In addition, 1.4 units alkaline phosphatase was mixed 
with different concentrations of AMP as a standard positive control, and the reactions 
without FAD or DAK were carried out as the negative controls. During the 
incubation, a Pi reagent was prepared containing 6 volumes of 3.4mM ammonium 
molybdate (in 0.5M H2SO4), 1 volume of 130mM SDS and 1 volume of 570mM 
ascorbic acid (all purchased from Sigma). After the incubation, 1ml Pi reagent was 
added into the reaction and further incubated at 45oC in a water bath for 20min (the 
colour of the reaction would turn to blue at this stage). To stop the reaction, the 
samples were incubated in ice for 10min. The absorbance values at 820nm were 
measured in 1.4 ml UV quartz cuvettes (Sigma) with a Cary UV-Visible spectrometer 
(Varian). 
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I-6. Protein crystallization screening and optimization 
For FL-DAK, 9mg ml-1 and 18mg ml-1 FL-DAK were used for the initial 
crystallization trials. A variety of commercially available crystallization screens such 
as Index (Hampton Research), SaltRx (Hampton Research), Crystal Screen (Hampton 
Research), Wizard (Emerald BioSystems), Cryo I&II (Emerald BioSystems), 
JCSG+Suite (Qiagen), PACT Suite (Qiagen) and PEGs Suite (Qiagen) were selected 
for protein crystallization screening by a Honeybee 963 robot system (Genomic 
Solutions). For each of the 96-well sitting-drop vapour-diffusion screens (MRC 
plates, Greiner), 150nl of protein solution was mixed with 150nl of precipitant and 
equilibrated against a reservoir of 75µl precipitant. The sealed plates were then 
incubated at both 20oC and 4oC. The plates were checked under the microscope every 
1-2 days in the first two weeks followed by once a week. To distinguish protein 
crystals from salt crystals, 0.1µl Izit crystal dye (Hampton Research) was mixed into 
the drops containing crystals for 30min. Protein crystals are expected to stain to a dark 
blue colour while salt crystals remain transparent. The crystal optimizations were then 
carried out from the related conditions after the crystals were confirmed as protein. In 
each optimization round, stochastic optimization in a 96-well crystallization plate 
(Douglas Instruments) where salt and precipitant concentrations were varied around 
the initial condition were performed. In each condition, 100µl of precipitant was 
added to each reservoir well and 1µl 18mg ml-1 protein solution was mixed with 1µl 
of reservoir solution. The plates were sealed with sealing tape and incubated at 20oC. 
In this case, Additive Screen (Hampton Research) was used for further optimization, 
in which, 0.9µl 18mg ml-1 protein solution, 0.9µl of reservoir solution and 0.2µl 
additive screen condition were used in the drops. The initial FL-DAK crystals were 
obtained in condition 5 (0.1M SPG (molar ratios 2: 7: 7 of succinic acid: sodium 
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dihydrogen phosphate: glycine) buffer pH8, 25%(w/v) PEG 1500) and condition 49 
(200mM NaF and 20%(w/v) PEG 3350) of the PACT Suite screen. After rounds of 
optimization, the best crystals were obtained in 200mM KF, 5mM MgCl2, 18%(w/v) 
PEG 3350, 6%(w/v) MPD and 25mM glycine. The FL-DAK crystals appeared after 2 
days and reached their maximum size after 5 days at 20oC (Figure 2.11a in Chapter 2).  
For MU-DAK, the same method was used as described above. The initial 
crystallization conditions of MU-DAK were found to be both in the original FL-DAK 
crystallization condition (200mM KF, 5mM MgCl2, 18%(w/v) PEG 3350, 6%(w/v) 
MPD and 25mM glycine) and in condition 54 (200mM sodium formate and 20%(w/v) 
PEG3350) of the PACT Suite screen (Qiagen). Comparing both conditions, the 
original FL-DAK crystallization condition gives higher quality diffraction patterns, 
therefore optimization based on this condition was carried out, and the best crystals 
were obtained after 4 days in the condition of 140mM KF, 14%(w/v) PEG 3350 and 
6%(w/v) MPD with sitting drop vapor diffusion using 1µl of 10mg ml-1 protein mixed 
with 1µl reservoir solution (Figure 3.4a in Chapter 3). For the complex crystals, the 
protein solution at 10mg ml-1 MU-DAK was mixed with 5mM Dha and 5mM 
APC/CTP and incubated at 4oC for 30min. However, no ligand was bound to the 
protein under the same crystallization condition, therefore, further optimization was 
carried out using condition 54 of the PACT Suite. After several rounds of stochastic 
optimization following the procedure described above, the best complex crystals were 
achieved in 140mM sodium formate, 5mM MgCl2, 14% (w/v) PEG3350 and 6% 
(w/v) 1,6-hexanediol.  
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I-7. X-ray diffraction data collection and processing 
To determine the best cryo-protectant solutions for the crystals’ diffraction, the protein 
crystallization solution containing appropriate percentages of glycerol or different 
kinds of PEGs were tested. Each cryo-protectants was flash frozen in a -176oC 
nitrogen stream and an X-ray image was collected. Solutions which contained the 
highest proportion of mother liquor that did not lead to ice ring formation were 
selected. Eventually, mother liquor containing 10% PEG400 was used for all DAK 
crystal cryo-protection, and 5% ethylene glycol in mother liquor was employed for all 
NanA-CBM crystal cryo-protection. 
A single crystal in the crystallization drop was manually picked up using a suitable 
size loop (Mounted LithoLoops, Molecular Dimensions), and soaked in 10µl cryo-
protectant for 2-3sec at room temperature. The cryo-protected crystal was transferred 
into a crystal puck (SPINE Puck, Jena Bioscience) and stored in a cryogenic dewar 
(Molecular Dimensions) filled with liquid nitrogen. All of the crystals were 
preliminarily tested on the in-house X-ray machine (Rigaku 007HFM X-ray generator 
with a fixed wavelength of 1.54178Å, with a Saturn 944CCD Detector) to distinguish 
the initial parameters of the crystal form, such as the limit of the crystal diffraction, 
the unit cell and space group, which suggested basic strategies for further 
comprehensive data collection (Diamond, ESRF or in-house). The specific statistics 
of all data collections have been aforementioned in the previous chapters. 
All collected datasets were processed by the HKL2000 package (Otwinowski & 
Minor, 1997). The output.sca file from the program with acceptable data parameters 
was then used for structure determination.  
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I-8. Structure determination, refinement and validation 
C. freundii DAK (PDB code: 1UN9) (Siebold et al., 2003a) shares 39% amino acid 
sequence identity with FL-DAK, therefore initial phases of the FL-DAK structure 
were determined by MR. Space group P21 was suggested by the Pointless program 
(Evans, 2006) in the CCP4 suite (Winn et al., 2011). The Matthews program 
(Kantardjieff and Rupp, 2003) in the CCP4 suite (Winn et al., 2011) indicated that the 
asymmetric unit contained between 5 and 10 molecules. An ensemble containing the 
separated N- and C- terminal domains from one monomer of C. freundii DAK was 
used as the MR search model, and an initial, partial structure was obtained using the 
PHASER program (McCoy et al., 2007) in the CCP4 suite (Winn et al., 2011). The 
domains were manually incorporated into a single asymmetric unit using PyMol and 
Coot, and these coordinates were fixed for another PHASER run. Several rounds of 
manual inspection and phasing were required before the correct number of molecules 
(eight) were incorporated into the structure. The structure from the final phasing was 
used for restrained refinement in REFMAC5 (Vagin et al., 2004) from the CCP4 suite 
(Winn et al., 2011) using default values followed by manual rebuilding of the model 
with Coot (Emsley et al., 2004). The rebuilt model was refined again using 
REFMAC5, the output structure was inspected and rebuilt using Coot. The final 
structure was validated with MolProbity (Chen, et al. 2010).  
For MU-DAK structure determination, the FL-DAK structure was used as the MR 
search model. A single solution output structure with reasonable scores was obtained 
in the initial phasing. The structure was then refined with REFMAC5 with the 
geometric weighting term was decreased to 0.3 to tighten the geometric restraints. 
Further rounds of manual rebuilding in Coot and restrained refinement in REFMAC5 
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were carried out. For the complex structures, the ligands were manually added into 
the structure according to the Fo-Fc density in Coot.  The final structure was validated 
with MolProbity (Chen, et al. 2010). 
For NanA-CBM and the complex structure determination, the sequence of the NanA-
CBM was summited to Phyre2 for prediction of the secondary structure (Kelley and 
Sternberg, 2009), and the output structure was used as the MR search model. The 
refinement process was similar to that used for the MU-DAK structure as described 
above. The structures of N-terminal S. pneumoniae NanB (PDB code: 2VW0) (Xu et 
al., 2008b) and C. perfringens NanJ (PDB code: 2V73) (Boraston et al., 2007) were 
used for comparison models. The final structure was validated with MolProbity 
(Chen, et al. 2010).   
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I-9. NMR spectroscopy experiment  
To determine the extent of NanA-CBM protein folding, 15N labeled protein was 
analysed by NMR with both 1D 1H spectrum and 2D HSQC spectrum.  
Purified 15N labeled protein was diluted to 0.76mM (16mg ml-1) in buffer E. In each 
600µl reaction solution, 550µl 0.7mM 15N labeled protein and 50µl deuterated water 
(D2O, 99.9%, Sigma) was mixed. The mixture was then transferred into a 5mm NMR 
tube (Bruker) and the experiment with Watergate water suppression was recorded at 
25oC on a 500MHz Bruker DRX500 spectrometer equipped with a z-shielded gradient 
triple resonance probe. The instrument was controlled by the software Topspin 
(Bruker). 8 scans were accumulated at a digital resolution 9.76 Hz for 1H and 22.16 
Hz for 15N with 128 complex points in the indirect dimension. The spectrum was 
processed with NMRPipe (Delaglio et al., 1995) and analysed using CCPN Analysis 
2.1 (Vranken et al., 2005). The samples were measured and analysed by Dr U. 
Schwarz-Linek (School of Biology, University of St. Andrews).  
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I-10. The protein thermal shift assay 
The stabilization of a protein can be increased upon ligand binding, as shown in the 
increase of the melting temperature of the ligand-bound protein. This can be 
monitored by the protein thermal shift assay, in which the midpoint temperature (Tm) 
of the melting curve of the ligand bound protein will increase compared with the 
unliganded protein. The technique is widely used for applications such as drug 
discovery, improving protein stability and studying protein function (Lo et al., 2004). 
Therefore, to determine the stability of NanA-CBM folding with and without ligand 
binding, a protein thermal shift assay was carried out. For each reaction, 10µl 50µM 
NanA-CBM solution containing 3x Sypro orange protein dye (5000x in DMSO 
purchased from Life Technologies) was mixed with 40µl 2mM compounds (3’-SL, 6’-
SL and Neu5Ac2en). The mix was then transferred into an iCycler iQ 96-well Real-
Time PCR plate (Bio-Rad) and sealed with optical film. The plate was placed into the 
iCycler iQ5 Real-Time PCR Detection System (Bio-Rad), and the temperature was 
increased from 25oC to 90oC at a rate of 0.5oC per min. The Ex/Em of 490/530nm were 
used to measure the fluorescence intensity, which was recorded by the CCD camera 
and quantified by the iCycler iQ Optical System Program Version 3.1 (Bio-Rad). The 
results of the assay were generated by the same program, and the Tm of each melting 
curve could be identified by the middle point between the top of thermal ramp and the 
baseline of thermal ramp at the starting point, where the coordinate of the x value 
represents the Tm temperature. 
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